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ABSTRACT 
Nicole Rachele Zane: Predicting Pharmacokinetic Behavior and Dose of Sildenafil and 
Voriconazole in Neonatal and Pediatric Populations by In Vitro Metabolism and PBPK 
Modeling 
(Under the direction of Dhiren R. Thakker) 
 
Quantitative and qualitative differences in drug metabolizing enzymes (DMEs) from 
birth to adulthood affect drug clearance. Yet the effect of these differences on pediatric drug 
disposition is poorly understood. Moreover, drug disposition relies on both metabolic 
clearance and age-dependent differences in physiology. 
The overall goal of this dissertation was to develop a bottom-up experimental and 
modeling approach to predict pharmacokinetics (PK) of drugs in pediatric populations. 
Voriconazole and sildenafil were selected because they are (i) cleared predominantly by 
oxidative metabolism and (ii) administered to children and premature neonates, respectively. 
Hepatic intrinsic clearance from adult and pediatric tissues was elucidated and then 
incorporated into a physiologically based pharmacokinetic (PBPK) model to predict PK for 
each drug.  
The voriconazole model retrospectively validated this approach by comparing the 
model’s output against the abundant pediatric clinical data. It showed that the drug was 
cleared approximately 3-fold faster and bioavailability was nearly half in children ages 2-10 
years compared to adults due to contribution differences in CYP2C19 and CYP3A4. 
Quantitative proteomic analysis of hepatic tissues revealed higher expression of CYP2C19 
protein and higher catalytic efficiency in children compared to adults. 
Sildenafil metabolism studies demonstrated the predominant enzymes are CYP3A5 
and either CYP3A4 or CYP3A7, which refutes previous reports identifying CYP3A4 and 
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CYP2C9. Furthermore, these studies revealed that CYP3A7 is a steroid-specific enzyme that 
generates a unique testosterone metabolite. The expression and functional activity of the 
three CYP3A isoforms in fetal, pediatric, and adult hepatic tissues was elucidated. This data 
along with hepatic in vitro sildenafil metabolism was incorporated into a prospective PBPK 
model for premature neonates. The model revealed how ontogeny affects sildenafil clearance 
in premature neonates. It also predicted the influence of physiological factors and the potential 
effect of drug-drug interactions (DDI) on sildenafil PK.  
The key outcome was the development of a bottom-up PBPK model in pediatric 
populations by adapting a validated adult model, which was based on hepatic in vitro 
metabolism studies and expression of relevant enzymes from hepatic tissue incorporated with 
physiologic parameters. This innovative approach can be adapted to predict disposition and 
clinically significant DDI without relying solely on clinical trials. 
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CHAPTER 1 
Introduction to Developmental Pharmacology 
 
HISTORY OF PEDIATRIC DRUG DEVELOPMENT AND ETHICAL DILEMMAS  
Throughout the early 19th and 20th centuries, medicinal chemists and charlatans 
peddled cures for a variety of ailments. Most of these medications lacked efficacy while 
others were blatantly toxic. Over the years, these toxicities spurred the United States 
government to pass legislation to regulate the burgeoning pharmaceutical industry. Some of 
the more tragic events from unregulated medications involved the deaths of children. For 
instance, Mrs. Winslow’s soothing syrup was marketed as a medication to calm fussy 
children. However, it contained high levels of alcohol and morphine derivatives and, 
ultimately, many children passed away after ingesting it. Unfortunately, this was not the last 
event involving children’s’ deaths. In 1937, a company dispatched over 200 gallons of elixir 
sulfanilamide, which was administered to children, leading to renal failure in many children 
who ingested the drug because it contained diethylene glycol. In 1962, thalidomide was 
approved as a sleeping pill in Europe and caused severe birth defects. All of these tragedies 
led to amendments in the federal law that would allow the government greater control over 
the drug development process [1]. These amendments required drugs to be branded and 
advertised correctly, and also demonstrate safety and efficacy. It is remarkable that despite 
the relatively high rate of death and retardation in children due to these toxic medications, 
regulatory rules did not mandate companies to test their products in children until the early 
21st century.  
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However, the conceptualization of children as a special population began in the mid-
19th century. Abraham Jacobi, famously known as the “father of American pediatrics”, 
practiced medicine in New York City in the late 19th century. While the array of medical 
specialties was not as extensive as it is today, Dr. Jacobi became the premier doctor who 
treated children. He was the first doctor to open a free pediatric clinic in America and raise 
awareness of pediatrics by teaching new doctors and becoming one of the first professors of 
pediatrics [2]. Contrary to the belief that children required smaller doses since they were just 
smaller people, his teachings stressed the importance of pediatrics as an independent 
population with different disease etiologies that required unique dosing [3]. 
Many reasons could be cited for the slow response to national tragedies and Dr. 
Jacobi’s teachings. One prominent case is the clinical trials conducted at Willowbrook State 
School in New York, which housed children with moderate to severe mental retardation. 
Over the span of approximately two decades, these children were enrolled in hepatitis A 
clinical trials in which some participants were injected with the active hepatitis A virus [4]. 
Along with other unethical trials such as the exploitation of poor African American men in 
Tuskegee experiments [5], the Willowbrook studies helped to develop the idea of informed 
consent and the core values of ethics. A more recent example of an ethically contentious 
study involved observing the effect of lead on children living in homes with lead paint in 
Baltimore. This study, conducted by the Kennedy Krieger institute, led to a lawsuit that 
resulted in an increase in protective measures in pediatric clinical trials in Maryland [6].  
Pediatric patients are undoubtedly a vulnerable population. Before approving a 
pediatric clinical trial, an Institutional Review Board (IRB) must carefully consider the risk-to-
benefit ratio, the discomfort of the trial to the child, the volume of collected blood required for 
the study, and who is authorized to give informed consent for the study. It is now well known 
that pediatric populations exhibit significant differences in pharmacokinetics (PK). Drugs did 
not undergo pediatric studies prior to the late 1990s, leaving a significant dearth of dosing 
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information in newborn and pediatric patients for drugs that have not been approved for this 
population. Furthermore, it has been observed in clinic that some drugs have higher dose 
requirements in children versus adults, which could make children vulnerable to under-
dosing [7, 8]. As a result, scientific attitudes shifted the belief that not performing pediatric 
clinical trials is also unethical.  
The first regulatory document, the Food and Drug Administration Modernization Act 
(FDAMA), that involves pediatric research, was passed in 1997. FDAMA encouraged 
pediatric clinical trials with an economic incentive of an extended 6-month exclusivity on 
brand name drugs. In 2002, the Best Pharmaceuticals for Children Act was enacted to allow 
the FDA to request pediatric clinical trials. In 2003, the Pediatric Research Equity Act 
(PREA) was enacted which stated that pediatric clinical trials were mandated if children 
were likely to use the new drug [9]. As of November 2014, over 500 labeling changes have 
been made due to these key pieces of legislation in the United States [10]. Global regulatory 
bodies, such as the European Medicines Agency (EMA), have followed a similar path to 
protect children from the events described above [11].  
Despite these successes, there are still significant obstacles to performing pediatric 
clinical trials. Besides ethical concerns, one major challenge is selecting the optimal dose. 
Many pediatric trials have failed due to narrow dose ranges selected, while successful trials 
tested a wide range of doses with no overlap in doses [12]. Wider dose ranges also require 
a larger sample size, which makes it challenging since a large number of pediatric subjects 
need to be recruited for such studies. To improve the clinical trial outcomes, novel 
techniques are required for clinical trial design and dose range selection [8]. This 
introduction will cover traditional methods of dose selection, as well as newer techniques 
that are being employed to enhance trial design and dose selection in the clinic. 
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ALLOMETRIC SCALING TO PREDICT PEDIATRIC PHARMACOKINETICS  
Conventional pediatric dose determinations used allometrically scaled adult doses to 
establish a pediatric dose. This method was adopted as drug development plans have 
consistently utilized this method to scale from non-clinical animal models to first-in-human 
doses. Even though significant differences are observed in the DNA sequence homology of 
drug metabolizing enzymes (DMEs) between these animal species and adult humans, 
allometric scaling provided a reasonable prediction [13]. Once the dose was established in 
human adults, allometry was then used to scale the clearance and dose to pediatrics. Three 
distinct methods were developed to scale the dose including scaling by body weight, body 
surface area, and body weight raised to a power function (Table 1. 1) [14]. The exponent 
generally used in the allometric scaling of metabolic rates for children is 0.75 [14].  
Table 1. 1 Variations in Equations for Allometric Scaling. 
Allometric Scaling Method Equation 
Body-weight  = 
 ×  



 
Body surface area  = 
 ×  



 
Exponential Scaling  = 
 × (



) 
An instance where allometry will be effective is when the drug is administered 
intravenously and undergoes renal excretion, minimal metabolism, and minimal biliary 
excretion. Specifically, allometry works well for intravenous dosing in children 12 years of 
age and older because their physiology is similar to adult physiology and absorption is not 
involved. However, many drugs do not fit this profile, so allometric scaling has substantial 
limitations.  
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It is not unusual for the predicted pediatric drug clearance from allometry to be 
substantially different than that observed in clinic. Allometric models can either under- or 
over-predict clearance for drugs depending on the class of the drug, its metabolic route, and 
the age of the patient. An inverse relationship is observed between the age and size of the 
child and prediction errors for dose and clearance. In other words, errors in clearance 
prediction increase as the gestational age or size of the children decreases [15].  
In a review that examined the exponential scaling method, a span of values for the 
exponent applied (x) ranged from 0.75 to 1.0. This review by Mahmood et al. determined 
that none of these exponents worked well for every drug. Even for the same drug, none of 
the exponents worked well for all ages that were reviewed, with errors as high as 800% [16].  
In a report by Edginton et al., the clearance of 39 drugs in children were predicted by 
body weight and body surface area scaling using two different types of simulations [17]. The 
first simulation used a mean adult clearance and the second simulation used a distribution 
of adult clearances for each drug. The authors concluded that allometric scaling predicted 
clearance well for children 6 years of age and older. Despite this conclusion, celecoxib, 
leflunomide, nelfinavir, pantoprazole, quietiapine, and other drugs metabolized by hepatic 
DMEs exhibited larger prediction errors between observed and predicted clearances.  
In a follow-up review, Mahmood et al. investigated the previous method along with 
five additional methods [18]. Included in this analysis was a maturational model that 
accounted for maturation of clearance as a function of age. This model was described by 
the following equation:  
 =   × (

70)
.  ×   
!
 ! + (%)!
 
Where Clstd is the average population clearance, PMA is post-menstrual age in 
weeks, n is the hill coefficient, and Cl50% is the age that normalized clearance at 50% of the 
maximum value [18]. The results showed that exponential scaling with a fixed exponent of 
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0.75 had the highest prediction errors. In contrast, the maturational model had an average 
prediction error of approximately 35% with a range between 7 – 117%. This review clearly 
indicated that maturational changes need to be accounted for when predicting clearance 
and doses for pediatric patients. A limitation of this analysis was that only six drugs were 
considered. It is difficult to extrapolate this model to a wider array of drugs, since in the 
review by Edginton et al., larger predictive errors were seen with drugs that are metabolized 
by hepatic DMEs. 
Overall, allometric scaling assumes that all organs and enzyme function increase 
proportionally with body size and, therefore, with age. Notably, all of these methods fail to 
include hepatic or intestinal enzyme ontogeny, polymorphisms and physiologic 
developmental changes in renal function, gastrointestinal (GI) function, organ volumes, 
blood flows, and total body composition.  
MATURATION OF PEDIATRIC PHYSIOLOGY 
Developmental changes from the fetal period into adulthood include differences in 
the activity and abundance of DMEs and transporters, changes in GI function, adipose 
composition, water composition, organ sizes, and organ blood flows. All of these factors 
affect clearance and distribution of drugs within the body. This section will describe a few of 
the major age-dependent changes that affect drug PK and its variability. This section will 
introduce physiogical factors prioritized by the magnitude of their effect on pediatric PK. 
Clearance 
Total body clearance is described by the following equation:  
 = $%&'()*+ +  ,%!&) +  (-%,. 
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This equation establishes that the two 
main organs of clearance are the liver and the 
kidneys. Both systems undergo distinct 
maturation from the fetal period into adulthood. 
Many traditional drug development processes 
that utilize standard in vitro and in vivo 
screening methods and extrapolations do not 
take these developmental changes into account. 
The liver is the main organ of clearance that is responsible for oxidative metabolism. 
It undergoes significant changes during childhood development. The biliary canals begin to 
form when the embryo is 18 days old and continue to mature throughout gestation. Bile 
ducts are not completely formed until four weeks after birth [19]. After birth, the size of the 
liver continues to grow with age. However, hepatic growth is not proportional to body size. 
Liver size, as a ratio of liver size to total body mass, reaches a maximum ratio between 1-4 
years of age, which is then followed by a gradual decrease (Figure 1. 1) [20]. Hepatic DMEs 
undergo rapid changes from the fetal period into infancy, childhood, adolescence and finally 
adulthood. The total content of all cytochrome P450 (CYP) enzymes in fetal liver (30-60% 
compared to adults) increases at birth and 
approaches adult levels by 10 years of age 
[21]. However, significant changes in CYP 
enzymes occur throughout this period.  
The development of the renal system 
also begins during gestation [22]. However, the 
main function of the kidneys at this stage is to 
maintain amniotic fluid levels [23]. Kidneys are 
not truly functional until the last trimester before birth. After birth, the kidneys continue to 
 
Figure 1. 2 Developmental Changes in 
Renal Function (Adapted from G Kearns, NEJM, 2003) 
 
Figure 1. 1 Changes in Liver Size as a 
Function of Age  
(Adapted from J. Goldman, Biomark Med., 2011)  
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develop until they reach mature filtration values by approximately 1-2 years of age (Figure 1. 
2) [24]. This maturation function applies to only full term neonates. Glomerular filtration rates 
of premature neonates is approximately 30% compared to those of full term neonates at 2 
weeks of life [25]. The renal function of premature neonates takes years to reach the same 
milestones as those observed in children born at full term. 
Distribution 
Physiological factors that affect drug distribution also change with age. Body 
composition changes from the neonatal period into adulthood. Changes in body composition 
continue as adults enter the geriatric phase. Total blood volume and total fat content 
increase with age, whereas the reverse is true for total body water [26]. For instance, the 
total body water (as a percentage of body weight) decreases from over 70% at birth to 50% 
in adults. The primary changes are in the ratio of extracellular to intracellular fluid 
compartments. In neonates, body water is split evenly between these two compartments; 
whereas in adults, the water content is two-fold higher in the intracellular compartment 
compared to the extracellular compartment [27]. These differences affect the disposition 
and, ultimately, the clearance of drugs from the body. 
Cardiac output increases with childhood growth and development (Figure 1. 3) [28]. 
Despite this proportional increase in cardiac output, the percentage of the cardiac output to 
individual organs changes with 
age. Unique developmental 
patterns are seen with blood flow 
to each organ. For instance, blood 
flow to the brain is highest 
between the ages of two and 10 
years of age, and then decreases 
until adulthood. Liver blood flow increases steadily with a small peak in the first in the first f 
 
Figure 1. 3 Developmental Changes in Blood Flow 
(Adapted from K Krishnan, J Environ Science, 2005) 
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few years of life. Differences in blood flows will affect how drugs distribute within the body 
after both oral and intravenous administration. 
Protein binding is another major factor that influences the distribution of drugs. Both 
albumin and α1-acid glycoprotein are present at a lower levels in premature and full term 
neonates compared to adults [27]. Neonates and infants on average have 20% and 10% 
less albumin than adults, respectively [29]. One study, which examined the binding of 
diazepam in adults and neonates, showed that neonates had an unbound fraction 4-fold 
higher than adults indicating that the lower concentrations of albumin and plasma proteins 
significantly affect the binding of drugs in newborns [30]. Another study demonstrated that 
acetylsalicylic acid had lower binding in neonates compared to adults. Protein binding 
remained higher in adults even when adult plasma was diluted and bilirubin was added to 
bring the concentration to neonatal levels [31]. These results demonstrate that neonates 
have lower binding due to lower plasma protein expression, but also due to lower affinity of 
plasma proteins for drugs.  
Absorption 
Differences in the GI tract start to occur at the gastric level. In premature and full 
term neonates, the pH of the stomach is higher. Lower acidity in the stomach enhances the 
absorption of acid-labile drugs, such as penicillin [32]. Gastric emptying time also decreases 
with age. Preterm neonates had higher retention in the first few hours after birth compared 
to term neonates at the same post-natal age [33]. These data indicate that gestational age 
affects gastric emptying time which does not fully mature until approximately 6-8 months 
after birth [34].  
Absorption of the majority of drug and nutrient occurs in the small intestine. As in the 
case of the liver, the small intestine begins to form within a few weeks of gestation with the 
brush border having some functionality by the end of the first trimester [35]. The motility of 
the small intestine is slower in neonates compared to adults [34]. While it may seem that a 
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slower rate of peristalsis could increase absorption, another study showed that absorption 
rates in neonates who were given the GI stimulant, metoclopramide, were slower compared 
to the absorption rates in infants [36]. While there is a dearth of information about the 
development of the intestine, it is presumed that the intestine is mature by approximately 
four months of age [24]. In addition, bile salt concentrations in the intestinal lumen are lower 
than in adults, which affect the solubility of many drugs [34]. Furthermore, the intestine is the 
first-line barrier for entry of exogenous compounds into systemic circulation. Little is known 
about the innate immunity of newborns throughout childhood, so the intestine is vital to 
protecting children [37]. 
Absorption and permeability issues are important factors in oral drug delivery to 
premature infants. Due to developmental delays, premature neonates can experience 
problems with suckling and feedings. In order to deliver sufficient nutrition to these children, 
parenteral nutrition or gastrostomy tubes are utilized [38, 37]. These types of feedings can 
increase the risk of necrotizing enterocolitis [37]. Furthermore, decreases in carrier-mediated 
absorption and increases in permeability affect the absorption of nutrients and compounds 
across the intestinal barrier [39]. Overall, the small intestine is underdeveloped in premature 
neonates, which can affect absorption of drugs differently depending on their 
physicochemical properties.  
It should be noted that there are also differences in skin thickness and body surface 
area which could affect topically administered medications [24]. However, for the purpose of 
this research project, oral and intravenous drug delivery were the main focus.  
THE ONTOGENY OF DRUG METABOLIZING ENZYMES 
Hepatic clearance accounts for the clearance of almost 75% of the top marketed 
drugs, and about 75% of hepatic clearance is due solely to oxidative metabolism by phase I 
enzymes [40]. While there are many different families of enzymes and even more isoforms 
within each family, a few families metabolize a majority of drugs. Contributions of the major 
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cytochrome families 
includes 46% by 
CYP3A, 28% by 
CYP2C, 12% for 
CYP2D6, and 9% 
by CYP1A (Figure 
1. 4) [40]. Families 
of enymes exhibit different maturational profiles [41, 24]. These differences in ontogeny can 
affect how drugs are metabolized in children, especially when two enzymes with different 
maturation profiles are involved. Preliminary studies utilized western-blot analysis and 
differential metabolism in an attempt to quantify the expression of these DMEs. While these 
methods are prone to generate confounding data due to antibody cross-reactivity and a lack 
of selectivity and specificity, they generated the first estimation of enzyme expression. 
CYP3A 
The CYP3A family is the most abundant DME in the liver [42]. CYP3A4 mediates 
oxidative metabolism of many drugs on the market [43]. Despite the significant role it plays 
toward hepatic drug metabolism in adults, it is 
virtually absent in fetal tissues where the 
dominant CYP3A isoform is CYP3A7. Gene 
expression of CYP3A7 is high throughout fetal 
gestation, is downregulated at birth, and by 
approximately 1 year of age, is virtually 
undetectable. This downregulation of CYP3A7 
expression corresponds to a switch from 
CYP3A7 to the CYP3A4 isoform, which is upregulated over time until it reaches adult 
expression levels (Figure 1. 5) [44]. CYP3A5 is genetically polymorphic and African 
 
Figure 1. 4 Major Routes of Clearance (Adapted from LC Wienkers, Nat Rev Dr, 2005) 
 
Figure 1. 5 Age-dependent CYP3A 
Expression (Adapted from J. Stevens, JPET, 2003) 
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Americans are found to express this enzyme at higher levels compared to other ethnicities 
[45, 41]. Due to the higher variability in CYP3A5 expression, a unique ontogeny profile of 
this enzyme has yet to be elucidated [46, 45].  
Differences in the activities of these isoforms during development contribute to 
altered PK between adults and children. Midazolam and testosterone are two probes that 
are recommended for CYP3A activity. In vitro and in vivo studies have demonstrated a lower 
metabolic activity of CYP3A7 compared to CYP3A4 [47-49]. It has been reported that 
metabolic activity of CYP3A7 is greater than 5-fold lower compared to that of CYP3A4 [50]. 
Furthermore, it is possible that these two isoforms of CYP3A display varying substrate 
affinities [49]. This difference in affinity and specificity was revealed during CYP3A7-
mediated DHEA metabolism during which CYP3A7 converted DHEA to the 16α-OH 
metabolite preferentially over the 7β-OH metabolite [44]. Overall, CYP3A7 displayed a lower 
metabolic activity compared to CYP3A5 and CYP3A4 [51].  
CYP2C 
CYP2C9 expression in the fetus is low during the first two trimesters of pregnancy. 
Expression levels begin to increase gradually during the third trimester, but reach adult 
levels within a week or two after birth [52]. CYP2C9 activity peaks within the first five months 
after birth and gradually declines to adult levels [52]. Dosing requirements for phenytoin is 
14 mg/kg/day for infants (6 months to 3 years) and decreases to 8 mg/kg/day in children (4 
years of age and older). This phenomenom was attributed to a higher Vmax [24, 53]. 
However, enzyme expression data do not explain this higher weight-based dosing 
requirement in infants compared to children and adults.  
CYP2C19 is also expressed at low levels during fetal gestation, but is up-regulated 
at birth [52]. During the first 5 months of life, CYP2C19 increases linearly in expression and 
activity. Although there is a positive correlation between age and CYP2C19 expression, 
there is a significant variability in the expression levels of this enzyme at birth, with 
13 
 
expression as high as adult levels in some neonates soon after birth. Polymorphisms in the 
CYP2C19 gene code for poor metabolizers (by CYP2C19*2 which is a nonfunctional allele 
of CYP2C19) and ultra-rapid metabolizers (by CYP2C19*17). Polymorphisms in the 
CYP2C19 pathway affect clearance of most proton pump inhibitors, clopidogrel, 
voriconazole, and other drugs [54-56]. This hypervariability in CYP2C19 expression needs 
to be taken into consideration, in addition to its ontogeny, during pediatric drug development 
programs. 
Despite the positive correlation between age and the expression of CYP2C19, 
clinical observations have described lower bioavailabilty of drugs in children (2-12 years of 
age) compared to adults. These differences in bioavailability have been observed for drugs 
such as proton pump inhibitors, nelfinavir, and voriconazole [7, 57-62]. In vitro experiments 
utilizing pediatric liver microsomes established that the contribution of CYP2C19 to 
voriconazole metabolism was higher in children (2-10 years of age) compared to adults [63]. 
This discovery led to the hypothesis that higher hepatic clearance accounted for the lower 
bioavailability of voriconazole in children compared to adults. While this study also examined 
CYP2C19 protein expression, the variability in the western blots hindered a definitive 
determination of higher protein expression of this enzyme in children.  
CYP2D6 
The ontogeny of CYP2D6, that was determined by immunochemical inhibition of the 
enzyme, suggested that neonates had very low expression of CYP2D6 which steadily 
increased over the first few months of life [64]. Microsomal activity analyses showed that 
catalytic efficiency increased significantly from newborns into adulthood. These results were 
further substantiated in another in vitro experiment using the probe substrate 
dextromethorphan. Results from this experiment revealed that with a 5 µM concentration of 
fetal human liver microsomes (HLM), there was no detectable formation of dextrorphan, the 
active metabolite of  dextromethorphan. With 50 µM microsomal protein, a 17-fold lower 
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activity was observed with fetal HLM compared to adult HLM [65]. A full ontogeny profile of 
CYP2D6  was not determined until dextromethorphan was administered to infants during the 
first year of life. The ratio of parent-to-metabolite showed that metabolism of 
dextromethorphan via CYP2D6 was similar from the first few weeks after birth to 12 years of 
age [66]. Further, these results showed that polymorphisms in CYP2D6 were consistent 
across these age groups indicating that CYP2D6 undergoes rapid maturation to adult levels 
within the first month after birth.  
CYP1A2 
CYP1A2 is an important hepatic enzyme in premature neonates since it is 
responsible for over 90% of caffeine metabolism, Caffeine is administered to premature 
neonates as a first-line therapy for apnea and bradycardia [41]. CYP1A2 expression is 
negligible in the fetal period and undergoes gradual increase. Development of CYP1A2 
activity takes anywhere between 4-10 months after birth [41, 67, 24]. Litmited data are 
available on quantitative gene or protein expression of CYP1A2.  
Flavin-containing Monooxygenases 
Flavin-containing monooxygenases (FMO) oxidize nitrogen- and sulfur-containing 
compounds. As with CYPs, FMOs have different isoforms, including FMO1, FMO2, FMO3, 
FMO4, and FMO5. Using quantitative real-time polymerase chain reactions (qRT-PCR), 
gene expression of each of these isoforms was established in various tissues [68]. FMO1, 
FMO3, FMO4, and FMO5 were located in the liver, with FMO1 and FMO3 being the most 
highly expressed hepatic isoforms in fetal and adult liver, respectively. FMO1, FMO2, and 
FMO4 were expressed in the kidney and FMO2 was located primarily in the lung. A 15-fold 
greater expression of FMO3 was observed in the adult liver compared to the expression of 
FMO1 in the fetal liver, suggesting that the ontogeny of hepatic FMO isoforms exhibits a 
similar developmental pattern to that of CYP3A.  
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Protein expression of hepatic FMO1 and FMO3 was examined in another report 
(Figure 1. 6) [69]. Results from this study corrorborated gene expression data that FMO1 is 
the predominant fetal isoform that is expressed at highest levels during weeks 8-15 of 
gestation. These levels of enzyme expression decline during fetal development until they 
are undectable by the first week after birth. FMO3, the adult hepatic isoform, then replaces 
FMO1 as the predominant isoform by approximately 1-2 years of age. However, there was 
only a 3-fold difference between hepatic FMO1 to FMO3 in contrast to the previous report. 
This dichotomy led to questions about whether the fold-differences between gene and 
protein expression were due to assay conditions or post-translational modifications. It also 
raised questions about which assay and report was a better estimate of actual expression.  
FMO isoforms exhibit distinct 
substrate specificity [70]. FMO3 metabolizes 
trimethylamine at a rate 100-fold greater than 
FMO1. Similarly, FMO3 also metabolizes 
benzydamine, another probe of FMO, at a 
rate 6-fold greater than FMO1 [71]. For most 
drugs, such as nicotine and cimetidine, FMO3 
is thought to be the predominant enzyme due 
to its higher expression and greater metabolic 
efficiency for these substrates [72].  
Intestinal Oxidative Metabolism 
The intestine is the first barrier to admission into the systemic circulation that 
exogenous compounds encounter after oral administration. The small intestine is the site of 
highest absorption and contains a variety of protective mechanisms. For instance, the 
intestine has a high level of transporters, both efflux and uptake, to help regulate the 
passage of compounds [73]. The intestine also has DMEs that regulate the absorption of 
 
Figure 1. 6 Ontogeny of Human Hepatic 
FMO (Adapted from R. Hines, Expert Opin Drug Metab Toxicol, 2006) 
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medications. CYP3A4 is the most highly expressed oxidative enzyme located within the 
small intestine followed by CYP2C9 and CYP2C19 [43, 74-78]. In adults, the regulation of 
intestinal CYP2C enzyme expression was not correlated to hepatic CYP2C regulation [79], 
which limits the extrapolation of regulation by hepatic DMEs to intestinal DME expression 
and functional activity in adults.  
The ontogeny of DMEs in the small intestine is an area that is in need of significant 
research. Since the intestine constitutes only one component of first-pass metabolism, it is 
difficult to assess the ontogeny of all intestinal DMEs using in vivo studies as the data could 
be confounded by hepatic metabolism and overlapping metabolic routes. However, one 
small clinical study utilized oral midazolam, a prototypical intestinal CYP3A probe, to study 
first-pass metabolism and clearance in preterm neonates [47]. The 15 preterm neonates 
included in the study showed a lower midazolam clearance that was hypothesized to be due 
to lower CYP3A intestinal activity. The challenges associated with in vitro studies include the 
collection of healthy intestinal tissue from neonates to children (2-12 years of age). These 
procurement difficulties present an obstacle to determining the ontogeny of protein 
expression and functional activity of pediatric intestinal DMEs. However, one study has 
reported the gene expression of CYP3A in neonates and children using qRT-PCR to [80]. 
The results suggest that children (1 month to 6 years of age) expressed CYP3A4 and 
CYP3A5 at higher levels compared to children 6 years of age and older. One limitation in 
this study was the lack of a comparison to expression of the CYP2C family, which is the next 
most prominent intestinal DME, and a lack of information on differences in activity in relation 
to the differences in gene expression. Additional information on the activity and expression 
of DMEs in the pediatric intestine is needed to confirm the trend of higher levels of CYP3A 
expression in the small intestine of children, and its implication on pediatric intestinal first-
pass metabolism. Due to the limited supply of fresh, healthy pediatric intestinal tissue, an 
innovative in vitro method must be developed to fill this knowledge gap.  
17 
 
The Ontogeny of Drug Transporters in Pediatric PK 
While the major focus of this dissertation was on drugs that are completely cleared 
by oxidative metabolism, it should be noted that transporters play an equally important role 
in drug clearance. Additionally, the ontogeny of these drug transporters could be particularly 
important for drug-drug interactions (DDI) and drug-induced liver injury in neonates and 
children. Transporter-related changes with maturation have only begun to be studied [81]. A 
level of complexity associated with the study of the ontogeny, regulation, and function of 
transporters is their co-expression and overlapping substrate specificity [82, 83]. This 
overlap leads to redundancy in function. Furthermore, unlike the expression of DMEs, which 
are mainly confined to the liver and intestine, transporters can be found throughout all 
organs in the body [73]. This wide spread expression of transporters adds another level of 
intricacy to correlating ontogeny and whole-body PK. Finally, unlike the DMEs, only the 
transporter proteins that are on cell membrane can modulate the movement of drug 
molecules in and out of the cell. Hence, quantitation of total transporter protein does not 
reflect its functional activity. It is expected that the ontogeny of transporters will play as much 
or greater role in defining drug PK and therapeutic outcomes as DMEs. Therefore, the 
ontogeny of transporters has not been covered in this section. 
CLINICAL TRIAL LIMITATIONS 
Despite all the challenges associated with pediatric clinical trials, they are 
nonetheless being conducted. Many of these trials are conducted without accounting for the 
ontogeny of the metabolic routes. One prominent example of this was the pediatric clinical 
trials for voriconazole, which is a known CYP3A4 and CYP2C19 substrate. Over the span of 
10 years, four different clinical trials for voriconazole in pediatric patients were conducted. 
Each trial attempted to explain the hypervariable PK, higher clearance, and lower 
bioavailability of voriconazole in children (2-12 years of age) compared to adults [57, 58, 60, 
61]. However, none of these trials were able to accurately describe why children exhibited 
18 
 
linear voriconazole PK over a larger dose range whereas adults showed non-linear PK when 
the drug was administered over a very narrow dose range, even when the doses were 
normalized to weight.  
Pediatric clinical trials have been conducted in an attempt to explain PK variability 
due to genetic polymorphisms. Clinical trials that investigate a specific genetic polymorphism 
require a large cohort to prove an effect. To gain approval, pediatric clinical trials need to 
demonstrate benefit to the child. Therefore, assessing the effect of genetic polymorphisms 
on drug PK is challenging due to the impracticality of recruiting pediatric patients to 
investigate the effect of a specific allele-carrier on the PK of drugs. It was also challenging 
for pediatric clinical trials that attempted to assess genetic polymorphisms to prove the effect 
of the polymorphism on PK. One specific example is a pediatric study that included 
CYP2C19*2 poor metabolizers of pantoprazole, a proton-pump inhibitor. This study was 
able to recruit only two patients with the allele of interest, and therefore, could make no 
conclusions about the effect of the polymorphism on pediatric PK of pantoprazole [84]. Age 
and ontogeny can mask the effects of genetic polymorphisms on drug PK, thus adding 
another layer of complexity to pediatric clinical studies [85]. Therefore, a new method is 
required where a large number of patients are included in the study to increase the power to 
assess the effect of genetic polymorphisms on pediatric PK.  
TOP-DOWN OR BOTTOM-UP MODELING 
Clinical trials are costly and challenging and need to meet rigorous requirements to 
gain approval from IRBs to test drugs in the pediatric population. On the other hand, 
allometric scaling failed to capture the range of developmental changes in the physiology 
and ontogeny of enzymes. So, old techniques combined with new computational methods 
were able to integrate changes in macro- and micro-physiology. Modeling methods have 
increased in popularity and importance over the past three decades (Figure 1. 7). The figure 
shows data retrieved from PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) listing all of the 
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population PK and 
PBPK models that 
were published 
between 1988-
2014 [A] and all of 
the pediatric 
population PK and 
PBPK models that were published between 1990-2014 [B].  
Two types of whole-body modeling exist: top-down and bottom-up (Figure 1. 8). Top-
down models analyze clinical PK profiles to understand variability within the population. Of 
the top-down modeling techniques used, population PK analysis is the more established 
technique. Population PK analyses derive inter- and intra-patient variability from plasma 
concentration-time profiles generated for each individual within a clinical trial [86]. The 
advantage of population PK studies is the ability of the model to utilize sparse samples to 
generate population estimates of PK parameters. This method succeeds pediatric clinical 
trials since blood draws are limited due 
to small blood volumes in children, and 
therefore only a few plasma samples are 
usually collected [87]. Unlike allometric 
scaling, population PK evaluates 
pediatric plasma-concentration profiles 
for more than one covariate. These 
models enable detection of multiple 
covariates, such as gestational age, weight, or gender, to better understand the causes of 
PK variability. Population PK analyses are useful to identify covariates and determine 
effective doses for a variety of medications [88, 89]. Although one notable pediatric 
 
Figure 1. 7 Number of Computational PK Modeling Papers Published  
 
Figure 1. 8 Diagram of Top-down Versus 
Bottom-up Modeling Approaches.  
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population PK study predicted a dose range for voriconazole in children (2-12 years of age), 
a follow-up clinical trial assessing these predictions revealed that even higher voriconazole 
doses were needed as the doses determined by the population PK analysis were found to 
be inadequate [58, 90].  
There are a few significant limitations with population PK studies. First, the size of 
the sample population used in the analysis can affect predictions. If a sample cohort is 
analyzed, then any random chances in PK variability have a greater effect on the output of 
the analysis. This limitation is amplified if the pediatric samples cover a large age range. As 
previously mentioned, many maturational changes occur during childhood requiring that 
children be binned into a specific age group [91]. Secondly, the PK predictions generated by 
the model do not always extrapolate to other age groups [92, 93]. Thus, if the population PK 
study only analyzes children within a narrow age range, then the results cannot always be 
applied to younger or older patients that are at a different stage of maturation. Finally, 
population PK studies cannot determine the cellular mechanisms for differences in PK.  
PBPK models are the other PK modeling technique that can be used to generate 
population predictions. PBPK models can be split into top-down and bottom-up approaches. 
Both PBPK model types require the integration of clearance mechanisms and 
physiochemical properties of the drug into the model. These models offer the advantage of 
allowing users to test how different input parameters could affect the predicted PK in 
simulated patients. This feature provides the ability to understand cellular and drug 
characteristics that most affect the model.  
The first type of PBPK model is the top-down approach. Similar to population PK 
analyses, top-down PBPK models use clinical clearance values to simulate individuals. For 
this reason, this type of PBPK model has the same limitations as population PK models. 
These models integrate clearance as a whole-organ clearance or a back-extrapolation from 
in vivo clearance. These clearance parameters are specific to the age-range studied and do 
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not necessarily represent younger or older individuals [94]. This limits the ability of the 
model to extrapolate predicted PK to other pediatric populations. Moreover, top-down PBPK 
models must also rely on external validation sets. Without these external validation sets, the 
model predictions are validated based on the same data set that was used to develop the 
model. An example of the challenge in modeling with in vivo clearance is shown by Yang et 
al. In their PBPK model, two pediatric data sets were discarded due to failure to correctly 
model methylphenidate in adolescents [95].  
The bottom-up method is the second approach that can be used for PBPK modeling. 
Bottom-up PBPK models rely on in vitro data to calculate clearance within the model. This 
method generates clearance by scaling the in vitro data with cellular enzyme expression and 
ontogeny. These input parameters are incorporated into a model that also includes age-
dependent physiological data. Since this type of model utilizes intrinsic clearance by a 
specific enzyme, changes can be simulated across a wide range of ages. In addition, it can 
also predict DDI and the fraction of drug metabolized by a specific isoform [96]. This method 
relies heavily on enzyme expression and the ontogeny of individual enzymes and 
transporters since in vitro data are utilized for generating predicted clearance. Without 
accurate experimentally derived abundance and ontogeny data, the model will not be able to 
predict PK parameters. To date, bottom-up pediatric PBPK models have exclusively 
employed data generated with recombinant enzymes. When data generated with adult HLM 
were utilized in a bottom-up PBPK model to predict the PK of morphine, the model under-
predicted morphine clearance by over 60% in children [97], which clearly  demonstrates a 
need for improving the bottom-up pediatric PBPK models. It has been shown that oxidative 
enzymes in pediatric tissues can metabolize a drug at a different rate and with a different 
percent contribution compared to adult tissues [63]. Thus, scaling intrinsic clearance from 
adult HLM introduces errors that potentially could be overcome by using pediatric HLM.  
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CURRENT DIRECTIONS AND DISSERTATION PROJECT 
In March 2012, the FDA Clinical Advisory Committee concluded that PBPK modeling 
should be incorporated into pediatric drug development programs [98]. PBPK models are a 
useful tool to evaluate drug disposition and clearance in adults. Since its acceptance by the 
FDA, the use of PBPK modeling in pediatric drug development is rising, with specific 
emphasis on understanding the role of DMEs and transporters in defining the PK of drugs 
[99-104]. This modeling approach aids in optimizing trial design and dose selection, and 
permits drawing fewer samples from children, whose smaller blood volumes limit the use of 
comprehensive serial sampling. It also requires fewer subjects, thereby reducing the cost, 
and more importantly exposure of this vulnerable population to experimental drugs.  
Bottom-up PBPK modeling is the most promising approach to determine pediatric PK 
without conducting extensive clinical studies involving children. However, previous research 
suggests that significant refinement is necessary. The overarching strategy developed for 
this dissertation research has certain unique aspects that have been applied to the bottom-
up PBPK modeling for the first time (Figure 1. 9). Since these are the first set of studies 
being pursued to test the novel approach, the scope of the research was limited to drugs, 
voriconazole and silidenafil, that are 
predominantly cleared by oxidative metabolism. 
The strategy involves characterizing metabolic 
clearance in an in vitro system from adult 
tissues. Then a bottom-up PBPK model is 
constructed and refined using an iterative 
process until the predictions of the model 
converge with the observed clinical PK values in the adult population. Once validated, this 
process is adpated for children using in vitro data generated from pediatric tissues and then 
a preliminary validation of the pediatric model is made with available pediatric clinical data. 
 
Figure 1. 9 Proposed Pediatric Drug 
Development algorithm.  
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PROJECT RATIONALE AND SPECIFIC AIMS 
The objective of this research was to develop a translational technique to evaluate 
how age-dependent differences in DMEs affect the PK of drugs. The approach involved 
studying differences in metabolism between adults and specific pediatric populations using 
hepatic and intestinal tissue, and correlating these in vitro data to in vivo clearance and 
bioavailability by developing a PBPK model so as to predict PK in target pediatric populations 
from PK in the adult population.  
In order to validate this novel approach, two drugs, voriconazole and sildenafil, were 
chosen based on their exclusive clearance through oxidative enzymes. First, a retrospective 
bottom-up PBPK model was created for voriconazole, and the model was validated against 
clinically observed data on voriconazole from pediatric trials in children 2-12 years of age. 
After validating this strategy in children, this method was applied prospectively to premature 
neonates receiving sildenafil to not only determine how the ontogeny of DMEs affects 
sildenafil PK, but to extend this technique to the neonatal population.  
The central hypothesis of the proposed research is that (i) age-dependent changes 
in the pattern and extent of expression in CYP and FMO enzymes play a pivotal role in 
determining the clearance and exposure of sildenafil and voriconazole in the neonatal and 
pediatric populations, respectively; (ii) clearance and bioavailability of drugs cleared 
predominantly by oxidative metabolism can be predicted in neonates and children using a 
PBPK model based on relevant in vitro metabolism data.  
AIM 1. Characterize the oxidative metabolism of sildenafil by hepatic microsomes from the 
neonatal population, and determine the expression of relevant oxidative enzymes (e.g. 
CYP3A, CYP2C, and FMO) in these tissues.  
1.1 Determine the rate of sildenafil metabolism by CYP3A, CYP2C, and FMO (intrinsic 
clearance Vmax/Km) by hepatic microsomes in neonatal subjects.  
1.2 Assess the relative contribution of individual enzymes to sildenafil clearance.  
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1.3 Establish CYP3A, 2C, and FMO gene and protein expression in neonatal hepatic 
samples by qRT-PCR and quantitative mass spectrometric analyses, respectively.  
AIM 2. Determine the gene and protein expression of CYP3A, CYP2C9, CYP2C19, and FMO 
enzymes in intestinal tissue, as was done with hepatic tissue in children (2-10 years), and 
optimize an in vitro method to study intestinal intrinsic metabolic clearance of voriconazole.  
2.1 Determine CYP3A4, CYP2C, and FMO gene expression in hepatic and intestinal 
samples by qRT-PCR. 
2.2 Quantify protein expression of the aforementioned enzymes in hepatic tissue by 
quantitative mass spectrometric analyses. 
2.3 Optimize an in vitro method to measure the rate of voriconazole metabolism utilizing 
a small sample of pediatric intestinal tissue. 
AIM 3. Develop PBPK models using in vitro data from Aims 1 and 2 to describe the PK 
behavior of sildenafil and voriconazole in neonates and children ages 2-10, respectively.  
3.1 Develop a PBPK model to determine the clearance of sildenafil in neonates based on 
available clinical data, known and experimentally derived ontogeny of organs and 
enzymes, as well as in vitro metabolism data generated in Aim 1 
3.2 Develop a PBPK model to determine the oral bioavailability of voriconazole in adults 
and children based on available clinical data and in vitro metabolism data generated 
in Aim 2 
3.3 Validate the results from Aims 3a & b by comparing predicted outcomes to observed 
pediatric clinical data 
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CHAPTER 2 
A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts 
Intestinal First-pass Metabolism in Children 
 
OVERVIEW 
Background & Objectives  
The effect of ontogeny in drug metabolizing enzymes on pediatric pharmacokinetics 
is poorly predicted. Voriconazole, a potent antifungal, is cleared predominantly via oxidative 
metabolism and exhibits vastly different pharmacokinetics between adults and children. A 
physiologically based pharmacokinetic (PBPK) model was developed integrating hepatic in 
vitro metabolism data with physiological parameters to predict pharmacokinetic parameters 
of voriconazole in adult and pediatric populations. 
Methods  
Adult and pediatric PBPK integrated voriconazole physicochemical properties with 
hepatic in vitro data into the models. Simulated populations contained 100 patients (10 trials 
with 10 patients each). Trial design and dosing was based on published clinical trials. 
Simulations yielded PK parameters which were compared against published values and 
visual predictive checks were employed to validate models.  
Results  
All adult models and the pediatric intravenous model predicted pharmacokinetic 
parameters that corresponded with observed values within a 20% prediction error, whereas 
  
This chapter has been published in Clinical Pharmacokinetics (2014 Dec;53(12):1171-82) 
and is presented in the style of that journal. 
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the pediatric oral model predicted an oral bioavailability 2-fold higher than observed ranges. 
After incorporating intestinal first-pass metabolism into the model, the prediction of oral 
bioavailability improved substantially, suggesting that voriconazole is subject to intestinal 
first-pass metabolism in children, but not adults.  
Conclusions  
The PBPK approach utilized in this study suggests a mechanistic reason for 
differences in bioavailability between adults and children. If verified, this would be the first 
example of differential first-pass metabolism in children and adults. 
Key Points 
• Previous clinical trials have shown marked differences in voriconazole 
pharmacokinetic parameters between adults and children without providing a 
mechanistic basis for these disparities. 
• The simulations using the PBPK models suggest that intestinal first-pass metabolism 
is an important factor that contributes to lower oral bioavailability of voriconazole in 
children compared to adults.  
• This study provides a new paradigm for predicting therapeutic doses in children, in 
which adult in vitro metabolism are related to in vivo pharmacokinetics to create and 
validate a PBPK model and then adapted to utilize pediatric in vitro metabolism to 
predict pediatric pharmacokinetics.  
• The most important use of this approach is to develop safe and effective pediatric 
dosing regimens, despite limited clinical data 
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INTRODUCTION 
Voriconazole (Vfend ®; Pfizer, New York, NY) is a potent triazole antifungal 
commonly used in patients with life-threatening invasive fungal infections [1]. Since its 
approval in 2002, studies demonstrated that voriconazole improves survival and produces 
fewer severe adverse effects compared to amphotericin B, the original standard of care for 
invasive aspergillus infections [2], making it first-line treatment for patients of all ages. 
However, voriconazole displays wide variability and significant pharmacokinetic differences 
in clearance, exposure, and bioavailability between adults and children, with no consensus 
on pediatric doses that match adult exposures, thereby limiting successful therapy [3-6].  
Voriconazole is extensively metabolized by the liver, with only 2% of the parent 
excreted in urine [7]. Oral bioavailability of voriconazole in adults is ~ 96%, while pediatric 
bioavailability is 45- 66% [4, 6, 7]. Voriconazole exhibits 3-fold higher clearance in pediatric 
patients compared to adults, and over a narrow dose range of 3-5 mg/kg, it displays non-
linear pharmacokinetics in adults but not in children suggesting saturation of metabolic 
enzymes [6, 7]. Developmental changes in these drug metabolizing enzymes (DMEs) have 
been implicated in the pharmacokinetic differences between children (aged 2-10) and adults 
[8-11]. In vitro studies in our laboratory revealed developmental changes in these DMEs 
showing that two cytochrome P450 (P450) enzymes, CYP3A4 and CYP2C19, and flavin-
containing mono-oxygenase (FMO) 3 contribute to 50%, 35% and 15% of voriconazole 
metabolism in adults, respectively, versus 20%, 50% and 30% in children. Hepatic intrinsic 
clearance (Clint) scaled to in vivo clearance accounted for 80% of clinically observed values, 
suggesting that the above differences conferred the increased clearance of voriconazole in 
children [12]. 
Although scaling of intrinsic clearance values explains differences in voriconazole 
clearance between adults and children, it does not provide insights into differences in other 
pharmacokinetic parameters between these two populations. This study describes a 
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physiologically based pharmacokinetic (PBPK) model for voriconazole that integrates in vitro 
hepatic metabolism data, voriconazole physicochemical properties, and physiologic 
parameters associated with adult and pediatric populations. The models were tested against 
clinically observed data. The model predictions of pharmacokinetics in children led to a 
hypothesis that intestinal first-pass metabolism of voriconazole in children would explain its 
lower bioavailability in children compared to adults. PBPK modeling has proven to be useful 
in understanding mechanisms underlying the differences in pharmacokinetics of 
voriconazole between adults and children, and can be applied to predict the influence of 
drug-drug interactions, genetic polymorphisms, and other factors on voriconazole disposition 
in children.  
MATERIALS AND METHODS 
Model Structure 
Metabolic assays to generate hepatic in vitro pharmacokinetic parameters, Vmax and 
Km, for voriconazole from healthy adult and pediatric tissues were adapted from previously 
published work [12].  
Intial models were created in Berkeley Madonna (version 8.3.18; University of 
California at Berkeley) to assess linearity. A perfusion-limited model (Supplementary Figure 
2.1) incorporated physicochemical properties (Table 2. 1), with tissue distribution 
compartments based on published data [13]. Age-dependent physiologic characteristics 
were averaged between males and females [14, 15]. To assess linearity, multiple 
intravenous infusion doses of 3 to 6 mg/kg were simulated for both adult and pediatric 
populations and AUC was calculated using Phoenix WinNonlin (version 6.2, Certara). The 
proportionality of the models was assessed by dividing the AUC of 4-, 5,- and 6 mg/kg 
doses by AUC of the 3 mg/kg dose, and comparing it to the fold change in dose. Finally, 
clearance and bioavailability were assessed for these simulations.  
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Next, a population-based model was developed employing Simcyp (version 12.1; 
Certara) using a step-wise approach (Figure 2. 1). A perfusion-limited model incorporating 
adult clearance values and physiologic characteristics was created first using adult 
intravenous infusion dosing of 3-, 4-, and 5 mg/kg infused over 1-hour and dispensed every 
12 hours for 7 days. Fasting oral dosing was simulated for 200 mg dispensed every 12 
hours for 7 days. Similarly, a pediatric model was created utilizing in vitro Vmax and Km 
generated from pediatric (2-10 years old) liver microsomes and the Simcyp Paediatric 
Simulator®. Pediatric intravenous infusion simulated doses of 4- and 6 mg/kg infused every 
12 hours for 7 days at a maximal rate of 3 mg/kg/hr and oral dosing of 4-, 6- and 8 mg/kg 
dispensed every 12 hours for 4 days. Trial designs and dosing were based on published 
clinical trials and simulated populations contained 100 patients each (10 trials with 10 
patients per trial) [5, 16, 17]. Simulations integrated the age ranges and male to female 
ratios recorded for each respective trial. Physiologic characteristics were predicted applying 
Method 1 (Poulin and Theil). Method 1 best describe unionized compounds in plasma, such 
as voriconazole, and predict compound distribution based on tissue-specific parameters [18, 
19]. Physicochemical properties and absorption values, along with in vitro data, were 
combined into a full PBPK model using whole organ metabolic clearance. In vitro 
voriconazole metabolic rates generated are listed in Table 2. 1 along with other pertinent 
parameters employed in model development [4, 7, 12, 20, 21].  
Model Validation 
Simulations yielded pharmacokinetic parameters which were compared against 
published values expressed as geometric means. First, models were validated by comparing 
the predicted pharmacokinetic parameters against observed pharmacokinetic parameters. 
Given the immense clinical variability in voriconazole pharmacokinetics in both the adult and 
pediatric population, differences <50% were considered acceptable. If the predicted 
parameters were within 50% of the observed values, then visual predictive checks were 
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employed to confirm that the model predicted observed concentrations and standard 
deviation. Concentration-time profiles from a food effect trial conducted in healthy volunteers 
and a trial in immunocompromised children were digitized using GetGraph data digitizer 
version 2.25.0.32. Observed voriconazole concentrations were superimposed on predicted 
mean and 90% confidence intervals. Lastly, a distributional analysis of hepatic and intestinal 
CYP enzymes from simulated trials was generated [22]. 
Sensitivity Analysis 
Sensitivity analyses, utilized to assess factors that could influence model 
performance, were performed for gastric emptying time and small intestinal transit time, both 
of which could significantly influence pharmacokinetic parameters after enteral absorption. 
Both values were replicated with a 10-fold change in the mean to determine if either 
parameter significantly affected pertinent pharmacokinetic parameters of AUC and Cmax. 
RESULTS 
Simulations to Assess Linearity 
In Berkeley Madonna, non-linear behavior was predicted by the adult model as 
evidenced by greater than proportional increase in AUC (1.7-, 2.7-, and 4.2-fold) when the 
doses increased from 3- to 6 mg/kg (1.3-, 1.7-, and 2-fold, respectively). In contrast, the 
pediatric model displayed linear kinetics with proportional increase in AUCs (1.4-, 1.8-, and 
2.3-fold, respectively), (Supplementary Figure 2.2). Predicted clearance was 3.1 and 6.0 
mL/min/kg, which were within 25% and 11% of the published values of 2.0 and 6.7 
mL/min/kg, respectively. Preliminary analysis of oral bioavailability yielded a prediction of 
88% for adults and approximately 100% for children, showing appropriate prediction for the 
adults but over-prediction for children. Predictions in the adult and pediatric populations, 
using Berkeley Madonna, utilized average physiologic and in vitro parameters, and omitted 
ranges and standard deviations. Due to this limitation and the unusual preliminary result of 
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predicting nearly double the observed pediatric oral bioavailability, a population-based 
approach was deemed essential. 
Model Simulations in Healthy Adult Volunteers 
Initial population-based model development utilized standard Simcyp parameters 
from the healthy adult volunteer simulator. The model was customized for voriconazole 
(Figure 2. 2) based on specific hepatic in vitro metabolism and physicochemical properties 
(Table 2. 1). The pilot simulations tested both intravenous infusions and oral doses as 
described in the Methods Section. The output demonstrated a biphasic profile indicating a 
two-compartment model, consistent with published data [4] 
Initially, simulations were used to test the model’s capacity to describe voriconazole 
plasma concentration after multiple intravenous infusion doses in adults. Table 2. 2 lists 
pharmacokinetic parameters predicted by the model relative to corresponding published 
values. Model output for intravenous infusions generated a predicted clearance value of 2.4 
mL/min/kg (range 1.0-4.8 mL/min/kg), agreeing well with the clinically observed clearance of 
2.0 mL/min/kg, a 17% prediction error. Predicted Vd ranged from 3.39-3.65 L/kg, which 
differed from the observed values of 4.6 L/kg by 20.7-26.3%. The prediction error for AUC 
and Cmax in adults increased from 2.6% to 82% and 2.6% to 39.7%, respectively, as the 
dose decreased from 5 to 3 mg/kg. This is due to the known inability of the model to 
simulate non-linearity of metabolism. For the 200 mg oral dose in adults, the predicted AUC 
and Cmax values corresponded well with observed values (Table 2. 3). The model predicted 
the mean oral bioavailability of 83% in adults, which agrees well with the clinically observed 
mean value of 87%. The predicted 90% confidence interval for oral bioavailability was 69-
93%, matching the clinically observed range of 75-96% [23-25]. Thus, with the exception of 
AUC prediction at the low dose of 3 mg/kg, the errors for predictions of all pharmacokinetic 
parameters were within the accepted limit of <50%, indicating the validity of the model.  
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After validating the predictions of the pharmacokinetic parameters, the plasma 
concentrations of the intravenous infusion and oral simulations were overlaid on observed 
data for visual predictive checks. Figure 2. 3a shows plots of plasma concentrations as a 
function of time for 4 mg/kg dose, yielding good fit to observed plasma concentration. 
Despite differences in the visual predictive checks for an oral dose of 200mg, the 90% 
confidence interval of predicted plasma concentrations encompassed most of the variability 
(shown as standard deviation) observed in clinical trials in both dosing regimens (Figure 2. 
3b). The model prediction of the individual plasma concentrations for oral dosing captures 
the concentrations at the early time points, but not the concentrations at later time points 
due to the software’s inability to simulate non-linearity. Despite this, the model accurately 
predicted the pharmacokinetic parameters, including AUC, Cmax, and bioavailability, 
demonstrating that the adult model adequately describes voriconazole in the adult 
population.  
Initial Model Simulations in the Pediatric Population 
Using a similar approach to the adult model, a pediatric model was created by 
integrating appropriate in vitro data and physiologic parameters. The pharmacokinetic 
parameters generated by the pediatric intravenous infusion model are listed in Table 2. 2. 
The model predicted a clearance of 5.0 mL/min/kg (range of 1.3-12.3 mL/min/kg) compared 
to the clinically observed clearance of 6.7 mL/min/kg, representing a 25% error. The value 
for Vd in adults was used, as pediatric-specific Vd value is unavailable. The model predicted 
the values for AUC and Cmax that corresponded well to the observed values with an error of 
2.5-32.3% and 1.0-22.4%, respectively. Simulated AUC of the 8 mg/kg dose was similar to 
pharmacokinetic parameters of the adult 4 mg/kg dose.  
For the oral doses, the predicted AUC and Cmax were overestimated by more than 
100% and 30%, respectively (Table 2. 3). Furthermore, the model over predicted the 
bioavailability by 24-82%, and the values within the 90% confidence interval were 60-94%, 
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nearly 2-fold higher than observed clinical values. The overestimates for AUC and 
bioavailability suggest that the initial model does not adequately account for the factors that 
contribute to poor oral bioavailability, e.g. intestinal permeability and/or first-pass 
metabolism, during the absorption phase.  
The visual predictive checks for the pediatric population are shown in Figure 2. 4a-c 
represent the multiple intravenous infusions at doses of 4-, 6- and 8 mg/kg, respectively. 
These profiles show that the simulated mean concentrations for both doses yielded good fit 
to observed plasma concentrations. Conversely, the calculated profiles for oral 4- and 6 
mg/kg doses (Figure 2. 4d and Figure 2. 4f, respectively) over predict plasma concentrations 
over the entire time period, indicating that the model does not account for all pediatric 
metabolism and/or absorption barriers, at early or later time points. However, the shapes of 
the predicted profiles resemble the shape of the profiles for the observed data, suggesting 
that the absorption parameters are appropriate. 
Incorporation of Intestinal Metabolism Improves Predictions of Oral Bioavailability in 
children 
Since the oral bioavailability of voriconazole in adults is nearly 90%, it is reasonable 
to conclude that first-pass metabolism is negligible/absent in this population. Despite 
accounting for the higher hepatic clearance of voriconazole, the pediatric model was unable 
to predict lower oral bioavailability of voriconazole compared to adults. Since Tmax values 
were within 20% of the observed data, the absorption rate constant was ruled out as a 
problem in the model. Therefore, it was hypothesized that the lower oral bioavailability in 
children is due to intestinal first-pass metabolism. In order to test the hypothesis, a 
hypothetical intestinal whole organ clearance was incorporated into the pediatric model. A 
range of Clint values, based on hepatic Vmax and Km data from in vitro experiments, were 
tested. Km values were retained in each simulation since values from adult and pediatric 
hepatic microsomal in vitro experiments were similar. The initial unchanged Vmax was 
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subsequently reduced until simulated pharmacokinetic parameters fit the observed ranges 
(Supplementary Table 2. 1).  
Incorporating intestinal clearance into the model reduced prediction errors for AUC 
by ~70% and for Cmax by over 50%. Most importantly, the predicted values for oral 
bioavailability decreased from 82% to 51% for both doses, with a 90% confidence interval 
range of 27-76%. Thus, the predicted bioavailability better corresponded to the clinically 
observed bioavailability range of 44-66%. Finally, visual predictive checks of the refined 
pediatric model, shown in Figure 2. 4e & Figure 2. 4g, demonstrate that the simulated 
concentrations for both oral doses better predict the observed concentrations, with most of 
the observed data superimposing over the predicted values and the 90% confidence 
intervals incorporating observed variability.  
DISCUSSION 
Despite significant progress in understanding the ontogeny of drug metabolizing 
enzymes [9-11, 26], our ability to use this knowledge to predict the pharmacokinetic 
behavior of drugs is far from adequate. Voriconazole is commonly prescribed in vulnerable 
pediatric populations despite a lack of information on optimal dosing based on clinical 
evidence. Limited clinical data available for voriconazole disposition in children demonstrate 
that the drug is cleared ~3-fold more rapidly and has ~50% lower oral bioavailability in 
children compared to adults, with significant inter- and intra-individual variability. This type of 
information has led to therapeutic dose monitoring in children to achieve a concentration 
range of 1-5.5 µg/mL, and upward adjustment of doses from 4 mg/kg (adult dose) to 9 
mg/kg to reach this range [27, 28]. Notably, these doses are higher than the recommended 
doses in regulatory documents for voriconazole. This approach must be replaced with a 
more rigorous approach to achieve safe and effective dosing for pediatric populations.  
The allometric scaling performed by Yanni et al. showed that hepatic microsomal 
data, obtained using tissues from children (2-10 years of age) and adults, could predict the 
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striking differences in in vivo clearance of voriconazole between these two populations [12]. 
This work was able to show that differences in contribution and capacity of the enzymes 
allow children to metabolize voriconazole more efficiently, leading to the increased 
clearance. However, this work did not provide an explanation for the differences in the oral 
bioavailability. The PBPK model developed in the present study represents a further 
refinement by integrating the ontogeny of DMEs with changing physiologic parameters. 
We demonstrate the proof of concept for this approach using voriconazole as a 
model drug because (i) clinical pharmacokinetic data are available for adult and pediatric 
populations for intravenous and oral doses, (ii) the pharmacokinetic behavior in children is 
different from adults with respect to clearance and oral bioavailability, and (iii) the current 
approaches have not produced a satisfactory dosing strategy for children. In this approach, 
after confirming the dichotomy of pharmacokinetic behavior between two populations in 
Berkeley Madonna, Simcyp was utilized due to the availability of both a standardized adult 
and pediatric populations. Differences in physiology between these two populations were 
included in Simcyp; therefore only those parameters reflecting age-related changes in DMEs 
would be considered.  
It has been shown previously that voriconazole is predominantly metabolized by 
CYP3A4, CYP2C19, and FMO3, all of which are highly expressed in the liver and are 
localized in the endoplasmic reticulum [29-31]. Therefore, metabolism of voriconazole by 
hepatic microsomes was an appropriate input parameter for the model. Voriconazole is a 
lipophilic compound of moderate size with no net charge at physiologic pH values, and thus 
its translocation across cell membranes should occur via passive diffusion without the 
assistance of transporters. The simulated output of the PBPK model corresponded with 
previously published pharmacokinetic data in adult subjects, which determined that 
voriconazole conforms to a two-compartment model [4]. Furthermore, the calculated AUC, 
Cmax, and Vd values of intravenous infusions in adult subjects were in agreement with 
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published clinical data demonstrating that the applied physiologic and metabolic 
characteristics could predict clearances and that the liver is the main organ of elimination. In 
the multiple oral dosing regimens, pharmacokinetic values were in accordance with those 
published in the literature. The model was also able to predict bioavailability in adults [7].  
However, the bioavailability of voriconazole predicted by the initial pediatric model 
(60-94%) was strikingly different from the published values of 45-66% [5-7], and closer to 
the high oral bioavailability observed in adults. Multiple clinical trials and population 
pharmacokinetic analyses have not revealed the underlying mechanism that contributes to 
the difference in bioavailability between children and adults. Many of these reports 
implicated an increased ratio of “body mass to liver volume” in children compared to adults 
as a potential reason for differences in clearance and disposition. In apparent agreement 
with this hypothesis, the results reported by the Thakker laboratory confirmed that higher 
hepatic Vmax conferred an increased clearance [12]. Simple allometric scaling of this work 
determined that in vitro clearance parameters could accurately determine liver clearance. 
Consequently, higher hepatic clearance was suspected to be the reason for the decreased 
bioavailability. The initial pediatric model output included only hepatic metabolism of 
voriconazole to confirm that an increased Vmax conferred higher clearance. The model 
demonstrated that clearance in both adult and pediatric population agreed with published 
reports, but it was unable to predict bioavailability in children, even after taking into account 
the increased hepatic clearance and “liver to body mass” ratio. Since the pharmacokinetic 
parameters of the intravenous model and the Tmax of the oral models were accurate, this 
finding suggested that intestinal first-pass metabolism may contribute to the lower oral 
bioavailability of voriconazole in the pediatric population.  
One of the first reports to demonstrate that intestinal first-pass metabolism by 
CYP3A4 plays a critical role in overall first-pass metabolism was conducted in a study by 
Kolars et al. [32]. Prior to this pivotal study, cyclosporine metabolism was widely associated 
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with the liver, but not the intestine [32]. Their evidence, based on studies with anhepatic 
patients during liver transplant procedure, definitively demonstrated that the intestine can 
play a major role in first-pass metabolism. Although Walsh et al. speculated that 
developmental differences in intestinal enzyme activity could be responsible for the 
decrease in voriconazole bioavailability [5], experimental or theoretical evidence that 
intestinal first-pass metabolism of voriconazole reduces oral bioavailability in children is 
lacking. In order to model the intestinal first-pass metabolism, the apparent Vmax and Km 
generated from adult and pediatric human liver microsomes were considered as a starting 
point to establish a hypothetical intestinal Clint. It is reasonable to assume that voriconazole 
would have similar affinity for its metabolizing enzymes expressed in different tissues. 
Therefore, the Km was fixed, but the Vmax was adjusted to find the appropriate rate of 
metabolism in the intestines to account for the lower observed bioavailability. After 
incorporating a hypothetical intestinal metabolism into the pediatric PBPK model, the 
bioavailability of voriconazole was within the range published in the literature, suggesting 
that the intestine could play an important role in voriconazole metabolism.  
The successful modeling of pediatric oral bioavailability that implicates intestinal first 
pass metabolism requires that the source of higher Vmax of children compared to adult be 
investigated. According to Fakhoury et al., increased CYP3A and P-gp expression in 
children allude to a marked difference in the “intestinal pie” compared to adult profiles 
reported by Paine et al. [33, 34]. To our knowledge, pediatric intestinal enzyme content and 
activity has not been thoroughly studied. So, abundance data from the adult and pediatric 
simulated populations (n=400/group) were entered into SigmaPlot (version 10.0; Systat 
Software) and a histogram with 10 bins was created for hepatic and intestinal CYP3A4 and 
CYP2C19. A distributional analysis was performed to determine if differences in enzyme 
content could account for pharmacokinetic differences of voriconazole (Figure 2. 5). In both 
populations, CYP3A4 content was higher than CYP2C19 in intestinal and hepatic tissues, 
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and hepatic abundance of both enzymes was higher as compared to the intestine, which is 
consistent with literature reports. This contrasts with the study revealing that (i) CYP2C19 
contributes towards a greater percentage of voriconazole metabolism and (ii) a trend that 
pediatric CYP2C19 content was higher compared to adults [12]. Furthermore, despite 
limited published data on pediatric intestinal CYP2C19 enzyme expression, the distribution 
plots showed age-dependent differences in intestinal enzyme expression [33, 35]. Clearly 
the model and distributional analysis highlight the need to determine both the expression 
and activity of DMEs in the intestine as a function of age.  
Although incorporation of the first-pass intestinal metabolism of voriconazole appears 
to improve the ability of the model to predict the oral bioavailability of the drug in children, it 
does not rule out a potential role of physiological factors in bioavailability. As voriconazole is 
traditionally considered a low extraction compound due to its high bioavailability in adults, 
blood flow is not expected to cause a large difference in its clearance, which implies that 
gastric emptying time and small intestinal transit time may be implicated as important 
parameters affecting rate of drug absorption and systemic exposure in children [36-39]. A 
sensitivity analysis was conducted to determine if intestinal physiology could influence 
voriconazole bioavailability in the models. Figure 2. 6 shows no changes in AUC and Cmax 
associated with both a 10-fold increase and decrease in small intestinal transit time (data 
not shown for gastric emptying time), suggesting that they do not influence absorption. 
One limitation was the software’s inability to predict non-linear pharmacokinetic 
behavior of voriconazole in adults, since Vmax and Km are not input options. This is due to the 
requirement of Simcyp to employ whole organ clearance instead of enzyme kinetic 
parameters. Hence the model overestimated concentrations at later time points because of 
the inability to account for changes in metabolic rate as concentrations decrease over time. 
However, the adult model was accepted due to the model’s ability to accurately predict 
observed adult pharmacokinetic parameters within 50% of observed values. For the 
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pediatric model, visual predictive checks showed greater accuracy than the adult model, 
which is not surprising as voriconazole displays linear pharmacokinetics in children and non-
linear pharmacokinetics in adults over the same dose range.  
Lastly, a published population pharmacokinetic model attempted to connect the 
sparse data from pediatric clinical trials to improve dosing [4]. However in a follow-up clinical 
trial assessing these dosing recommendations, it was concluded that they were inadequate 
[3, 40]. The PBPK models presented in this paper are the first to identify a potential 
underlying cause for the pharmacokinetic differences of voriconazole in children compared 
to adults.  
CONCLUSION  
The contribution of this study is to test a novel paradigm in developing a rational 
strategy for pediatric dosing of drugs extensively cleared by metabolism. By relating in vitro 
metabolism to clinical data, a “bottom-up” approach to finding doses can be validated and 
then used to prospectively pick a dose or predict drug-drug interactions [41]. A large number 
of pediatric clinical trials fail due to inadequate dose selection and lack of response. [42]. 
Modeling has successfully been utilized to determine optimal doses and increase the 
efficacy of pediatric clinical trials [43, 44]. This study’s algorithm provides an appealing 
approach to modeling pediatric drug disposition that can improve prediction of 
pharmacokinetic parameters in children, and thus reduce ineffective therapy and the need 
for costly and uncomfortable therapeutic drug monitoring.  
In addition, these models are the first important step in identifying underlying 
mechanistic reasons for the pharmacokinetic differences seen between adults and children. 
The true significance of this work lies in the fact that our modeling approach suggests age-
dependent differences in intestinal enzymatic composition with major impact on drug 
bioavailability. Further, it provides a clear path for future studies to investigate this very 
interesting possibility that children have a stronger intestinal barrier to oral drug absorption. 
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Table 2. 1 Summary of Voriconazole Intrinsic Pharmacokinetic Parameters and 
Physiochemical Properties Used for Model Development. Fa fraction of voriconazole 
absorbed in intestines; Vd volume of distribution; Plasma fu fraction unbound in the plasma; 
fu,Mic fraction unbound in microsomal incubation; Clint intrinsic clearance; CV coefficient of 
variation 
 
Parameter Input 
Molecular Weight (g/mol) 349.3 [7] 
Compound Type Monoprotic Base [20] 
LogP 2.56 [21] 
pKa 1.76 [20] 
Absorption Model 1st order 
Fa 0.96 (CV: 10%) [20] 
Ka (1/h) 0.849 (CV: 40%) [4] 
Distribution Model Full PBPK Model 
Prediction Model Poulin and Theil (Method 1) 
Vd (L/kg) 4.6 [7] 
Plasma fu 0.42 [7] 
fu,Mic predicted 0.711 
Renal Clearance (L/h) 0.096 [7] 
Elimination: Whole Organ Clearance 
 Adult Pediatric 
Hepatic Clint (μL/min/mg) 
[12] 
4.3 10.9 
Hepatic CV (%) 35.0 82.0 
 
 
 
Table 2. 2 Summary of Voriconazole Pharmacokinetic Parameters in the Pediatric and Adult Populations for Multiple 
Intravenous Infusion Dosing Regimens. 
  AUC Cmax tmax 
Population Dosing Observed Simulation Error Observed Simulation Error Observed Simulation Error 
  (mg/kg) (mg●h/L) (mg●h/L) (%) (mg/L) (mg/L) (%) (hours) (hours) (%) 
Adult 3 13.9 25.3 82.0 3.0 4.2 39.7 1.1 1.0 10.3 
Adult 4 29.5 33.2 12.6 5.4 5.5 2.6 1.0 1.0 7.7 
Adult 5 43.4 42.2 2.6 7.2 7.0 2.6 1.0 1.0 5.9 
Pediatric 4 11.8 15.7 32.3 3.2 3.2 1.0 1.4 1.4 0.0 
Pediatric 6 22.9 23.5 2.5 4.4 4.2 4.2 2.0 2.0 0.5 
Pediatric 8 29.8 30.6 2.7 5.8 4.5 22.4 2.8 2.7 3.6 
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Table 2. 3 Summary of Voriconazole Pharmacokinetic Parameters in the Pediatric and Adult Populations for Multiple Oral 
Dosing Regimens. 
 
 
 
 
Population Dose 
AUC Cmax tmax F 
Observed Simulation Error Observed Simulation Error Observed Simulation Error Observed Simulation Error 
(mg●h/L) (mg●h/L) (%) (mg/L) (mg/L) (%) (hours) (hours) (%) (%) (%) (%) 
Adult 
200 
mg 
19.3 19.1 0.8 2.0 2.1 5.0 1.5 1.5 2.0 87.0 83.0 4.6 
Pediatric 
(- Intestinal 
Metabolism) 
4 
mg/kg 
5.2 11.6 123.4 1.2 1.6 35.8 1.4 1.2 19.6 66.0 82.0 24.2 
Pediatric 
(+ Intestinal 
Metabolism) 
4 
mg/kg 
5.2 7.2 38.1 1.2 1.0 16.0 1.4 1.2 19.6 66.0 51.0 22.7 
Pediatric 
(- Intestinal 
Metabolism) 
6 
mg/kg 
8.4 17.5 108.8 1.8 2.4 37.4 1.3 1.2 14.2 65.1 82.0 26.0 
Pediatric 
(+ Intestinal 
Metabolism) 
6 
mg/kg 
8.4 10.8 29.1 1.8 1.5 14.8 1.3 1.2 14.2 65.1 51.0 21.7 
5
5
 
 
 
Supplementary Table 2. 1 Summary of Voriconazole PK Parameters in the Pediatric Populations for the Multiple Oral Dosing 
Regimens with Differing Intestinal Whole Organ Clearance Values Compared Against the Observed Data. Observed data was 
reported by Walsh et al. [5]. 
 
 
 
 
 
 
 
 
 
 
 
 
Dose 
 AUC Cmax F 
Clint  Observed Simulation Error Observed Simulation Error Observed Simulation Error 
(μL/min/mg) (mg*h/L) (mg*h/L) (%) (mg/L) (mg/L) (%) (%) (%) (%) 
4 mg/kg 
10.9 
5.2 
3.5 31.9 
1.2 
0.5 58.4 
66.0 
28.0 57.0 
5.5 5.3 1.5 0.7 38.0 39.0 40.1 
3.7 6.3 22.1 0.9 25.3 46.0 29.3 
2.7 7.2 38.1 1.0 16.0 51.0 21.7 
2.2 7.7 48.0 1.1 10.0 54.0 17.1 
6 mg/kg 
10.9 
8.4 
5.3 36.8 
1.8 
0.7 58.5 
65.1 
28.0 57.0 
5.5 7.9 5.8 1.1 38.1 39.0 40.1 
3.7 9.5 13.3 1.3 25.6 46.0 29.3 
2.7 10.8 29.1 1.5 14.8 51.0 21.7 
2.2 11.5 37.5 1.6 9.7 54.0 17.1 
5
6
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Figure 2. 1 Experimental Workflow for the Bottom-up Approach to Scaling 
Voriconazole from Adults to the Pediatric Population.  
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Figure 2. 2 Compound and PBPK Model Structure. The figure includes the compound 
structure as well as the model structure. The model structure defines all organ 
compartments and blood flow that were utilized in the simulations. Hashed arrows indicate 
dosing compartments, including intravenous and oral regimens. Thick black, downwards 
arrows indicate elimination from kidneys and liver for both the adult and pediatric 
populations and from the intestines in the pediatric population. 
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Figure 2. 3 Adult Intravenous and Oral Visual Predictive Checks. Concentration versus 
time profiles for (A) 4 mg/kg intravenous (infusion) dose and (B) 200 mg oral dose. The 
squares represent observed data with the associated standard deviation. The solid line 
represents the simulated mean concentrations as predicted by the PBPK model for adult 
population, and the dashed lines show the simulated 90% confidence interval. Adult visual 
predictive checks were based on the dosing regimen reported by Purkins et al. [16, 17] 
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Figure 2. 4 Pediatric Intravenous and Oral Visual Predictive Checks. Concentration 
versus time profiles for an intravenous dose of (A) 4 mg/kg, (B) 6 mg/kg, and (C) 8 mg/kg 4 
mg/kg oral dose (D) without and (E) with intestinal metabolism (intestinal clearance of 2.7 
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µL/min/mg), and 6 mg/kg oral dose without (F) and with (G) intestinal metabolism (intestinal 
clearance of 2.7 µL/min/mg). Squares represent the experimental values with the associated 
standard deviation reported by Walsh et al. [5]. The solid lines represent the simulated mean 
and the dashed lines show the simulated 90% confidence interval. 
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Figure 2. 5 Adult and Pediatric Distributional Analysis of Hepatic and Intestinal 
CYP3A4 and CYP2C19 Abundance. Adults are represented by the dotted lines and 
children (2-12 years of age) are represented by the solid lines. Panels represent the 
abundance of (A) hepatic CYP3A4, (B) hepatic CYP2C19, (C) intestinal CYP3A4, and (D) 
intestinal CYP2C19.  
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Figure 2. 6 Sensitivity Analyses for Small Intestinal Transit Time in Adults and 
Children. These analyses show the effect of alterations in the alpha and beta parameters of 
the Weibull distribution for adult oral dosing on (A) AUC and (B) Cmax, and for pediatric oral 
dosing on (C) AUC and (D) Cmax. 
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CHAPTER 3 
Refining In Vitro Techniques to Predict Intestinal First-pass Metabolism in Children 
 
OVERVIEW 
Intestinal first-pass metabolism can clear a significant portion of an oral drug before it 
reaches the liver, which is traditionally considered the organ of first-pass metabolism. 
However, little is known about how differences in the intestinal expression or activity of drug 
metabolizing enzymes lead to variability in first pass-metabolism between children and 
adults. In this study, an in vitro method was developed to investigate age-dependent 
differences in the expression and functional activity of intestinal oxidative drug metabolizing 
enzymes using frozen intestinal tissue specimens. Assessment of functional activity of 
human intestinal microsomes (HIM), prepared from frozen post-mortem tissues, established 
that a combination of elution and homogenization is required to preserve enzyme function 
and protein content. Results suggested degradation of cytochrome P450 and flavin-
containing monooxygenase (FMO) mRNA/protein as well as functional enzyme activity in 
HIM from post-mortem tissues over surgical tissues. Thus, intestinal tissue samples begin to 
degrade rapidly post-mortem. A comparison of gene expression between post-mortem adult 
and pediatric intestinal tissue samples showed similarity in expression for all enzymes 
except CYP3A4, which was higher in pediatric samples. This study has significant clinical 
relevance as in vitro drug metabolism data generated using healthy intestinal tissue samples 
from pediatric surgical patients can be integrated into a physiologically based 
  
This chapter has been submitted to Drug Metabolism and Disposition and is presented in 
the style of that journal. 
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pharmacokinetic (PBPK) model to predict intestinal first-pass metabolism in children. This 
strategy will be valuable in screening and optimizing new drug candidates for adult and 
pediatric indications.  
INTRODUCTION 
Intestinal first-pass metabolism is an important factor that often determines the 
bioavailability of oral medications. The first drug shown to undergo significant intestinal first-
pass oxidative metabolism was cyclosporine, previously thought to be cleared solely by 
hepatic metabolism [1]. Since then, cytochrome P450-mediated intestinal first-pass 
metabolism has emerged as an important barrier to oral drug absorption. Spurred by the 
findings of CYP3A4-mediated cyclosporine intestinal first-pass metabolism, subsequent 
studies demonstrated that cytochrome P450s in the intestine significantly impact the 
metabolism of many drugs [2-5], and led to the characterization of intestinal cytochrome 
P450 expression, which was presented as an adult intestinal “pie” [6]. However, no such 
intestinal “pie” exists for children despite attempts to describe enzymatic intestinal content in 
neonatal and pediatric populations [7, 8].  
Differences in the oral bioavailability of drugs between adult and pediatric 
populations have raised questions about the intestinal enzymatic composition and activity 
between adults and children. One example of this striking dichotomy is voriconazole. 
Voriconazole oral bioavailability is approximately 90% in adults, suggesting little to no first-
pass metabolism, which allows clinicians to prescribe the same voriconazole dose orally or 
intravenously. Conversely, the bioavailability of voriconazole in children (2-10 years of age) 
is 44-66%, approximately half of that observed in adults, and its clearance is nearly three 
times higher than in adults [9]. Voriconazole is cleared predominantly via oxidative 
metabolism by CYP3A4, CYP2C19, and FMO3 [10, 11]. Physiologically based 
pharmacokinetic (PBPK) models, developed for adults and children by incorporating known 
differences in hepatic enzyme content and activity in these two populations, simulated 
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voriconazole PK after IV dosing in children but were unable to simulate its lower oral 
bioavailability in children after oral dosing [12]. Therefore, we proposed that voriconazole 
undergoes intestinal first-pass metabolism in children but not in adults. Clinical differences in 
voriconazole bioavailability between adults and children warrant consideration of 
maturational changes in intestinal drug metabolizing enzymes, which may exhibit a different 
ontogeny to that observed in the liver [7, 13]. 
Due to ethical constraints, pediatric clinical trials present significant obstacles (such 
as recruitment, safety, and blood volume sampling among others), which limit the ability of in 
vivo studies to clinically test the hypothesis that intestinal first-pass metabolism reduces oral 
bioavailability of voriconazole in children. An alternative approach to test the hypothesis is to 
refine the “bottom-up” pediatric PBPK model for oral dosing of voriconazole (that was 
developed using hepatic voriconazole clearance data) by also incorporating intestinal 
clearance of the drug. To achieve this objective, it is necessary to assess rates of 
voriconazole metabolism by intestinal enzymes and quantitative assessment of the 
expression of relevant enzymes.  
A variety of in vitro techniques have been employed to study intestinal metabolism of 
drugs, but none has been applied to pediatric tissues. The aim of this study was to apply 
and refine existing in vitro techniques to study oxidative metabolism by microsomes from 
pediatric intestinal tissue, so that data can be generated for the development of a “bottom-
up” PBPK model that incorporates intestinal first-pass oxidative metabolism.  
MATERIALS AND METHODS 
Chemicals, Reagents, and Samples.  
Voriconazole, voriconazole N-oxide, midazolam, 1’-OH midazolam, diclofenac, and 
alprazolam were purchased from Sigma-Aldrich (St. Louis, MO). Frozen surgical and post-
mortem duodenal and jejunal tissue from adults (> 18 years) and children (2-8 years) were 
obtained from the NICHD Brain and Tissue Bank for Developmental Disorders (Contract 
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#HHSN275200900001 1C, Ref. No. NO1-HD-9-0011). Discarded surgical jejunal samples 
were procured from patients undergoing gastric bypass at UNC Hospitals.  
Gene Expression.  
Gene expression was measured by isolating mRNA from tissues (25mg) using a 
Qiagen RNEasy Kit, and mixed with iScript™ cDNA Synthesis Kit (Biorad) to synthesize 
cDNA. The cDNA was mixed with iTaq™ Supermix (BioRad) and TaqMan Gene Expression 
Assay for CYP3A4, CYP2C9, CYP2C19, FMO1, FMO3, and FMO4 (Applied Bio-systems). 
Enzyme gene expression was measured by quantitative RT-PCR and normalized to 18s 
rRNA. 
Enterocyte Isolation & Microsome Preparation.  
Elution of enterocytes was performed as previously described [14]. Briefly, 1-2 
inches of intestinal samples were incubated at 4°C in Buffer 1 (1.5mM KCl, 96mM NaCl, 
27mM sodium citrate dehydrate, 8mM KH2PO4, 5.6mM Na2HPO4). After 30 minutes, the 
solution was drained and replaced by Buffer 2 (1.5mM EDTA, 3 units/mL heparin, and 
0.5mM dithiothreitol) and shaken vigorously at 4°C for 15 minutes. The solution containing 
enterocytes was collected and this step was repeated 6-7 times. After centrifugation, the 
pellet was used to isolate human intestinal microsomes (HIM) and protein concentration was 
measured using a BCA assay [15].  
Functional Assay for Metabolic Activity.  
Human intestinal microsomes were validated using a standard midazolam assay. 
Adult and pediatric HIM (0.2 mg/mL) were incubated with midazolam or voriconazole (4 or 2 
μM, respectively), NADPH (1 mM) and MgCl2 (3 mM) in phosphate buffer (pH 7.4) at 37ºC. 
Aliquots (100 μL) were taken at specified time points up to 15 minutes for midazolam or 2 
hours for voriconazole. Aliquots were then quenched with 300 μL ice-cold methanol, 
containing internal standard (alprazolam 0.02 µg/mL for the midazolam assay or diclofenac 
0.3 μM for the voriconazole assay). 
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Metabolite Analysis.  
Samples were analyzed using a LC/MS/MS system consisting of mobile phases (A) 
0.1% formic acid in water and (B) 0.1% formic acid in acetonitrile with a flow rate of 0.7 
mL/min. A Sciex API-4000 triple quadropole mass spectrometer, coupled with a Zorbax SB-
C18 column (2.1 x 50 mm, 5 µm) was used. The samples were ionized using an APCI ion 
source and, following the injection of 10uL of supernatant, the positive ions were monitored 
at the following MRM Q1/Q3 transitions (m/z): 342.3→203.2 for 1’OH midazolam, 
309.3→281 for alprazolam (IS), 366.1→224.2 N-oxide voriconazole, and 296.2→215.1 
diclofenac. 
RESULTS AND DISCUSSION 
In order to determine the optimal method to isolate enterocytes and create 
subcellular fractions from a small amount of pediatric intestinal tissue samples, two 
methods, namely elution and homogenization, were assessed. Since only 1-2 inches of 
frozen pediatric intestinal tissue samples could be acquired, microsomes that were prepared 
utilizing the elution and homogenization methods were first evaluated for retention of 
enzymatic activity. Midazolam was chosen as a probe substrate for validating enzymatic 
activity due to its extensive metabolism by intestinal microsomes [3]. The yield of 
microsomal protein obtained by the elution method (approximately 37.5 µg) was much lower 
compared to the protein yield (approximately 2mg) from homogenization (Inserts i and ii in 
figure 1A). However, microsomes prepared by elution (Figure 1A) retained significantly 
higher enzymatic activity than those isolated by homogenization (Figure 1b) (p < 0.01). Next, 
enterocytes were eluted from a two tissue samples and then after elution the epithelium of 
tissue samples was homogenized assess any remaining activity in tissues after elution. The 
residual activity in the HIM prepared by homogenized tissues post-elution was 
approximately half that of the HIM prepared solely by elution (Figure 1B). Therefore, in order 
to retain high enzymatic activity of microsomes prepared by the elution method while 
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simultaneously generating a sufficient quantity of microsomal protein and capture all 
residual activity, frozen tissue samples were subjected to elution followed by 
homogenization of the epithelial layer. By combining these two methods, 1-2 inches of 
tissue produced HIM with a high protein concentration (~20mg/mL) could be obtained and 
utilized to complete multiple in vitro assays.  
Utilizing another set of intestinal tissues, HIM were prepared by the combined 
method. The formation of 1’-OH midazolam by HIM isolated from adult surgical (ages of 
donors 66 and 81 years) and post-mortem (age of donor 32 years) intestinal tissue samples 
was compared to that formed by HIM isolated from pediatric post-mortem (ages 3-6 years) 
intestinal tissue sample and pooled adult human liver microsomes (HLM; Xenotech, LLC). In 
general, HIM prepared from surgical tissues retained higher enzymatic activity compared to 
those prepared from post-mortem adult or pediatric samples. Degradation of intestinal tissue 
begins within 2 hours post-mortem affecting the enzymatic activity of HIM prepared from 
post-mortem tissues, whereas surgical intestinal tissue samples retain greater enzymatic 
activity even when stored for a prolonged period at -80ºC prior to microsomal preparation 
and functional analysis. Moreover, pediatric HIM yielded lower CYP3A activity compared to 
HIM prepared from adult intestinal specimens (Figure 2a). HIM prepared from surgical 
samples had ~5-fold lower activity compared to the activity of pooled HLM, which is 
comparable to the ~4-fold difference in intrinsic clearance from adult liver and intestinal 
samples taken during organ procurement surgery [3]; conversely adult post-mortem HIM 
and all pediatric HIM exhibited 40- to 100-fold lower CYP3A activity. These data suggest 
that HIM prepared from frozen post mortem intestinal samples, which is the only source of 
pediatric intestinal samples, have inadequate CYP3A (and likely other CYP) activity for 
evaluating metabolic activity. The sample with the highest enzymatic activity was used to 
evaluate voriconazole metabolism in adult intestinal tissue (Figure 2b). Voriconazole was 
metabolized by HIM, but the rate of metabolism was nearly 20-fold slower than that of 
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midazolam. This result is expected as voriconazole undergoes little to no first-pass 
metabolism in adults. Thus, it was clear that the other samples of HIM would not generate 
meaningful data on the metabolism of voriconazole.  
Finally, expression of metabolic enzyme genes in frozen post-mortem intestinal 
tissues was characterized to gain a better understanding of degradation of the tissue post-
mortem. Tissue integrity was assessed by comparing gene expression between post-
mortem intestinal samples and surgical tissues obtained from gastric bypass patients, 
assuming that gene expression is similar between healthy and morbidly obese adults. Our 
findings showed that all samples (from post-mortem collection and gastric bypass surgeries) 
exhibited substantial variability in the expression of oxidative enzyme genes, which is 
expected in intestinal tissues. Despite this high variability, a trend towards higher values for 
oxidative enzyme gene expression in surgical samples compared to post-mortem samples 
was observed, indicating substantial degradation of tissue nucleic acids post-mortem 
(Figure 3). This could be due to the long post-mortem interval (i.e., time from death to tissue 
collection) or failure to rinse intestinal tissues with phosphatase/esterase inhibitors, both of 
which could result in tissue degradation by intestinal hydrolytic enzymes. Despite the 
degradation of tissue, post-mortem samples exhibited an interesting trend towards higher 
intestinal gene expression of CYP3A4 in children versus adults. While corresponding protein 
expression cannot be inferred from gene expression data, the trend observed does suggest 
a possible rationale for the lower bioavailability of voriconazole in children compared to 
adults. This possibility needs to be further explored since CYP3A4 is the predominant 
metabolizing enzyme in the intestine, and therefore, higher expression of this enzyme in 
children could have significant implications on oral drug delivery in the pediatric population.  
A variety of in vitro methods have previously been evaluated using pre-clinical and 
human adult intestinal tissue samples to determine their ability to predict in vivo intestinal 
metabolism after oral dosing [16]. These studies demonstrated that techniques utilizing the 
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Ussing-chamber and everted sacs that require the use of intact intestinal tissues (which is 
unobtainable for the pediatric population) retained the best predictive power. Additionally, 
other previously reported techniques used to isolate primary intestinal cells used an entire 
section of the adult intestine (such as the duodenum or jejunum) obtained from surgeries. 
However, it is challenging to apply this methodology to the pediatric population where tissue 
samples are small, and availability is limited to scavenging healthy tissue surrounding the 
excised diseased tissue. Unlike pre-clinical and clinical adult intestinal tissue samples which 
are collected during surgical procedures, pediatric intestinal tissue specimens used in this 
study were obtained from deceased patients and frozen within a few hours post-mortem. 
The technique reported here uses a very small section of intestinal tissue, which could 
feasibly be collected during pediatric gastrointestinal surgeries or pooled from a few 
surgeries to provide a reliable method to assess differences in enzyme functionality.  
In addition to differences in drug metabolizing enzymes, it is also crucial to define 
differences in the expression of transporters between pediatric and adult populations. 
Current regulatory guidance documents for pediatric formulations focus mainly on the ease 
of use, palatability, and toxicity of excipients, but fail to consider interactions between the 
active ingredient or excipients and age-dependent enzymatic and transporter expression 
that affect the pharmacokinetics and, therefore, the efficacy of pediatric oral medications 
[17]. These data must be obtained using human tissues, as allometric scaling from 
pre-clinical species to adult humans is ineffective; therefore scaling intrinsic clearance from 
pre-clinical species or adults does not accurately translate the maturation of drug 
metabolizing enzymes [18]. While a few studies have attempted to describe the intestinal 
expression of drug metabolizing enzymes that affect intrinsic clearance, and hence 
bioavailability in neonatal and pediatric populations [8, 7], this report is the first to compare 
enzyme expression between children (2-8 years of age) and adults using frozen intestinal 
samples.  
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Current techniques used to predict bioavailability and intestinal clearance of drugs in 
children rely on scaling adult enzyme expression, as previously discussed [12], without 
considering differences in the contribution of intestinal drug metabolizing enzymes. Clinical 
trials are not the most desirable approach for investigating the bioavailability of drugs in 
children, as they are costly and challenging. Thus, the research presented here provides an 
innovative improvement of existing in vitro methods where a small sample of intestinal tissue 
(1-2 inches) can be used to isolate HIM using a combination of elution and homogenization 
techniques. This improved strategy provides a practical approach for studying intestinal drug 
metabolism in children. If healthy intestinal tissue samples are obtained from pediatric 
surgical patients, intestinal first-pass metabolism can be predicted in children by integrating 
in vitro metabolism data into a PBPK model. These in vitro first-pass intestinal metabolism 
data and modeling predictions are valuable in the screening and optimization of new drug 
candidates for adult and pediatric indications, and are critical for dosing recommendations in 
these two populations. 
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Figure 3. 1 Formation of 1’-OH Midazolam by HIM that were Prepared Using Elution 
and Homogenization (Whole Tissue or Intestinal Epithelium Only). Panel A represents 
formation after each technique and the inserts show the resulting pellet from [i] elution and 
[ii] homogenization. While the elution method retained 30% more activity (p < 0.01), the 
protein yield was very poor. In panel B, enterocytes were eluted off the tissue and then the 
tissue was subjected to homogenization to measure the residual activity.  
 
 
 
Figure 3. 2 Activity of Adult and Pediatric HIM Prepared by Elution and Homogenization. [A] Metabolite formation by adult 
and pediatric HIM prepared from surgical and post- mortem tissues by elution and homogenization. HIM exhibited a high degree 
of variability in metabolic activity. Samples obtained during surgery had higher enzymatic functional activity compared to post-
mortem samples. [B] Comparison of the formation of voriconazole N-oxide by HLM and HIM (sample A-IN-04) shows that adult 
intestinal tissue metabolizes voriconazole, but at a much lower rate than liver tissue.    
7
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Figure 3. 3 Intestinal CYP3A, CYP2C, and FMO Gene Expression. Comparison of expression of [A] cytochrome P450 and [B] 
FMO genes determined in post-mortem pediatric and adult intestinal tissues to surgical intestinal samples obtained from gastric 
7
7
 
 
 
by-pass patients, normalized to pediatric FMO1. The main graph shows that CYP enzyme expression is much higher compared 
to FMO enzyme expression. Solid bars represent pediatric intestinal tissue samples, bars with horizontal lines are adult samples, 
and bars with dots represent surgical jejunal samples obtained from adult gastric by-pass patients. For most enzymes, gastric by-
pass samples have a markedly higher expression of intestinal enzyme genes compared to post-mortem samples, indicating a 
striking degradation of intestinal tissue harvested post-mortem. Interestingly, among post-mortem intestinal tissue samples, there 
was a trend towards higher expression of CYP3A4 (the predominant intestinal enzyme) in pediatric tissues than in adult intestinal 
tissue samples.  
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CHAPTER 4 
Characterization of CYP and FMO Families Shows Age-dependent Differences in 
Expression and Functional Activity 
 
OVERVIEW 
Significant age-dependent differences in pharmacokinetic (PK) parameters exist for 
metabolically cleared medications in a wide range of therapeutic classes. While the 
ontogeny of drug metabolizing enzymes (DMEs) has been delineated, there remains a lack 
of knowledge about how differences in the intracellular enzymatic system affect the PK of 
drugs during maturation. In this dissertation research, bottom-up physiologically based 
pharmacokinetic (PBPK) models were developed to simulate and predict pharmacokinetic 
behavior of two drugs, voriconazole and sildenafil, in pediatric and premature neonates, 
respectively. For the development of these models, it is essential to obtain self-consistent 
data on the expression of genes and proteins of CYP3A, CYP2C, and FMO families in adult, 
pediatric, and fetal hepatic tissues as well as the corresponding catalytic activity. Although 
expression of genes and proteins of the above enzymes have been published previously, 
this is the first study in which quantitative values of the expression of genes and proteins of 
these enzymes were correlated with the corresponding functional activity in the same set of 
samples. Both the CYP3A and FMO families showed a distinct switch from fetal isoforms 
(CYP3A7, FMO1) to adult isoforms (CYP3A4, FMO3) at birth, while the CYP2C9 enzyme 
showed a linear maturation from birth into adulthood. In contrast, CYP2C19 expression was 
higher in pediatric hepatic samples compared to fetal and adult samples. Functional activity 
of the CYP2C family was linearly correlated with enzyme protein expression in the pediatric 
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and adult tissues, while both CYP3A and FMO required the inclusion of the expression of 
the fetal forms before a correlation between protein expression and phenotypic activity could 
be achieved. CYP3A7 formed a unique and previously unidentified hydroxyl metabolite of 
testosterone, and showed high catalytic activity, even higher than CYP3A4, when this 
metabolite was included in the measurement. In contrast, CYP3A7 exhibited poor catalytic 
activity in metabolizing midazolam. Thus, it is hypothesized that the fetal form of CYP3A, i.e. 
CYP3A7, is a steroid-specific CYP3A enzyme. Similarly, FMO1, which forms cimetidine 
sulfoxide with high turnover rate, is likely a steroid-specific FMO since cimetidine exhibits 
anti-androgenic activity. Finally, the catalytic efficiency of CYP2C19 was greater in the 
pediatric hepatic tissue than in the adult tissues; this is a surprising finding and suggests 
that cytochrome P450 enzymes may encounter different micro environment in children 
versus adults. These data are important to understanding the mechanistic basis of why 
some medications are cleared faster in children compared to adults, and can be 
incorporated into PBPK models to enhance the accuracy of PK predictions and, therefore, 
safety and efficacy in children. 
INTRODUCTION 
Hepatic clearance accounts for nearly 75% of the top 200 drugs on the market and 
over three-quarters of hepatic clearance is due to phase I drug metabolizing enzymes 
(DMEs) [1]. However, the effect of the ontogeny of these DMEs on pharmacokinetics (PK) in 
children is poorly understood for many of these drugs. In a study comparing the PK of 45 
drugs, the medications studied had, on average, a higher clearance and shorter half-life in 
children 2-12 years of age compared to adults, owing to age-related differences in metabolic 
clearance [2]. For example, proton pump inhibitors, such as omeprazole and lansoprazole, 
as well as phenytoin are commonly prescribed in the pediatric population and all have 
higher clearance in children, necessitating higher weight-based doses [3-6]. 
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Voriconazole is another prominent example of a drug that was only studied in adult 
volunteers, but later exhibited markedly different PK in children of ages 2-10. As described 
in Chapter 2, voriconazole is cleared predominantly by oxidative metabolism through 
cytochrome P450 (CYP) 3A4, CYP2C19, and flavin-containing monooxygenases (FMO) 3. 
Differences in voriconazole PK in pediatrics is attributed to the contribution of metabolic 
enzymes to voriconazole metabolism in children versus adults [7]. Sildenafil is the other 
main substrate studied in this dissertation. CYP3A and CYP2C9 were specified as the two 
main metabolizing enzymes responsible for its metabolism [8, 9]. For these reasons, 
expression and function of the CYP3A, CYP2C, and FMO families were studied.  
Early studies examined age-dependent differences in expression of major 
metabolizing enzymes responsible for medications cleared by oxidative metabolism. For 
both CYP2C and FMO expression analyses, over 200 fetal, pediatric and adult samples 
were subjected to Western blotting to determine the ontogeny of enzyme expression [10, 
11]. The CYP2C family exhibited low expression in the fetal population, but increased to 
adult levels after birth (CYP2C9) and after 5 months postnatal age (CYP2C19). A trend 
towards higher functional activity was observed in samples from children aged 5 months to 
10 years compared to samples that were obtained from children 10 years and above [11, 7]. 
Yet, the authors failed to mention this unique finding, which could not be explained by 
enzyme expression, leaving questions about differences in factors other than enzyme 
expression that could affect the activity of the CYP2C family. Furthermore, the quantitation 
of the CYP2C9 and 2C19 isoforms could have been confounded by cross-reactivity of the 
antibody with CYP2C8.  
The same sample population set also generated an ontogeny profile for FMO, 
showing that the main hepatic isoforms switched from FMO1 to FMO3 during development. 
FMO1 is the predominant fetal isoform that is expressed at highest levels during weeks 8-15 
of gestation. Expression of FMO1 declines during fetal development until it is undetectable 
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by the first week after birth. FMO3, the adult hepatic isoform, then replaces FMO1 as the 
predominant isoform and reaches adult expression levels by approximately 1-2 years of age 
[10].  
Unlike the CYP2C and FMO families, CYP3A expression was measured by 
differential metabolism of dehydroepiandrosterone (DHEA) as antibodies lacked specificity 
and selectivity for the individual 3A isoforms. Since CYP3A7 differentially metabolizes DHEA 
to 16α-OH DHEA and CYP3A4 metabolizes DHEA to 7β-OH DHEA, the ratio of the 16α-OH 
to the 7β-OH DHEA metabolite was used to assess the contribution of either CYP3A7 or 
CYP3A4, respectively. A nonlinear multivariate regression analysis was used to determine 
the protein concentration of each isoform based on the ratio of the 16α –OH to 7β-OH 
metabolites. However, both these metabolites were also produced by CYP1B1, CYP2C19, 
and CYP3A5, which could confound the assessment of the expression of CYP3A isoforms.  
While these initial studies have improved our understanding of the ontogeny of 
DMEs, there are still knowledge gaps, which limit current attempts to determine factors that 
are responsible for differences in drug metabolism across age ranges spanning from birth to 
adulthood. Without a comprehensive knowledge of the maturational changes in expression 
and function of DMEs at the cellular level, any dosing or safety predictions will either over- or 
under-predict PK parameters in children. Ethical concerns and high variability confound 
clinical trials aimed at investigating the effect of ontogeny of DMEs on the PK of drugs in 
pediatric populations. Therefore, a more feasible strategy is to study the differences in 
cellular mechanisms of clearance in pediatric versus adult hepatic tissues, and relate the 
expression and functional activity differences in an integrated model. The aim of this study 
was to elucidate the cellular mechanisms that cause differences in metabolic clearance from 
birth until adulthood. Thus, gene and protein expression, as well as functional activity of 
CYP3A, CYP2C, and FMO families were evaluated. In light of the deficiencies that existed in 
determination of protein expression for CYP2C and CYP3A family members, as pointed out 
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earlier, LC-MS techniques were employed to determine expression of CYP2C, CYP3A, and 
FMO enzymes. 
MATERIALS AND METHODS 
Chemicals, Reagents, and Sample Selection  
Testosterone, 6-β OH-testosterone, S-mephenytoin, 4’-OH S-mephenytoin, 
diclofenac, 4’-OH diclofenac, cimetidine, NAPDH, and voriconazole were purchased from 
Sigma-Aldrich (St. Louis, MO). Cimetidine sulfoxide was purchased from Abcam 
(Cambridge, MA). Liver tissues from healthy adult (>18 years old), pediatric (aged 5 months-
10 years), and fetal (14-29 weeks gestation) donors were obtained from the NICHD Brain 
and Tissue Bank for Developmental Disorders (Contract #HHSN275200900011C, Ref. No. 
NO1-HD-9-0011; Baltimore, MD) under an approved UNC-Chapel Hill IRB protocol. Donor 
information is listed in Table 4.1.  
Preparation of Microsomes 
Human liver microsomes (HLM) were prepared as previously reported [12]. Briefly, 
0.5 mg of hepatic tissue was homogenized in a buffer containing 50 mM Tris-HCl, 1 mM 
EDTA, and 154 mM KCl with protease inhibitors (pH 7.4). After homogenization, samples 
were centrifuged at 10,000 x g for 30 minutes, the supernatant was collected, and this step 
was repeated. The supernatant was mixed with a second buffer containing 100 mM sodium 
pyrophosphate and 0.1 mM EDTA (pH 7.4) and then centrifuged at 100,000 x g for 70 
minutes. This step was repeated one final time. The resulting pellet was then resuspended 
in a buffer containing 10 mM potassium phosphate, 1 mM EDTA, and 20% glycerol (pH 7.4). 
Microsomal protein concentration was measured using a BCA assay. HLM were stored at 20 
µL aliquots at -80oC.  
Gene Expression 
Liver tissue samples (25mg) were lysed, sonicated until complete homogenization, 
and then centrifuged at 10,000 x g for 12 minutes. Phase separation and binding of the 
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mRNA was completed using a Qiagen RNEasy Kit. RNA was diluted to 500 ng/µL for each 
sample. The isolated RNA was mixed with iScript™ cDNA Synthesis Kit (Biorad) and 
incubated at 25ºC x 5 min, 42ºC x 30 min, and then 85ºC x 5 min to synthesize cDNA. The 
cDNA was mixed with iTaq™ Supermix (BioRad) and TaqMan Gene Expression Assay for 
CYP3A4, 3A5, 3A7, 2C9, 2C19, FMO1, FMO3 and 18s (Applied Bio-systems). Expression 
for each enzyme gene was measured (quantitative rt-PCR) and normalized to 18s rRNA.  
Protein Expression 
For enzyme protein quantitation, HLM were subjected to proteomic analysis by mass 
spectrometry [13]. HLM (30 µg, Xenotech, Lenexa, KS) and recombinant CYP3A4, 3A5, 
3A7, 2C9, 2C19, FMO1, FMO3, and FMO5 (BD Gentest, San Jose, CA) was each diluted in 
90 µL denaturation solution (44.4 mM NH4HCO3, 4.44 mM DTT) and incubated at 60 °C for 
1 hour. Iodoacetamide (10 mM) was then added to the solution and kept in the dark for 20 
min at room temperature. Next, the solution was incubated for 4 hours at 37 °C with trypsin 
(1 µg). Samples were spiked with 10 µL of mixed isotope labeled peptides as internal 
standards and centrifuged at 16,100 x g for 10 min. Separation was achieved using an 
Acquity UPLC BEH130 C18 column (1.7 µm 2.1 x 100 mm, Waters) at a flow rate of 0.4 
mL/min using mobile phases of water containing 0.1% formic acid (A) and ACN containing 
0.1% formic acid (B). Protein expression in adult and pediatric liver samples (n=10/group) 
were assessed by comparing the peak area normalized to the internal standard with known 
protein content in recombinant enzyme standard curves.  
Functional Assays 
Adult and pediatric HLM (0.1 mg/mL) were incubated with the probe substrate of 
each respective enzyme (Table 4. 2), NADPH (1 mM) and MgCl2 (3 mM) in phosphate buffer 
(pH 7.4) at 37ºC for up to 60 min. Aliquots (100 μL) of samples were taken at specified time 
points, quenched with 300 μL methanol containing internal standard (0.1 μM of either 
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voriconazole for the CYP assays or phenformin for the FMO assay). Samples were then 
centrifuged at 10,000g x 10 min and analyzed by LC-MS/MS.  
Metabolite Analysis 
The LC-MS/MS system consisted of mobile phase (A) 0.1% formic acid in water and 
(B) 0.1% formic acid in methanol with a total flow rate of 0.6 mL/min. A Sciex API-4000 triple 
quadropole mass spectrometer was used with a Zorbax SB-C18 column (2.1 x 50 mm, 5 
µm). Samples were ionized using an ESI ion source and, following the injection of 10µL of 
supernatant, positive ions were monitored at the following MRM Q1/Q3 transitions (m/z): 
235.2→150.2 for 4’-OH S-mephenytoin, 312.3→230.2 for 4’--OH diclofenac and 
350.2→127.2 for voriconazole. For the testosterone assay, samples were ionized using an 
APCI ion source and monitored at the following MRM Q1/Q3 transitions (m/z): 289.2→97.1 
for testosterone, 305.1→269.3 for 6β-OH testosterone and 350.2→127.2 voriconazole. 
Statistical Analysis 
Differences between populations for gene and protein expression as well as 
differences in metabolite formation were analyzed using a two-way ANOVA. The linearity of 
maturation profiles and correlation analyses were determined by fitting a linear regression 
curve and 95% confidence intervals to the model. For all analyses, a p-value less than 0.05 
was considered significant.  
RESULTS 
The CYP3A Family 
Gene Expression 
Relative gene expression (Figure 4. 1a) of the three major CYP3A enzymes revealed 
that CYP3A7 gene was expressed to the highest level in fetal hepatic samples while 
pediatric samples had a lower, but detectable, level of this gene. Juxtaposing the fetal and 
pediatric CYP3A7 gene expression, its expression was undetectable in adults. In contrast, 
the CYP3A4 gene was undetectable in fetal tissue, but its expression increased with age 
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and was similar between the pediatric and adult populations. Taken together, a clear switch 
in the expression of the gene for predominant CYP3A isoform is observed from the fetal 
population (CYP3A7) into adulthood (CYP3A4). Unlike CYP3A4 and CYP3A7, expression of 
CYP3A5 remained relatively stable across all three groups with no discernable ontogeny 
profile. 
Protein Expression 
The trends revealed by the relative gene expression corresponded well to protein 
expression, which was measured by quantitative proteomic analysis using mass 
spectrometry. As expected, fetal samples had very high expression of CYP3A7 (0.535 
nmol/mg) with a corresponding low expression of CYP3A4 (0.0003 nmol/mg). During 
maturation, CYP3A7 levels decreased in the pediatric and adult populations (0.051- and 
0.019 nmol/mg, respectively; Figure 4. 2a). On the other hand, CYP3A4 levels increased 
from undetectable levels in the fetal period until it reached adult levels (0.069-
0.078 nmol/mg) around 1 year of age. Abundance of CYP3A7 was over 10-fold higher and 
abundance of CYP3A4 was over 200-fold lower in the fetal tissues compared to either the 
pediatric or adult tissues (p < 0.0001; Figure 4. 2d). This switch from CYP3A7 as the 
predominant isoform in fetal tissues to CYP3A4 in adult tissues was seen previously in the 
literature [14]. CYP3A5 remains relatively stable (0.001-0.005 nmol/mg) across all three 
groups with no statistically significant difference among the three populations. 
Functional Activity 
Expression patterns were also examined by measuring enzyme activity with enzyme-
specific probe substrates. Initially, testosterone was chosen as the probe substrate to 
assess functional activity of the CYP3A family in these three populations as well as in 
recombinant CYP3A4, 3A5, and 3A7 (Figure 4. 3). The rates of formation of testosterone 
metabolites by fetal, pediatric, and adult HLM samples as well as recombinant CYP3A4, 
3A5, and 3A7 were normalized to the total protein in each sample (Figure 4. 3a). Fetal 
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samples had a high rate of metabolite formation (665.9 pmol/min/mg protein) compared to 
pediatric and adult samples (256.8 and 278 pmol/min/mg protein, respectively). 
Recombinant CYP3A4, 3A5, and 3A7 formed metabolite at rates of 1433.6, 375.6, and 
199.2 pmol/min/mg protein. However, after normalizing the formation of metabolite to the 
total amount of CYP3A in each sample, a clear maturation trend was observed across the 
three populations (1.2, 1.6, and 2.8 pmol/min/pmol 3A, respectively) which correlated well 
with the formation of metabolite by the recombinant 3A4, 3A5 and 3A7 enzymes (3.9, 3.0, 
and 1.4 pmol/min/pmol 3A respectively; Figure 4. 3b).  
Detection of a Novel CYP3A7-specific Testosterone Metabolite 
Upon further analysis of the LC-MS/MS chromatograms, a distinct shift in retention 
time was observed between the major metabolite formed by fetal enzymes and recombinant 
CYP3A7 compared to the major metabolite formed by adult and pediatric enzymes, and 
recombinant CYP3A4 and CYP3A5 (Figure 4. 4). Adult/pediatric HLM and recombinant 
CYP3A4 metabolized testosterone to 6β-OH testosterone (peak at 2.51 min) and to a minor 
hydroxylated testosterone metabolite (M+16) that eluted at 2.61 min. Interestingly, fetal HLM 
and recombinant CYP3A7 formed the testosterone metabolite eluting at 2.61 min as the 
major product, with 6β-OH testosterone (2.51 min) as a minor product. These results 
indicate that the main metabolite of testosterone formed by CYP3A7 and fetal samples is 
not 6β-OH testosterone.  
CYP3A7 is a Steroid-specific Enzyme 
Due to the unexpected testosterone metabolite formed by fetal enzymes and 
CYP3A7, midazolam, another FDA approved CYP3A in vitro probe, was evaluated to 
assess if a similar result is observed with fetal enzymes and CYP3A7 (Figure 4. 5). In 
contrast to the testosterone metabolism, 1’OH midazolam formation by fetal samples and 
recombinant CYP3A7 was very low (0.4 and 0.25 pmol/min/pmol P450). Metabolite 
formation of 1’OH midazolam increased with age from the pediatric to adult samples (3.9 
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versus 7.8 pmol/min/pmol P450, respectively). Recombinant CYP3A4 generated 1’OH 
midazolam at a lower rate (8.9 pmol/min/pmol P450) compared to recombinant CYP3A5 
(28.6 pmol/min/pmol P450), indicating that CYP3A5 is the predominant CYP3A enzyme 
responsible for midazolam metabolism.  
A correlation between enzyme abundance and functional activity was assessed to 
illustrate the contribution of each isoform to both testosterone and midazolam metabolism 
(Figure 4. 6). When the rate of testosterone metabolism was compared to total CYP3A4 and 
CYP3A5 abundance, an inverse correlation was observed. Conversely, when the metabolic 
rate was compared to the total CYP3A abundance of all three isoforms, a positive 
correlation was observed indicating that CYP3A7 is a major contributor to testosterone 
metabolism. However, these results were reversed for midazolam. A positive correlation was 
attained only when the metabolic rate was compared to the total abundance of CYP3A4 and 
CYP3A5. No correlation was seen when midazolam metabolite formation was plotted 
against the abundance of all three isoforms; this is consistent with the fact that CYP3A7 is 
not involved in midazolam metabolism. These results suggest that CYP3A7 preferentially 
metabolizes steroids.  
The CYP2C Family 
Fetal expression of both CYP2C9 and CYP2C19 genes was low to undetectable, 
with approximately a 100-fold lower expression compared to the pediatric and adult 
samples. No significant differences were observed for CYP2C9 or CYP2C19 gene 
expression in adults versus children. However, there was a trend towards higher CYP2C19 
expression in the pediatric population compared to the adult population (p < 0.06). 
Expression of CYP2C9 protein increased linearly over time (r2 = 0.31; p < 0.0001) 
and adult level expression was reached in the pediatric population (Figure 4. 2b). Overall, 
CYP2C9 protein expression corresponded to gene expression (Figure 4. 2e). Fetal tissue 
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expressed significantly lower levels (0.001 nmol/mg) of CYP2C9 protein compared to 
pediatric and adult tissues (0.052 and 0.054 nmol/mg, respectively; p< 0.0001). 
In contrast to the linear maturation profile of CYP2C9 protein, CYP2C19 protein 
expression peaked during the pediatric period (Figure 4. 2b). The pattern of differences in 
CYP2C9 gene expression in pediatric samples compared to adult samples was also 
reflected in protein expression (Figure 4. 2e). CYP2C9 protein expression in pediatric 
tissues was over 2-fold higher compared to adult tissues (0.0093 nmol/mg versus 0.0043 
nmol/mg; p<0.05). 
To assess how expression affects functional activity, diclofenac and S-mephenytoin 
were used as probe substrates for CYP2C9 and CYP2C19, respectively. Formation of 
4’-hydroxylation of diclofenac by fetal tissue, normalized to total microsomal protein (Figure 
4. 7a), was over 200-fold lower than by pediatric and adult samples (0.61 versus 240 versus 
208 pmol/min/mg protein, respectively). After normalizing metabolite formation to the total 
CYP2C9 abundance in each sample (Figure 4. 7b), fetal samples still had much lower 
metabolic activity compared to pediatric and adult samples (0.51 versus 4.0 versus 3.6 
pmol/mg/pmol CYP2C9 respectively) and there were no significant differences in CYP2C9 
activity between adult and pediatric populations. 
CYP2C19 displayed differential maturation in activity compared to CYP2C9. Similar 
to CYP2C9, formation of 4’-hydroxylation of S-mephenytoin by fetal samples was 
undetectable (Figure 4. 8). However, metabolic activity in pediatric samples was higher than 
that in adult samples when normalized to total microsomal protein (4.0 versus 1.3 
pmol/min/mg protein respectively; p = 0.04). After normalizing for the higher expression of 
CYP2C19 in pediatric samples, a significant difference was still apparent between the 
metabolite formation rates by the pediatric and adult enzyme (364 versus 199 
pmol/min/pmol CYP2C19, respectively; p < 0.003). These results signify that another cellular 
mechanism, in combination with higher CYP2C19 expression, confers higher metabolic 
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activity in the pediatric population. Finally, both CYP2C9 and CYP2C19 activity toward their 
respective probe substrates is significantly correlated with abundance (Figure 4. 9).  
The FMO Family 
The relative gene expression (Figure 4. 1c) of both FMO1 and FMO3 revealed that 
FMO1 had the highest expression in fetal samples while adult and pediatric samples had 
low to undetectable expression. On the other hand, FMO3 gene expression was low in the 
fetal tissue and increased to mature levels in the pediatric and adult populations. As seen in 
the CYP3A family, FMO exhibited a switch from a predominant fetal isoform to an adult 
isoform after birth.  
Similar trends were displayed by the FMO protein expression. As expected, high 
protein expression of FMO1 was observed in fetal samples (0.007 nmol/mg) with a low 
expression of FMO3 (0.001 nmol/mg; Figure 4. 2c). FMO1 expression was virtually 
undetectable in pediatric and adult samples (0.00002 nmol/mg in each population), 
confirming the notion that FMO1 is a fetal isoform. Because of the specificity, and in turn low 
variability of of the protein expression assay, a significant difference was seen among all 
three populations as FMO3 increased from 0.001- to 0.02- to 0.037 nmol/mg in the fetal, 
pediatric, and adult samples, respectively (p < 0.001; Figure 4. 2f). A clear ontogeny profile 
is seen for FMO3 as expression increased linearly from the fetal period into adulthood (r2 = 
0.52; p < 0.0001).  
Finally, functional activity of FMO was assessed using cimetidine as a probe 
substrate. Formation of cimetidine sulfoxide by recombinant FMO1 was 2-fold higher than by 
recombinant FMO3. Fetal samples, which had a higher expression of FMO1, generated 
cimetidine sulfoxide at a rate 2-fold higher than did pediatric and adult samples (p < 0.001; 
Figure 4. 10a). Normalization of functional activity to the abundance of FMO in each sample 
revealed that FMO activity remained significantly higher (p < 0.0001) in fetal samples (507 
pmol/min/pmol FMO) compared to pediatric and adult samples (79 and 74 pmol/min/pmol 
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FMO, respectively; Figure 4. 10b). An inverse correlation was observed when functional 
activity of FMO isoforms was plotted against total FMO1 and FMO3 abundance (Figure 4. 
11), indicating that the metabolic activity of FMO3 toward cimetidine is much lower as 
compared with FMO1.  
DISCUSSION 
It has been recognized for over a decade that expression of DMEs changes, in some 
cases by more than an order of magnitude, from birth through childhood and adolescence to 
adulthood. Numerous studies have been published to delineate the age-associated changes 
in DMEs, and more recently in drug transporters as well as receptors and other mediators of 
biological effects. However, the expression level of enzyme (and transporter) proteins, 
determined by Western blot analyses, has been semi-quantitative at best. This work 
represents the first attempt to undertake a comprehensive study in which expression of DME 
genes and proteins, as well as phenotypic activity of these enzymes have been determined 
and related within the same study. Furthermore, the expression of DME proteins, in addition 
to the expression of corresponding genes, was determined using quantitative proteomic 
analysis using LC-MS. For this comprehensive analysis of the relationship among gene and 
protein expression as well as phenotypic activity of DMEs, CYP3A, CYP2C, and FMO family 
of enzymes were selected because of their known or anticipated role in the clearance of the 
two drugs studied in this dissertation work, i.e. voriconazole and sildenafil. 
The gene expression profiles shown in Figure 4. 1a-b correspond well to the protein 
expression profiles in Figure 4.2d-f, indicating that gene expression can reveal relative 
protein expression trends among isoforms within the same family. However, absolute 
quantitation of DMEs is critical, especially for incorporating into a PBPK model, and one 
cannot rely on gene expression data to predict protein expression as specificity of the 
primers can affect gene expression results, and factors such as post-translational 
modifications can alter the final protein expression, as is seen with CYP2C9. Relative gene 
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expression of CYP2C9 indicates that this enzyme has similar abundance to that of CYP3A7 
and potentially higher expression than CYP3A4. Yet protein expression studies show that 
the CYP3A family has higher expression than CYP2C9, which is in agreement with 
published reports on hepatic protein content [15].  
Initial Western blot analysis and differential metabolism studies provided a 
reasonable estimate of protein expression [7]. However, the enzyme abundance data 
reported here are more reliable. Quantitative mass spectrometry-based proteomic analysis 
provides significant advantages over traditional antibody-based analysis. Only a small 
amount of sample (30 µg) was used to quantify peptide sequences of multiple enzymes 
simultaneously. Most importantly, by choosing a peptide sequence unique to an isoform of 
an enzyme, specificity of the measurement is greatly increased [16]. This improvement over 
antibody techniques reduces the likelihood of confounding enzyme abundance data due to 
cross-reactivity of an antibody with a different isoform within the same DME family. This is 
the first study to report hepatic expression of enzymes in the CYP3A, CYP2C, and FMO 
families based on quantitative proteomic analysis by LC-MS/MS. 
In order to study the CYP3A-mediated functional activity of HLM, testosterone was 
chosen as a probe substrate, which was quantified using LC-MS/MS. Previous studies and 
reviews have reported that CYP3A7 has a lower catalytic activity for oxidation of 
testosterone as determined by testosterone 6β hydroxylation, the reaction catalyzed by 
CYP3A4 and presumed to be catalyzed by CYP3A7 as well, compared to CYP3A4 with as 
much as an 18-fold lower metabolite formation [17, 18, 14]. The results presented in this 
report agree with published data that the CYP3A7 forms 6β-OH testosterone at a much 
lower rate than does CYP3A4. However, the results also report an exciting new finding that 
CYP3A7 metabolizes testosterone to a hydroxylated metabolite of testosterone that is 
distinctly different from 6β-OH testosterone, the major metabolite of CYP3A4 and CYP3A5, 
as evidenced by its different retention time on LC-MS chromatogram but same mass-to-
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charge ratio as 6β-OH testosterone. Thus, the novel hydroxylated testosterone metabolite 
found in this work is either a stereoisomer or a positional isomer of 6β-OH testosterone; 
many hydroxylated testosterone metabolites are formed by rat liver microsomes [19], by 
different Cyp enzymes. The results further show this new metabolite is a major metabolite of 
CYP3A7 with the-6β-OH testosterone, formed as a minor metabolite. Finally, the results 
show that fetal HLM form the new metabolite as a major metabolite from testosterone, 
reflective of CYP3A7 as the major form of CYP3A present in these samples. If one assumes 
that the mass spectrometric response factor for the new hydroxylated metabolite is similar to 
that of 6β-OH testosterone, which is a reasonable assumption since both are hydroxylated 
derivatives of testosterone, then this study, for the first time, provides evidence that fetal 
hepatic HLM can metabolize testosterone at a higher rate than pediatric or adult liver HLM. 
The high abundance of CYP3A7 in fetal tissue, which is approximately 6-fold higher than 
adult CYP3A4 expression, combined with high catalytic rate of CYP3A7 to metabolize 
testosterone to the new metabolite, accounts for this high rate of testosterone metabolism 
by fetal HLM.  
In order to determine if this high rate of testosterone metabolism by fetal tissues was 
a general or substrate-specific effect, the metabolism of a second probe for CYP3A-
mediated activity, midazolam, by the same fetal, pediatric, adult, and recombinant CYP3A 
samples was examined. In contrast to high rate of testosterone metabolism by fetal HLM 
and recombinant CYP3A7, little to no 1’OH midazolam was formed by these enzymes, and 
there was no evidence that a different midazolam metabolite was produced by these 
enzymes. A clear maturation of functional activity was progressively observed with fetal, 
pediatric and adult samples, which corresponded to the expression and function of CYP3A4 
and CYP3A5. These results were confirmed by a correlation analysis where midazolam was 
significantly correlated with only CYP3A4 and CYP3A5 expression, but testosterone 
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metabolism required the inclusion of CYP3A7 in the abundance data to show a significant 
correlation. 
As mentioned in the introduction, relative CYP3A4 and CYP3A7 expression were 
originally estimated by the metabolites formed from DHEA, an endogenous steroid [14]. 
Analogous to the unique hydroxylated DHEA metabolite formed by CYP3A7, these results 
demonstrate for the first time that CYP3A7, the fetal form of CYP3A, metabolizes 
testosterone to a novel hydroxylated metabolite. 
Based on these results a new hypothesis is proposed regarding the role of CYP3A7 
in human metabolism; that is, CYP3A7 is a steroid-specific cytochrome P450 that is evolved 
to be expressed in the fetus to metabolically degrade the steroidal hormones of the mother 
of which the fetus is exposed. The hypothesis is supported by the physiological and 
hormonal changes associated with pregnancy. During pregnancy the progesterone and 
estrogen levels increase 3- and 20 fold, respectively, and drop precipitously at birth [20]. 
The switch from CYP3A7 to CYP3A4 occurs almost immediately after birth, [18], supporting 
the hypothesis that the physiologic function of CYP3A7 is to metabolically degrade the 
steroidal hormones from the mother. Furthermore, testosterone levels increase in the first 
and second trimester, but is significantly higher in women carrying male fetuses [21]. These 
hormonal changes are handled by the mother as well as the fetus and the placenta. Within 
the fetus itself, the liver begins forming within the first few weeks of embryonic development 
and begins functioning by the third month of pregnancy [22, 23]. In addition, the placenta 
and the fetal membrane surrounding the fetus express CYP3A4, CYP3A5 and CYP3A7. The 
placenta exhibits a 2-fold higher expression of CYP3A4 compared to fetal membrane, 
whereas the fetal membrane show higher expression of CYP3A7 and CYP3A5. 
Homogenates from placentas and fetal membranes established that both these organs had 
CYP3A functional activity, providing an additional barrier to protect the fetus from circulating 
compounds [24, 25]. It has also been shown that estradiol and progesterone, two main 
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circulating hormones during pregnancy, affect the expression and function of hepatic DMEs 
and it is possible that the metabolites of these steroids produced by either the mother or the 
fetus could also affect gestational development [26, 27].  
As testosterone is a standard probe for CYP3A activity, the significance of these 
findings will impact the use of both in vitro and in vivo probe assays. These findings will yield 
a unique method to discriminate testosterone metabolism by CYP3A4 versus CYP3A7. 
Identification of the CYP3A7-specific testosterone metabolite will lead to an in vivo probe for 
CYP3A7 activity in fetal, neonatal, and pregnant populations. 
The ontogeny of FMO is similar to that of the CYP3A family in that the predominant 
isoform switches at birth from the fetal FMO1 isoform to the adult FMO3 isoform. Previous 
studies have examined the differences in FMO isoform activity for a variety of substrates. 
These studies have shown that FMO3 metabolizes substrates, such as ranitidine, more 
efficiently than FMO1 [28]. Another substrate of FMO is nicotine, which has a similar 
metabolic profile between children and adults, but a significantly reduced metabolism in 
neonates [29]. These published reports indicate that FMO3 potentially has higher activity 
compared to the fetal isoform FMO1. 
To investigate these reports, functional FMO activity of the fetal, pediatric, and adult 
HLM were assessed using cimetidine as a probe. Cimetidine has been studied in pre-clinical 
species as well as in human clinical studies, and the evidence provided thus far suggest that 
FMO3 is the major metabolizing enzyme of cimetidine in adult humans [30, 31]. 
Interestingly, the results presented in this study show that the rate of cimetidine sulfoxide 
formation by fetal HLM and FMO1 was approximately 2-fold higher than the rate of 
cimetidine metabolism by pediatric and adult HLM and by FMO3. Upon closer inspection of 
cimetidine structure and function, these results indicate that FMO1 may also be a steroid 
specific fetal isoform as cimetidine has mild antiandrogen properties. Cimetidine has the 
ability to displace both testosterone and dihydrotestosterone from the androgen receptors 
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[32, 33]. Due to this anti-androgen property, it has been studied for its perinatal effects on 
male rat sex organ development as well as on cancer prevention in humans [34, 35]. As was 
seen with CYP3A, the switch from FMO1 to FMO3 is linked to parturition rather than with 
gestational age [36, 10]. Thus, the hypothesis extends to FMO1 as a likely a steroid-specific 
enzyme, which declines in function and expression after the decrease in pregnancy 
hormones. Thus, CYP3A7 and FMO1 are fetal DMEs that are an evolutionary response to 
the surge in steroid hormones during pregnancy.  
For the CYP2C families, no fetal isoforms exist for either 2C9 or 2C19, and enzymes 
exhibit virtually no expression in fetal samples. Between the pediatric and adult populations, 
CYP2C9 expression was comparable, corresponding to the maturation of the gene and 
protein expression and, as seen in the correlation analysis, higher abundance was linearly 
associated with higher activity. In contrast, expression of CYP2C19 protein was higher 
(nearly 2-fold) in pediatric liver samples compared to adult liver samples. While this trend 
has been observed previously [7], the sensitivity of the LC-MS/MS proteomic assay 
decreased variability to provide definitive evidence for a significant difference in 2C19 
protein expression between these two populations. This higher expression in children may 
explain, in part, the higher clearance of voriconazole in children compared to adults, and the 
previous finding that CYP2C19 accounts for higher percentage of voriconazole metabolism 
(~50%) in children versus adults [7, 37]. Surprisingly though, when catalytic activity was 
normalized to CYP2C19 protein expression, the turnover rate of the CYP2C19 probe S-
mephenytoin was higher for pediatric HLM compared to adult HLM, suggesting that 
CYP2C19 exhibits higher catalytic efficiency in children compared to adults. Higher catalytic 
efficiency of the same enzyme in children compared to adults is a novel finding, and may 
provide additional explanation for the higher contribution of CYP2C19 toward voriconazole 
metabolism and its higher clearance in children compared to adults. These results warrant 
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investigation of other drugs that are oxidatively metabolized by CYP2C19 and that require 
higher doses in children compared to adults. 
The higher catalytic efficiency of CYP2C19 in children compared to adults is 
surprising. One likely explanation for this may be increased linking between NADPH 
cytochrome P450 oxidoreductase and CYP2C19. Many studies have been conducted 
assessing the structure and function of NADPH cytochrome P450 oxidoreductase, including 
how genetic variations of this enzyme affect drug metabolism of compounds such as 
steroids and midazolam [38-41]. While many genetic polymorphisms can decrease the 
function of this enzyme, a few variants can increase the metabolic activity as was shown for 
both CYP2C19 and CYP1A2 [42]. Another likely factor that can affect catalytic efficiency of a 
cytochrome P450 enzyme is the lipid composition of the membrane within the endoplasmic 
reticulum. Since the access of a cytochrome P450 active site to its substrate requires the 
substrate to traverse the lipid membrane in which the enzyme is embedded, the same 
cytochrome P450 enzyme may catalyze the same substrate at different efficiency in two 
different species or two different populations within a species. In addition, different lipid 
composition also can lead to different level of coupling between a cytochrome P450 enzyme 
and NADPH cytochrome P450 oxidoreductase, leading to different catalytic efficiency of the 
P450 enzyme. Thus, the higher catalytic efficiency of CYP2C19 in pediatric HLM compared 
to adult HLM is an interesting new finding that needs to be further examined to elucidate the 
molecular or biophysical mechanism underlying the difference.  
One limitation of this study is that the sample size is considerably smaller than the 
200 samples used in the initial protein expression analyses. However, the post-mortem 
interval of the 200 samples ranged from 1-41 hours with a median of 17 hours [11] whereas 
the post-mortem interval of the samples chosen for this research was less than 18 hours 
with a median of 3 hours. Potential degradation of DMEs during this post-mortem interval 
could affect functional activity and expression. So despite the small sample size, the short 
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post-mortem interval as well as the techniques utilized in this research allowed an increased 
ability to detect differences in expression between pediatric versus adult samples. It is 
important to note that the small sample size limits the ability of this work to detect 
differences in expression or function due to polymorphisms. A few clinically significant 
polymorphisms have been documented for CYP2C19, CYP2C9, FMO, and CYP3A5 [43-47]. 
Due to these polymorphisms, the differences in expression of these enzymes reported here 
require additional analysis to understand the influence of genetic variation on the 
maturational profile of the DMEs.  
The CYP3A and CYP2C families account for 60% of the hepatic enzyme content and 
metabolize over 70% of the drugs currently on the market [1, 15]. While the FMO family has 
lower expression, it plays a pivotal role in regulating reactive oxygen species and 
metabolizing nitrogen- and sulfur-containing compounds [36]. Unique differences in enzyme 
contributions exist among these three enzyme families during development, and these 
differences affect the PK of medications administered to children. While changes in the 
hepatic expression of these proteins and their genes with age as well as the corresponding 
changes in the catalytic activity have been examined previously, the work presented here is 
the first study in which the changes in the gene and protein expression as well as in the 
catalytic activity are measured using the same tissue samples within the same study, with 
quantitative analysis of protein expression using LC-MS/MS.   
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Table 4.1 Individual Human Liver Donors. HLM were prepared from these liver samples. * 
indicates that information was not provided. 
 
Group Sample Age Gender Race 
Fetal 
F1 18 weeks Female African American 
F5 15 weeks Male African American 
F6 20 weeks Female African American 
F7 16 weeks Male African American 
F8 15 weeks Male African American 
F9 19 weeks Male Caucasian 
F10 16 weeks Male African American 
Pediatric 
P1 6 years Male Caucasian 
P2 4 years Male Caucasian 
P3 2 years Male African American 
P4 2 years * * 
P5 1 years * * 
P6 4 months * * 
P7 4 years Male Caucasian 
P8 8 years Male Caucasian 
P9 2 years Male African American 
P10 9 years Female Hispanic 
P11 111 days Female Caucasian 
P12 92 days Female Caucasian 
P13 63 days Male African American 
P14 57 days Female African American 
P15 97 days Female African American 
P16 71 days Male African American 
Adult 
A1 54 years Male Caucasian 
A2 40 years Female Caucasian 
A4 23 years Male Hispanic 
A5 23 years Male Hispanic 
A7 80 years Male Caucasian 
A8 22 years Female Caucasian 
A9 32 years Female Caucasian 
A10 46 years Female Caucasian 
A11 45 years Female Caucasian 
A12 32 years Female Caucasian 
 
 
 
Table 4. 2 Probe Substrates for Enzymatic Activity of Cytochrome P450 and FMO Enzymes. The chemical structures of the 
substrates and their major metabolite as well as the concentration of the substrates used in phenotypic assay.  
Enzyme Probe Parent Structure [S] Metabolite Metabolite Structure 
CYP3A Testosterone 
 
10 µM 6β-OH Testosterone 
 
CYP3A Midazolam 
 
4 µM 1’OH Midazolam 
 
CYP2C19 S-mephenytoin 
 
10 µM 4’OH S-mephenytoin 
 
CYP2C9 Diclofenac 
 
10 µM 4’OH Diclofenac 
 
FMO Cimetidine 
 
10 µM Cimetidine Sulfoxide 
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Figure 4. 1 Expression of CYP and FMO Genes in the Fetal, Pediatric and Adult 
Hepatic Tissues. Gene expression was normalized to the lowest expressed enzyme gene, 
namely adult FMO1, in order to show relative expression across all enzymes and all three 
populations. Fetal, pediatric, and adult samples are represented by the blue, yellow, and 
green bars, respectively. Inserts depict the relative expression of the CYP3A family [A], 
CYP2C family [B], and the FMO family [C]. 
 
 
 
Figure 4. 2 Expression of CYP3A, CYP2C, and FMO Proteins in Fetal, Pediatric, and Adult Hepatic Tissues Measured by 
Quantitative Proteomic Analysis Using LC-MS/MS. Panels depict the expression of the CYP3A family [A], CYP2C family [B], and 
1
0
6
 
 
 
the FMO family proteins. [C]. For the CYP3A family, the green, yellow, and blue squares represent CYP3A4, CYP3A5, and CYP3A7 
proteins, respectively. For the CYP2C family, the aqua and purple squares represent the CYP2C9 and CYP2C19 proteins, 
respectively. For the FMO family, the red, orange, and grey squares depict FMO1, FMO3, and FMO5 proteins, respectively. A 
comparison of mean enzyme protein expression across the fetal, pediatric and adult populations is shown in bar graphs for CYP3A 
[D], CYP2C [E], and FMO [F]. Fetal samples are depicted by white bars, the pediatric population by grey hatched bars, and the adult 
population by black bars.  
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Figure 4. 3 Functional Activity of CYP3A Represented by the Formation of 6β-OH 
Testosterone in HLM and Recombinant Enzymes. Panel A depicts the metabolite 
formation normalized to the total microsomal protein. Panel B represents the metabolite 
formation normalized to the CYP3A expressed in each sample. The horizontal line in each 
group represents the mean value. 
 
 
109 
 
 
Figure 4. 4 Representative Chromatographs from the LC-MS/MS Analysis of 
Testosterone Metabolite(s) Formed by CYP3A Enzymes. Each panel shows the 
chromatograms for testosterone (substrate), 6β-OH testosterone (metabolite), and 
voriconazole (internal standard). All chromatograms represent metabolite formation at the 
30 minute time point for adult HLM [A], recombinant CYP3A4 [B], fetal HLM [C], and 
recombinant CYP3A7 [D]. The X-axis represents time in minutes and the Y-axis represents 
abundance of mass to charge corresponding to the indicated analyte.  
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Figure 4. 5 Functional Activity of CYP3A Represented by the Formation of 1’OH 
Midazolam from Midazolam. Formation rates were normalized to the CYP3A protein 
expression in each sample.  
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Figure 4. 6 Correlation Analysis of Enzyme Expression to Functional Activity. 
Formation of 6β-OH testosterone is correlated with the expression of the sum of CYP3A4 
and CYP3A5 proteins [A] and expression of the sum of CYP3A4, CYP3A5, and CYP3A7 
proteins [B]. Formation of 1’OH midazolam is correlated with the expression of the sum of 
CYP3A4 and CYP3A5 proteins [C] and expression of the sum of CYP3A4, CYP3A5, and 
CYP3A7 proteins [D]. The graphs depict the linear correlation (solid line) and the 95th 
confidence intervals (dotted lines). 
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Figure 4. 7 CYP2C9 Functional Activity as Shown by the Formation of 4’OH 
Diclofenac. Formation rates were normalized to the total microsomal protein [A] and the 
CYP2C9 protein in each sample [B]. Horizontal lines represent the mean values in each 
panel. 
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Figure 4. 8 CYP2C19 Functional Activity as Shown by the Formation of 4’OH 
S-mephenytoin. Formation rates were normalized to the total microsomal protein [A] and 
the CYP2C19 protein in each sample [B]. Horizontal lines represent the mean values in 
each panel. 
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Figure 4. 9 Correlation Analysis of CYP2C Enzyme Expression to Functional Activity. 
Formation of 4’OH diclofenac is correlated with the expression of CYP2C9 protein [A]. 
Formation of 4’OH S-mephenytoin is correlated with the expression of CYP2C19 protein [B]. 
The graphs depict the linear correlation (solid line) and the 95th confidence intervals (dotted 
lines). 
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Figure 4. 10 FMO Functional Activity as Shown by the Formation of Cimetidine 
Sulfoxide. Samples were normalized to total microsomal protein [A] and the total FMO1 and 
FMO3 protein in each sample [B]. The bars [A] represent values derived from n= 6 and the 
error bars depict standard deviation. Horizontal lines [B] represent the mean values in each 
panel. 
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Figure 4. 11 Correlation Analysis of FMO enzyme expression to functional activity. 
Abundance measures the sum of the FMO1 and FMO3 isoforms. The graph depicts the 
linear correlation (solid line) and the 95th confidence intervals (dotted lines).  
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CHAPTER 5 
Integrating In Vitro Sildenafil Metabolism into a Physiologically Based Pharmacokinetic 
(PBPK) Model: Validating a Bottom-up Modeling Approach 
 
OVERVIEW 
Sildenafil, a phosphodiesterase-5 inhibitor, is approved for the treatment of 
pulmonary arterial hypertension in adults. It has become an attractive therapeutic option for 
premature neonates with pulmonary hypertension due to the lack of effective medications 
approved for this indication in this population. Characterization of sildenafil 
pharmacokinetics (PK) is necessary in premature neonates in order to reliably assess the 
efficacy of this drug in this population. Sildenafil is extensively metabolized by drug 
metabolizing enzymes (DMEs), with less than 2% of the parent compound being excreted 
unchanged in the urine. The ontogeny of these DMEs could impact sildenafil metabolism 
and, therefore, the PK in this vulnerable population. A physiologically based 
pharmacokinetic (PBPK) model was developed by integrating hepatic in vitro sildenafil 
metabolism data along with physiological parameters to predict the PK parameters of 
sildenafil in the adult population. Simulated populations contained 100 patients (10 trials with 
10 patients each), and the trial design and dosing was based on published clinical trials. 
Simulations yielded PK parameters which were compared against published values, and 
visual predictive checks were employed to validate the models. The validated adult PBPK 
model was then adapted to create a model for premature neonates so as to determine the 
major factors that contribute to sildenafil PK premature neonates. The adult PBPK models 
predicted sildenafil PK parameters that corresponded well with observed values within a 1.6 
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fold-error. A PBPK model for intravenous (IV) infusions in full term neonates accurately 
predicted sildenafil clearance, and also demonstrated that the fraction of unbound drug 
affected its volume of distribution (Vd) and clearance. The prospective PBPK model for 
premature neonates suggests that this population exhibits differences in the fraction of 
unbound sildenafil as well as the fraction of sildenafil absorbed. The PBPK approach 
employed in this study enables the investigation of physiologic mechanisms that could lead 
to high variability in sildenafil PK in premature neonates.  
INTRODUCTION 
Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor originally designed as a 
cardiovascular therapeutic agent. In 2005, seven years after its original approval, sildenafil 
was finally approved as a therapy for pulmonary arterial hypertension (PAH) in adults. PAH, 
a group of diseases with a wide range of causes including coronary heart disease and 
idiopathic PAH, has a high rate of mortality. Sildenafil is an optimal choice for treatment of 
PAH, as PDE5 is highly specific for cGMP [1]. Although protein expression of PDE5 has 
been quantified in the cerebellum, heart, pancreas, penile, and lung tissues, only lung and 
penile tissue demonstrate PDE5 activity [2]. By inhibiting PDE5, cGMP accumulates in the 
pulmonary smooth muscle cell and inhibits the sarcoplasmic reticulum from releasing 
calcium thereby inducing vasodilation (Figure 5. 1) [3].  
A pivotal randomized control trial conducted in 278 PAH patients confirmed 
improvement in exercise tolerance, decrease in pulmonary pressure, and improvement in 
functional status with sildenafil therapy [4]. As cardiac and pulmonary diseases are not 
restricted to adults, clinicians also began to evaluate the efficacy of sildenafil in the 
treatment of congenital heart disease and pulmonary hypertension (PH) in children [5-7]. 
These small scale studies demonstrated that sildenafil was effective in reducing peripheral 
vascular resistance, time to extubation, time to hospital discharge, and improved exercise 
tolerance. However, due to the small number of subjects, these studies did not provide 
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sufficient power to evaluate the effect of sildenafil on morbidity or mortality in children. Thus, 
to better understand the safety and efficacy of sildenafil treatment in the pediatric 
population, the STARTS-1 trial, and the follow-up STARTS-2 trial, enrolled over 200 children 
1-17 years of age [8, 9]. Results from these trials showed that a moderate dose of sildenafil 
led to modest improvements in hemodynamics and survival, whereas a high sildenafil dose 
resulted in increased mortality. Although the authors suggested that further trials are needed 
to determine optimal sildenafil dosing in children, the FDA issued a black box warning for 
sildenafil use in children 1-17 years of age.  
The STARTS-1 and STARTS-2 trials did not examine the efficacy and safety of 
sildenafil in pre-term and term neonates, despite the fact that of the more than 80,000 
infants born at ≤ 32 weeks of gestational age each year in the United States [10], 40% of 
neonates, specifically those born at ≤ 28 weeks of gestation, develop bronchopulmonary 
dysplasia (BPD), which can lead to pulmonary arterial hypertension [11]. Prematurity 
increases the risk of morbidity and mortality, with problems such as PAH, prolonged 
hospitalization, developmental delays [12-14] and cognitive [15, 16] and language [17, 18] 
impairments. The only approved treatment for PAH in neonates is inhaled nitric oxide from 
which it is difficult to wean these infants as that can lead to rebound hypertension. Other 
supportive measures that have been used are extracorporeal support, surfactant treatment, 
and ventilation [19]. Owing to the success in treating adult and pediatric PAH despite the 
FDA black-box warning, sildenafil is an attractive option in neonates as its off-label use in 
the premature neonatal population has been shown to improve  hemodynamics as 
determined by ECG, and case reports suggest that sildenafil also improves outcomes in 
premature infants with BPD and PAH.[20-22]  
Optimal sildenafil dosing in premature neonates is unknown and is extrapolated from 
adult dosing. Sildenafil is cleared predominantly by hepatic oxidative metabolism. During the 
drug development process, Pfizer identified cytochrome P450 (CYP) 3A4 and CYP2C9 as the 
120 
 
predominant enzymes that convert sildenafil to its main metabolite, N-desmethyl sildenafil 
(Figure 5. 2) [23, 24]. Orally administered sildenafil is subject to extensive first-pass 
metabolism to the primary metabolite [25]. In healthy adult volunteers, the bioavailability of 
sildenafil is approximately 41% [26]. Since its elimination and PK rely so heavily on oxidative 
metabolism, simple allometric scaling of adult sildenafil dosing regimens is inappropriate for 
neonates, as hepatic DMEs are actively undergoing maturational changes in this population 
(Figure 4.2). 
As was done for prediction of voriconazole PK in children of ages 2 to 10 (Chapter 2) 
[27], in vitro sildenafil metabolism data obtained with adult human liver microsomes (HLM) 
were used to create a bottom-up adult PBPK model. Using pediatric in vitro sildenafil 
metabolism data, the model was then adapted to the premature neonatal population for 
which clinical data are either sparse or not available. The pediatric PBPK model accurately 
described sildenafil PK in this population, as well as important physiological factors the 
affect the PK.  
MATERIALS AND METHODS 
Chemicals, Reagents, and Sample Selection  
Sildenafil, N-desmethyl sildenafil, ketoconazole, quinidine, sulphaphenazole, 
fluvoxamine, NAPDH, and voriconazole were purchased from Sigma-Aldrich (St. Louis, 
MO). Pooled HLM were purchased from Xenotech, LLC (Lenexa, KS) and recombinant 
CYP3A4, 3A5, and 3A7 were purchased from Corning (Corning, NY). Human liver tissues 
from healthy adult (>18 years old), infant (2-5 months), and fetal (14-39 weeks gestation) 
donors were obtained from the NICHD Brain and Tissue Bank (Contract 
#HHSN275200900011C; Baltimore, MD).  
Preparation of Microsomes 
Human liver microsomes (HLM) were prepared as previously reported [28]. Briefly, 
0.5mg of hepatic tissue was homogenized in buffer containing 50 mM Tris-HCl, 1 mM EDTA, 
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and 154 mM KCl with protease inhibitors (pH 7.4). After homogenization, the samples were 
centrifuged at 10,000 x g for 30 minutes, and the supernatant collected and centrifuged 
again. The supernatant from the second centrifugation was mixed with a buffer containing 
100mM sodium pyrophosphate and 0.1 mM EDTA (pH 7.4) and then centrifuged at 100,000 
x g for 70 minutes. This step was repeated and the resulting pellet was resuspended in a 
buffer containing 10 mM KPO4, 1 mM EDTA, and 20% glycerol (pH 7.4). Microsomal protein 
concentration was measured using a BCA assay and HLM were stored in 20 µL aliquots at -
80oC. 
Sildenafil Oxidative Metabolism by Human Liver Microsomes 
Infant and fetal HLM (n = 2 each) as well as pooled adult HLM were incubated with 
sildenafil (10 μM), NADPH (1 mM) and MgCl2 (3 mM) in phosphate buffer (pH 7.4) to assess 
metabolic linearity over 60 minutes and a range of microsomal protein concentrations of 
0.05 mg/mL – 0.4 mg/mL. After establishing the linearity of sildenafil metabolism, HLM were 
incubated with varying concentrations of sildenafil (0.5 – 250 µM) to determine Vmax and Km 
for microsomal metabolism in each population. At 15 minutes, 100 µL aliquots of the 
incubation mixture were quenched with 300 μL ice-cold methanol containing voriconazole 
(0.1 µM) as the internal standard. Samples were centrifuged and analyzed for N-desmethyl 
sildenafil formation by LC-MS/MS. Metabolite formation rate was subjected to nonlinear 
regression analysis (GraphPad Prism version 6; La Jolla, CA) using the Michaelis-Menten 
equation to determine Vmax and Km. 
Role of Cytochrome P450 and Flavin-containing Monooxygenase (FMO) Enzymes in 
the Formation of N-desmethyl sildenafil 
Involvement of CYP3A, 2C9, 2C19, and 2D6 in sildenafil metabolism was assessed 
by incubating pooled HLM with sildenafil and inhibitors for CYP3A (0.3 µM ketoconazole), 
CYP2C9 (30 µM sulphaphenazole), CYP2C19 (3 µM fluvoxamine), and CYP2D6 (5 µM 
quinidine). The concentrations for the enzyme inhibitors were chosen based on their 
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potency for enzyme inhibition. In order to determine the contribution of FMO to sildenafil 
metabolism, pooled HLM were pre-incubated for 5 minutes in a water bath set at 45°C to 
inactivate FMO activity, and sildenafil metabolism was compared against metabolism by 
HLM that were not exposed to heat inactivation. In addition, recombinant FMO1 and FMO3 
were incubated with sildenafil and monitored for metabolite formation. For all enzyme 
inhibition studies, N-desmethyl sildenafil formation was measured and the percent inhibition 
was assessed by comparing individual enzyme activity after inhibition to the activity of 
control. Finally, recombinant CYP3A enzymes (CYP3A4, CYP3A5, and CYP3A7) were 
incubated with sildenafil to determine the rate of metabolite formation. Differences in 
metabolite formation were analyzed using a Kruskal-Wallis non-parametric ANOVA. 
Metabolite Analysis 
The LC-MS/MS system consisted of mobile phase (A) 0.1% formic acid in water and 
(B) 0.1% formic acid in methanol with a total flow rate of 0.7 mL/min. A Sciex API-4000 triple 
quadropole mass spectrometer was used with a Zorbax SB-C18 column (2.1 x 50 mm, 5 
µm). Samples were ionized using an ESI ion source and, following the injection of 10µL of 
supernatant, positive ions were monitored at the following MRM Q1/Q3 transitions (m/z):  
461.3→283.2 for N-desmethyl sildenafil and 350.2→127.2 voriconazole. 
Model Structure 
A step-wise bottom-up approach (Figure 5. 3) was used to first validate the adult 
PBPK models and then prospectively determine sildenafil PK parameters in children (aged 
0-5 months). Model development employed Simcyp software (version 14; Certara). Intrinsic 
clearance was calculated from the Vmax and Km values generated for fetal, infant, and adult 
tissues, as described above. Protein expression, determined by quantitative proteomic 
analysis using LC-MS/MS (Chapter 4), was incorporated into the model in order to 
accurately reflect fetal enzyme isoforms present in premature and full-term infants. Using a 
minimal PBPK model structure (Figure 5. 4), the perfusion-limited sildenafil model 
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incorporated physicochemical properties of the drug, and generated its intrinsic elimination, 
absorption and distribution parameters (Table 5. 1). A single adjusting compartment was 
added to the model to account for the unexplored second compartment shown in clinical 
trials. Protein expression data generated in chapter 4 were incorporated into the model. 
Simulated populations were created from the healthy volunteer and pediatric simulators and 
contained 100 patients (10 trials with 10 patients in each trial). Adult simulations included 
both IV (20 mg and 40 mg infused over 40 minutes) and oral (50 mg and 100 mg) dosing 
regimens. For full term neonates, a clinically-used IV dose of 0.22 mg/h was infused over a 
mean time of 82.4 hour to simulate the PK profile. Finally, simulations were performed for 
the premature neonatal population using doses that are administered to patients in the 
Neonatal Intensive Care Unit at UNC Hospitals.  
Model Validation 
Simulations for sildenafil disposition in the adult population yielded PK parameters 
that were compared against published values as well as data submitted in NDA approval 
documents [29-33]. Full term neonatal infusion doses were validated against a population 
PK model [34]. Model accuracy was assessed by calculating average fold error of the 
predicted clearance in simulated individuals plotted as a function of age as defined by the 
following equation: 
 ./ =  10
1
2 ∑ 456 (
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AUC and Cmax were assessed by generating the fold error for all simulated PK 
parameters using the following equation:  
 Fold error = 
,%*+% B&)C%
D'%,B% B&)C%   (2) 
Predicted PK parameters were considered acceptable if they were within a 2-fold 
error of observed values [35, 36]. For individual plasma sample predictions, a percent error 
was utilized to determine the difference between observed and predicted using the equation:  
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Visual predictive checks were employed to confirm that the predictions of the 
sildenafil plasma concentrations by the model were consistent with the observed plasma 
concentrations and standard deviation. Concentration-time profiles for adults were taken 
from published reports as well as NDA submission documents and were digitized using 
GetGraph data digitizer version 2.25.0.32. Visual predictive checks were performed for full 
term neonates using data from a population PK study and for premature neonates  using 
data from a phase I clinical trial conducted at UNC Hospitals (data currently unpublished) 
[34]. Observed sildenafil concentrations were superimposed on profiles containing the 
simulated mean and the 90% confidence intervals. 
Sensitivity Analysis 
Sensitivity analyses were performed to assess factors that could influence model 
performance. Specifically, the impact of a single adjusting compartment and fraction 
unbound, which were expected to affect the PBPK models, was evaluated. The input values 
were varied with a 10-fold increase and decrease to determine if either parameter 
significantly affected AUC and Cmax. 
RESULTS 
In Vitro Metabolism of Sildenafil by Human Liver Microsomes 
Metabolism of sildenafil by adult HLM was linear up to 15 minutes with microsomal 
protein concentrations of 0.05 mg/mL to 0.2 mg/mL. With 0.4 mg/mL of microsomal protein, 
metabolite formation was non-linear at 15 minutes. With fetal and infant HLM, the 
metabolism of sildenafil was linear up to 30 minutes with little to no metabolite formation 
under 5 minutes. In order to ensure adequate metabolite formation for quantitation, all 
assays were incubated for 15 minutes. With adult HLM, as the microsomal protein 
concentration increased from 0.05 mg/mL, the rate of formation of metabolite per mg protein 
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decreased (p < 0.001; Figure 5. 5). With fetal samples, metabolite formation was only 
quantifiable at microsomal protein concentrations of 0.1 – 0.2 mg/mL, with no quantifiable 
metabolite present at a protein concentration of 0.05 mg/mL. Unlike adult HLM, the rate of 
metabolism (per mg protein) by fetal and infant HLM remained constant with protein 
concentrations up to 0.2 mg/mL. For all subsequent assays, a microsomal protein 
concentration of 0.1 mg/mL was used for all three populations, although for the adult HLM, 
the rate of metabolism per mg protein was slightly lower at 0.1 mg/mL versus 0.05 mg/mL 
protein.  
The concentration-dependence of the rate of N-desmethyl sildenafil formation 
followed Michaelis-Menten kinetics (Figure 5. 6). The apparent Km for fetal, infant, and adult 
HLM was similar (10.4 ± 2.7, 41.5 ± 22.3, and 16.4 ± 3.0 µM, respectively). However, a clear 
trend towards an increase in Vmax was observed from fetal to adult tissues. Vmax for adult 
HLM was 5-fold higher than that observed with fetal samples, and over 2-fold higher than 
Vmax obtained with infant tissues (23.5 ± 1.5, 65.8 ± 12.3, and 135.8 ± 7.0 pmol/min/mg 
protein, respectively; p < 0.01). At high sildenafil concentrations, infant samples displayed 
over a 100-fold difference in N-desmethyl sildenafil formation between subjects. Eadie-
Hofstee plots (data not shown) confirmed the involvement of two enzymes in the metabolism 
of sildenafil by adult HLM. The intrinsic clearance of sildenafil by these two enzymes differed 
by 8-fold (187.1 and 22.2 µL/min/mg protein). An Eadie-Hofstee plot for fetal samples 
demonstrated that only one enzyme was involved in sildenafil metabolism with an intrinsic 
clearance value of 4.9 µL/min/mg protein. 
Metabolism of Sildenafil by Human Liver Microsomes and Recombinant Enzymes to 
Assess Contribution of CYP3A and CYP2C9 
In order to confirm the involvement of CYP3A and CYP2C9 enzymes in sildenafil 
metabolism, chemical inhibitors for these two enzymes, namely ketoconazole (0.3µM) for 
CYP3A and sulphaphenazole (30µM) for CYP2C9 were used as previously described [37]. 
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Chemical inhibition by ketoconazole resulted in a 90% decrease in metabolite formation (p < 
0.05), confirming the involvement of CYP3A in sildenafil metabolism. However, no difference 
in metabolite formation was observed in the presence of sulphaphenazole (Figure 5. 7). 
Therefore, the chemical inhibition scheme was broadened to assess the possible 
involvement of CYP2C19, CYP2D6, and FMO; i.e. inhibition of CYP2C19 with fluvoxamine 
(3 µM), CYP2D6 with quinidine (5 µM), and FMO by thermal inactivation. No decrease in 
metabolic activity of HLM was observed with chemical inhibition of CYP2C19 or heat 
inactivation of FMO; furthermore, recombinant FMO1 and FMO3 did not form N-desmethyl 
sildenafil. These results clearly demonstrated that CYP2C19 and FMOs do not contribute to 
sildenafil metabolism. Although CYP2D6-mediated sildenafil metabolism decreased by 20% 
in the presence of quinidine, this difference was not statistically significant. 
Since chemical inhibition of CYP3A decreased metabolite formation by over 90%, 
the contributions of three isoforms of CYP3A, namely CYP3A4, CYP3A5, and CYP3A7, to 
sildenafil metabolism were evaluated using recombinant enzymes (Figure 5. 8a). All three 
isoforms formed N-desmethyl sildenafil, with CYP3A5 showing a 4-fold and 7-fold higher 
metabolite formation compared to CYP3A4 and CYP3A7, respectively. Next, metabolism of 
sildenafil by the three CYP3A isoforms was examined as a function of substrate 
concentration. CYP3A5 exhibited a higher Vmax than either CYP3A4 or CYP3A7 (77.1 ± 
17.1, 56.0 ± 6.5, and 4.6 ± 0.6 pmol/min/pmol of CYP3A; Figure 5. 8b), whereas the 
apparent Km was similar between CYP3A5 and CYP3A7 (49.9 ± 30.0 versus 44.3 ±15.1 
µM). The apparent Km for CYP3A4 was over 2.5-fold higher than the Km of the other two 
isoforms (118.1 µM ± 29.0), indicating that CYP3A4 has a low-affinity for sildenafil. 
Furthermore, intrinsic clearance of sildenafil by CYP3A5 (3.9 µL/min/pmol CYP3A) was 
3-fold higher than that observed with CYP3A4, and 14-fold higher than the intrinsic 
clearance by CYP3A7 (1.2 and 0.1 µL/min/pmol CYP3A). These results suggest that 
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CYP3A5 has a high-capacity and high-affinity for sildenafil, whereas CYP3A7 is a high-
affinity, low-capacity enzyme and CYP3A4 is a low-affinity, high-capacity for this substrate. 
Metabolism of sildenafil by adult HLM exhibited biphasic Eadie-Hofstee plots, 
suggesting involvement of two CYP3A enzymes, CYP3A4 and CYP3A5. To determine the 
intrinsic clearance of sildenafil by each CYP3A in adult HLM, the intrinsic clearance 
generated from individual recombinant CYP3A4 and CYP3A5 was multiplied by the mean 
abundance of the respective CYP3A enzymes in HLM (Chapter 4). This approach allowed a 
direct comparison between intrinsic clearance of sildenafil by recombinant CYP3A enzymes 
and its intrinsic clearance by the respective CYP3A enzymes in fetal and adult HLM.  The 
intrinsic clearance of sildenafil by the two enzymes in adult HLM, derived from Eadie-
Hofstee plots, was 187.1 and 22.2 µL/min/mg protein, respectively, with approximately eight- 
fold difference between the two clearances. The intrinsic clearance of sildenafil by 
recombinant CYP3A4 and CYP3A5 enzymes was 90 and 11.7µL/min/mg protein, 
respectively, also showing approximately eight-fold difference. Thus, it is reasonable to 
conclude that sildenafil clearance by CYP3A4 was 187.1 µL/min/mg protein and by CYP3A5 
was 22.2 µL/min/mg protein in HLM. These values were then used in the adult models.  
Adult PBPK Models for Oral and IV Administration of Sildenafil  
Initially, a bottom-up approach using the enzyme kinetics of sildenafil metabolism 
derived from adult HLM was utilized to test the ability of the PBPK model to describe adult 
sildenafil plasma concentrations following IV infusion and oral dosing. The model predicted 
a Vd of 1.4 L/kg (90% confidence interval of 1.1-1.8 L/kg), which corresponds well with 
published clinical values of 1.2-1.4 L/kg [29, 38]. The AUC for 20- and 40 mg IV infusions 
was slightly over-predicted with a mean fold error of 1.6 and 1.4, respectively, and the 
predicted Cmax for these doses was within a 0.9 and 0.7 fold error, respectively. Model 
predictions of the AUC and Cmax for oral doses of 50- and 100 mg doses were accurate, and 
were within a 1.1-fold and 1.3-fold error for the AUC and Cmax, respectively, as shown in 
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Figure 5.9. The simulated Tmax for oral doses averaged 1h (90% confidence interval of 0.73-
1.3 h), which is in agreement with the observed Tmax of 1.0-1.5 hours [29, 25]. Finally, the 
model predicted a mean sildenafil bioavailability of 39% for both oral doses, which is within 
the range of 38-41% of its reported bioavailability [29, 25, 38], and a predicted 90% 
confidence interval range of 35% to 40%. The mean IV sildenafil clearance of 17.9 L/h was 
under-predicted by a small degree, with a mean average fold error of 0.66. The PBPK 
models predicted an oral clearance of 45.4 L/h for sildenafil, which corresponded with the 
average oral clearance of 57 L/h, with a mean average fold error of 0.92. The average fold 
error for adults based on age is shown in Figure 5. 10a. Visual predictive checks for 
sildenafil IV dosing confirmed that simulated concentration-time profiles contained the mean 
sildenafil plasma concentration for each time point within the 90% confidence intervals 
(Figure 5. 11). For sildenafil oral doses, the 90% confidence interval predicted by the model 
included the concentrations at each time point  (Figure 5. 12).  
Neonatal PBPK Models for Oral and Intravenous Sildenafil 
Applying this approach to the neonatal population, data on sildenafil intrinsic 
clearance by CYP3A7, generated with fetal HLM were incorporated into a PBPK model. The 
initial neonatal PBPK model predicted a sildenafil clearance of 1.8 L/h, which corresponded 
well with a clearance of 1.72 L/h in full term neonates that was determined by population PK 
analysis. Figure 5. 10B shows the average fold error for sildenafil clearance in simulated 
neonates during the first 7 days of life. Since the population PK study reported that sildenafil 
is 93.9% protein-bound, the fraction unbound parameter was incorporated into the PBPK 
model. Following the integration of these changes into the model, the Vd of sildenafil 
increased from 1.1 L/kg to 1.6 L/kg, resulting in an increase in predicted total systemic 
clearance of this drug from 1.8 L/h to 2.5 L/h. The simulated means and 90% confidence 
intervals of the visual predictive checks for full term neonates encompassed 49% of all data 
points (Figure 5. 13). The change in sildenafil clearance normalized to bodyweight from birth 
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to adulthood is represented as a graph in Figure 5. 14. Model-predicted sildenafil clearance 
decreased from the first month of life to 6 months of age, with a 1.3-fold increase in 
clearance when the fraction unbound was doubled in the first month of life.  
In order to determine the effect of the ontogeny of the CYP3A family on sildenafil 
clearance from birth to adulthood, the fraction of sildenafil metabolized by each CYP3A 
isoform was estimated and the data are shown as a graph in Figure 5. 15. CYP3A7 
accounted for over 89% of sildenafil metabolism within the first month of life, which 
decreased to less than 1% by adulthood. Conversely, CYP3A4 and CYP3A5 accounted for 
8% and <0.1% in the first month of life, respectively, and increased to 92% and 2.8% in 
adults, respectively  
Finally, a prospective PBPK model for premature neonates was created, and model 
predictions were compared against clinical data from one of the patients enrolled in a recent 
phase I clinical trial that has currently enrolled and analyzed concentration-time data for four 
premature neonates. This patient received oral dexamethasone, a known CYP3A4 inducer, 
at the end of plasma sample collection, which was used to test if the model could identify a 
DDI. Four iterations were tested including a decrease in fraction absorbed, a decrease in 
fraction of unbound sildenafil, a decrease in both fraction unbound and fraction absorbed, 
and enzyme induction by dexamethasone. Visual predictive checks were conducted to 
determine if sildenafil concentrations in the sparse samples collected from a neonate born at 
25 weeks gestation were within the 90% confidence intervals (Figure 5. 16). The predictions 
of the first two iterations of the model that incorporated only the adjustments in the fraction 
of the sildenafil dose absorbed or in the fraction unbound showed that the sildenafil 
concentrations from three samples were within the 5th percentile of the model. However, the 
model over-predicted the concentrations of the final sample which was collected after the 
administration of dexamethasone, by more than 600%. Integrating a decrease in both the 
fraction of sildenafil absorbed and the fraction of unbound drug improved the model so that 
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two of the three samples were within a percent error of 3.4 % and 13.8 % of the simulated 
mean and the third sample was within the 5th percentile.  
The final step was to incorporate the potential increase in sildenafil intrinsic 
clearance by all three CYP3A isoforms due to enzyme induction by dexamethasone 
administration. This iteration kept the decrease in both the fraction of sildenafil absorbed 
and the fraction of unbound drug. These adjustments improved model predictions so that all 
four samples from the patient were contained within the 90% confidence intervals.  
Sensitivity Analyses  
Sensitivity analysis was applied to adjust the input parameters of the fraction 
unbound as well as components of a single adjusting compartment by 10-fold in both 
directions (i.e., increase or decrease) to determine how these changes affect AUC, 
clearance, Cmax, and other pertinent PK parameters. Sensitivity indices measure the ratio of 
changes in PK parameters over the change in input parameters (
∆HI HJKJLMNMK
∆OPQRN HJKJLMNMK). The 
sensitivity analysis of the single adjusting compartment in both neonatal and adult 
populations showed no significant differences in any PK parameters in either population. 
However, when the fraction unbound was increased, the Vd and total systemic clearance 
increased while AUC and Cmax decreased (Figure 5. 17).  
DISCUSSION 
It has been nearly two decades since sildenafil first received FDA approval. Since 
then, therapeutic indications have expanded from its original approved indication in adult 
males to include adult females and pediatric/neonates/premature neonates as patients. 
Despite including the patient population over a wide age range, little information is known 
about how the ontogeny of DMEs affects sildenafil PK. Since sildenafil is extensively 
metabolized, it is critical to understand how maturational changes in the predominant 
sildenafil metabolizing enzymes affect its PK. 
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Originally, Hyland et al. identified CYP3A4 and CYP2C9 as the two main enzymes 
responsible for sildenafil metabolism [23]. However, within the same year, Warrington et al. 
reported that CYP2C9 plays only a minor role in sildenafil metabolism, leaving a significant 
gap in knowledge that makes it important to elucidate the role of DMEs in sildenafil 
metabolism and its clearance, their ontogeny, and how they could play a role in DDI. The in 
vitro work presented in this research corroborated the work by Warrington et al., and 
implicated CYP3A as the primary enzyme that contributes to over 90% of sildenafil 
metabolism. Further, the current work expanded on the previous studies, and demonstrated 
that genetically polymorphic CYP3A5 [39] was also involved in sildenafil metabolism. In fact, 
studies with recombinant CYP3A enzymes showed that CYP3A5 had higher catalytic activity 
toward sildenafil than CYP3A4 or CYP3A7. Thus, it was necessary to predict the 
contribution of CYP3A5 to sildenafil metabolism based on its tissue expression. When the 
intrinsic clearance of recombinant CYP3A isoforms were normalized to their abundance, it 
was apparent that CYP3A4 would have greater contribution toward sildenafil metabolism 
than CYP3A5.  
The rate of sildenafil metabolism by fetal, infant, and adult HLM increased with 
increasing concentrations of the parent drug. Infant HLM, obtained from tissue samples 
harvested from individuals ranging in age from 2-5 months, displayed a high variability in 
sildenafil metabolism with some HLM exhibiting enzyme activity similar to that observed in 
adults, and other infant HLM with activity that was similar to fetal samples. This is not 
unexpected as CYP3A7 expression decreases and CYP3A4 increases over this age range. 
Due to this change in enzyme expression and overall enzyme activity, the intrinsic clearance 
of sildenafil as determined with an Eadie-Hofstee plot could not be resolved. However, 
because adult HLM express CYP3A4 and CYP3A5 and fetal samples primarily express 
CYP3A7, Eadie-Hofstee plots were utilized to determine the intrinsic clearance of sildenafil 
by each CYP3A isoform in HLM. The difference in intrinsic activity between CYP3A4 and 
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CYP3A5 in HLM was similar to that observed using recombinant enzymes. Interestingly, the 
intrinsic clearance for recombinant CYP3A7, normalized to enzyme expression, was 10-fold 
higher than the intrinsic clearance of sildenafil determined with HLM, demonstrating that 
recombinant systems are not always predictive of tissue enzyme activity. Recombinant 
systems typically reflect on adult cellular physiology, including protein and oxidoreductase 
composition, and do not necessarily reflect fetal or pediatric cellular physiology. These 
concepts were also discussed in Chapter 4.  
Incorporating adult CYP3A intrinsic clearance data into the PBPK model produced a 
reliable adult model for IV and oral dosing. These models provided strong evidence that the 
bottom-up modeling approach using intrinsic clearance data derived from hepatic HLM could 
accurately predict the PK parameters of sildenafil. Next, CYP3A7 intrinsic activity was 
incorporated into a neonatal PBPK model. Model simulations were based on the average 
sildenafil dose and the duration of sildenafil infusions that were presented in a population PK 
analysis. By incorporating the known value of sildenafil fraction unbound in adults, the PBPK 
model accurately predicted sildenafil clearance and accounted for 20% of the variability 
during the maintenance phase of the IV infusion. Next, the model was altered to incorporate 
a higher unbound fraction (6.1%) of sildenafil in the neonates. The simulated mean and the 
90% confidence intervals derived using the unbound fractions of 3.6% and 6.1%, comprised 
49% of all measured plasma samples. Differences in the infusion duration of sildenafil as 
seen with patient 1 or physiological differences observed in critically ill patients could 
account for plasma concentration data that were not within the 90% confidence intervals. 
The neonatal PBPK model also successfully predicted the fraction of sildenafil 
metabolized by CYP3A as well as clearance of the drug over the first year of life. In contrast 
to the published sildenafil population PK report by Mukherjee et al. [34], the neonatal PBPK 
model developed in the present study predicted that the fraction of sildenafil metabolized by 
each isoform over the first seven days of life would not be altered. In fact, the only significant 
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difference predicted by the model in sildenafil clearance was due to the sildenafil fraction 
unbound. Yet, while clearance and Vd were evaluated and presented, the model did not 
account for changes in protein binding. Thus, the primary conclusion that rapid maturation of 
enzymes contributes to increased sildenafil clearance was weakened by the authors’ failure 
to examine differences in protein binding.  
Furthermore, sildenafil clearance data published in their analysis was 1.72 L/h, which 
converts to 0.51 L/h/kg based on the average weight of the patients enrolled in the study. 
The IV clearance of this drug in adults is estimated to be approximately 27 L/hr, which is 
about 0.39 L/h/kg based on an average adult bodyweight of 70 kg. Based on these reported 
values, sildenafil clearance normalized to bodyweight decreases from the neonatal phase 
into adulthood, which corroborates the clearance profile presented in this research.  
Finally, by adapting the validated adult PBPK model to create a prospective neonatal 
PBPK model for sildenafil, we were able to confirm that the bottom-up approach could 
accurately predict CYP3A7-mediated in vivo clearance of the drug. In the premature 
neonatal model, the patient that was used for the visual predictive checks received 3 mg of 
sildenafil for over 500 hours before receiving dexamethasone, a known CYP3A inducer. 
However, in this case, food and medications were delivered via a G-tube which could lower 
the fraction of drug absorbed as reported previously [40]. Therefore, factors such as age, as 
well as absorption issues, had to be taken into consideration during the premature neonatal 
PBPK model development.  
It is known that the physiology of the gastrointestinal tract matures with age, and 
well-documented differences in medication absorption, and therefore PK, exist between 
neonates and adults. For example, it has been reported that absorption of doxapram is 
lower in premature neonates compared to adults [41]. The overall effects on drug absorption 
vary depending on the physicochemical properties of the drug. In an early example of this, 
acid-labile compounds, such as penicillin, were shown to have greater absorption in 
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premature and full term neonates compared to infants and children due to the higher gastric 
pH of the stomach [42]. For highly lipophilic compounds, the decrease in bile salts and 
slower gastric emptying time during the neonatal phase affect the extent of absorption [43]. 
Furthermore, food increases the pH in the stomach, thus diminishing the gastric dissolution 
of weak bases [44]. Studies in adults have shown that food slows down the absorption of 
sildenafil and also decreases both its Cmax and AUC [26]. While it was concluded that in 
adults these effects would not significantly affect the PK of sildenafil, these changes in 
sildenafil absorption could have a much larger and more clinically relevant effect in neonates 
where drug absorption is slower and often erratic [45]. Finally, differences in absorption can 
be seen when administering medications via a G-tube, in which all other medications and 
food are also delivered. For these reasons, the integration of a decrease in the fraction of 
the sildenafil dose absorbed in the premature neonatal model was warranted. 
Changes in protein binding associated with age creates a multifaceted concern with 
drug absorption in neonates. Protein binding is a complex process involving bilirubin, 
albumin, and other plasma proteins, and has been linked to differences in drug clearance in 
premature and full term neonates [46-48]. Despite normalization of protein concentrations in 
the plasma, binding is still lower in neonates compared to adults, indicating that neonatal 
plasma proteins have a lower affinity for substrates [49]. Increasing unbound fraction of a 
drug in the plasma increases the Vd of the compound [50], which was predicted for sildenafil 
by the PBPK model.  
When assessing whether protein binding can affect the pharmacokinetic profile of a 
compound, it is essential to understand the factors that affect clearance. Hepatic clearance 
(ClHepatic) is influenced primarily by blood flow (QH) and extraction ratio (E) as shown by 
equation (4).  
S%T&*+ = US  × /  (4) 
135 
 
Extraction ratio is the efficiency of an organ to clear a compound during one pass and ranges 
from 0 (no clearance) to 1 (complete clearance). Compounds are empirically labeled as low 
(≤ 0.3), intermediate (0.3 - 0.7) or high extraction (≥ 0.7), as per the values shown in the 
parentheses. The extraction ratio is calculated from the systemic unbound fraction (fu), 
intrinsic clearance (Clint), and hepatic blood flow (QH) as shown by equation (5).  
/ =  VW × X);2=YZ[ (VW × X);2=)  (5) 
Integrating equation 5 into equation 4, the final equation (6) for hepatic clearance is:   
S%T&*+ =  US × VW × X);2=YZ[ (VW × X);2=)  (6) 
In healthy adults, sildenafil is classified as an intermediate to high extraction 
compound with an extraction ratio between 0.6-0.7. As evidenced by equation 6, only 
hepatic blood flow influences clearance for high extraction compounds and changes in 
protein binding do not affect total compound concentrations. Therefore, in adults, changes in 
protein binding would not yield any differences in sildenafil PK.  
However, with intermediate extraction compounds, all three components (protein 
binding, blood flow, and intrinsic clearance) influence total compound concentration and 
systemic clearance. It is reasonable to assume that the lower intrinsic clearance in the fetal 
samples signifies a lower extraction ratio of sildenafil in premature neonates compared to 
adults, thereby making sildenafil at best an intermediate extraction compound in this 
population. This concept is important since premature neonates have lower expression of 
plasma proteins and a decreased affinity of compounds to these proteins.  
As shown in the population PK analysis by Mukherjee et al., full term neonates have 
a higher fraction of unbound sildenafil in plasma as well as higher weight-normalized 
clearance compared to adults supporting this hypothesis [34]. Similarly, a higher weight-
normalized clearance of micafungin is seen in neonates as compared to adults. Micafungin 
plasma binding was measured in serum taken from adults and neonates. This study found 
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that the higher fraction of unbound micafungin in neonates was responsible for the higher 
clearance compared to adults [48]. In addition, age-dependent differences in the extraction 
ratio have already been presented in this dissertation (Chapter 2). Accordingly, more data 
are necessary on the extent of sildenafil protein binding in premature and full term neonates. 
Both the contribution and the affinity to specific plasma proteins need to be elucidated in 
order to validate any premature or full term neonatal model for sildenafil.  
Combining these two physiological parameters improved the prediction of the model 
to include 75% of the measured plasma samples within 90% confidence intervals of the 
simulated mean. The only plasma sample that was not encompassed by the model was one 
that was collected following the administration of four doses of dexamethasone, a known 
inducer of CYP3A4.  
While CYP3A4 induction by a variety of medications has been conclusively shown, 
little is known about how these inducers affect CYP3A7. Induction of the CYP3A isoforms in 
fetal hepatocytes demonstrated that binding of ligands to glucocorticoid receptors can 
induce the gene expression of CYP3A7 [51, 52]. Limited data are available on the extent to 
which CYP3A7 activity is induced. Studies with CYP3A4 have shown that gene expression 
does not always correlate with induction of enzyme activity [53, 54]. These studies, as well 
as initial studies examining the effect of inducers on enzyme activity, revealed that, following 
induction, the apparent Km remains unchanged, while the Vmax can increase by 2- to 8-fold. 
Assuming an increase in the Vmax of CYP3A7, similar to that observed with CYP3A4 
induction by dexamethasone, the intrinsic clearance by all CYP3A isoforms was doubled. 
Following the incorporation of this higher intrinsic clearance into the premature neonatal 
PBPK model, the fit of the model improved to also include the sample with the lowest 
sildenafil concentration that was collected after four doses of dexamethasone.  
One limitation of this research is the inability to specifically inhibit only one CYP3A 
isoform without affecting the activity of the other isoforms. Due to this limitation, Eadie-
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Hofstee plots were required to determine the Vmax and Km of the two enzymes involved in 
sildenafil metabolism. Despite this limitation, a correlation was observed between the fold-
difference in the intrinsic activity of recombinant CYP3A4 and CYP3A5 and the intrinsic 
clearance of sildenafil by the two enzymes in HLM. Furthermore, the contribution of each 
isoform could be predicted as enzyme activity and protein expression were incorporated into 
the PBPK model. Model predictions showed that the fraction of sildenafil metabolized by 
each isoform was altered in different age groups, suggesting the maturation-related changes 
in the expression of CYP3A isoforms.  
Another challenge with this study was the limited data on the optimal AUC or Cmax 
that is required to reach the target endpoint. Current studies exploring target endpoints and 
the pharmacodynamics (PD) of sildenafil in premature neonates are ongoing. Until a specific 
target for the endpoint and further analysis of the PD profile are elucidated, a target dose 
cannot be reached. However, after validating the ability of the model to predict sildenafil PK 
and PD, this model can be utilized to assess the dose required to reach the target sildenafil 
exposure.  
The PBPK models presented here demonstrate that a bottom-up approach can be 
adopted to understand medications that are cleared extensively by oxidative metabolism. 
This strategy greatly advances our understanding of how the ontogeny of DMEs influences 
the contribution of enzymes to metabolic clearance of drugs. An in-depth understanding of 
the expression and activity of each DME can enable us to determine its interaction with 
physiological factors that play a pivotal role in the variability of drug PK in premature 
neonates. By identifying factors that affect this variability in PK, future clinical trials 
assessing sildenafil PK-PD in premature neonates can be improved in order to attain better 
outcomes. 
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Table 5. 1 Table Summary of Sildenafil Intrinsic PK Parameters and Physiochemical 
Properties Used for Model Development. Fa fraction of sildenafil absorbed; SAC single 
adjusting compartment; Plasma fu fraction unbound in the plasma; fu,Mic fraction unbound in 
microsomal incubation; Clint intrinsic clearance. 
Parameter Input 
Molecular Weight (g/mol) 474.58 
Compound Type Monoprotic Base [38] 
LogP 2.97 [38] 
pKa 6.5 [38, 55] 
Absorption Model 1st order [55] 
Fa 0.92 [55] 
Ka (1/h) 2.58 [55] 
Distribution Model Minimal PBPK Model 
Prediction Model Method 1 (Poulin and Theil) 
SAC Q (L/h) 3.57 [30] 
Plasma fu 0.036 [38] 
fu,Mic predicted 0.97 
Renal Clearance (L/h) 0.72 
Elimination: Enzyme Kinetics (HLM) 
 CYP3A4 CYP3A5 CYP3A7 
Hepatic Clint (μL/min/mg) 187.1 22.2 4.9 
  
 
Figure 5. 1 Sildenafil Mechanism of Action. Nitric oxide synthases (NOS) produces nitric oxide (NO) which is released to the 
pulmonary smooth muscle cells and activates guanylate cyclase to produce cGMP, preventing the release of calcium, which induces 
contractions, from the sarcoplasmic reticulum (SR) thereby allowing for vasodilation.   
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Figure 5. 2 Metabolism of Sildenafil by Drug Metabolizing Enzymes. Sildenafil is 
metabolized to the main circulating metabolite, N-desmethyl sildenafil. This metabolite is 
then eliminated into the feces (approximately 70-85% of the dose). An aliphatic 
hydroxylation of sildenafil occurs and that metabolite is excreted into the urine 
(approximately 10-15% of the dose)  
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Figure 5. 3 Sildenafil PBPK Model Workflow. The diagram outlines the bottom-up 
approach for scaling the in vitro intrinsic clearance of sildenafil from adults to full-term and 
premature neonates as well as the output from the model.  
 
 
 
 
Figure 5. 4 Sildenafil Minimal PBPK Model Utilized in Simcyp. The diagram demonstrates the model structure for the minimal 
PBPK model, which includes the rate of absorption (ka) from the small intestines into the portal vein. From the portal vein, sildenafil 
travels with the portal vein blood flow (QPV) to the liver where it can be metabolized. Sildenafil then moves with the hepatic blood flow 
(QH) to the systemic compartment from where it can flow back to the liver, the portal vein or into a single adjusting compartment. 
Intravenous infusions follow similar pathways except for absorption through the small intestine.  
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Figure 5. 5 Sildenafil Metabolism as a Function of Microsomal Protein Concentration 
by HLM from Fetal, Infant, and AdultTissues. Microsomes prepared from adult, fetal, and 
infant hepatic tissues were incubated in triplicate at microsomal concentrations between 
0.05 mg/mL and 0.4 mg/mL. Metabolism by adult, fetal, and infant samples are shown as 
the mean ± standard deviation in shades of blue, yellow, and purple, respectively.  
 
 
 
 
 
Figure 5. 6 Concentration-dependent Formation of N-desmethyl Sildenafil by HLM from Fetal, Infant, and Adult Tissues. 
Sildenafil at concentrations of 0.5 µM to 250 µM were incubated with fetal [A], infant [B], and adult [C] HLM (n = 6 per group) in 
triplicate and shown as the mean ± standard deviation for each individual. A nonlinear regression curve was fit to the data using the 
Michaelis-Menten equation.  
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Figure 5. 7 Contribution of CYP3A, CYP2C9, CYP2C19, CYP2D6, and FMO1/3 to Sildenafil Metabolism by Human Liver 
Microsomes. [A] Inhibition of sildenafil metabolism was assessed by incubating pooled HLM (n = 3) with chemical inhibitors of 
CYP3A (yellow), CYP2C9 (green), CYP2C19 (purple), and CYP2D6 (pink). [B] Contribution of FMO1/3 to sildenafil metabolism was 
assessed by heat inactivation of microsomes (compare blue bar and the bar with grey vertical lines), and by incubating sildenafil with 
recombinant FMO1 and FMO3. In vitro data are presented as mean ± standard deviation. 
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Figure 5. 8 Rates of Formation of N-desmethyl Sildenafil by Recombinant CYP3A4, CYP3A5, and CYP3A7. [A] Turnover rates 
of the formation of N-desmethyl sildenafil is depicted for CYP3A4 (blue), CYP3A5 (yellow), and CYP3A7 (green). [B] Rates of 
sildenafil metabolism to N-desmethylsildenafil by CYP3A4 (blue squares), CYP3A5 (yellow squares), and CYP3A7 (green squares) 
as a function of sildenafil concentrations. A nonlinear regression curve was fit to the data using the Michaelis-Menten equation. Data 
are presented as mean ± standard deviation.  
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Figure 5. 9 Predictive Accuracy Plots for AUC and Cmax. The fold error ± standard 
deviation for AUC (circles) and Cmax (squares) of the 100 simulated patients in each dosing 
simulation are shown for IV infusions of 20- (yellow) and 40 mg (green) as well as oral doses 
of 50- (blue) and 100 mg (purple) of sildenafil.  
 
 
 
 
Figure 5. 10 Predictive Accuracy Plots for Clearance. Average fold error was calculated for each simulated individual and 
compared against observed clearance. Adult clearance [A] depicts the average fold error for oral (blue squares) and IV (yellow 
circles) dosing. For full term neonatal clearance [B] average fold error was compared against typical clearance values for neonates 
within the first 7 days of life.  
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Figure 5. 11 Visual Predictive Checks for Adult Intravenous Infusions of Sildenafil. 
Concentration-time profiles are shown for the 20 mg [A] and 40 mg [B] doses of sildenafil 
infused over 40 minutes. For all graphs, the solid black lines represent the simulated mean 
and the dashed lines represent the 95th and 5th percentiles. Insets represent the 
concentration-profiles on a log scale.  
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Figure 5. 12 Visual Predictive Checks for Adult Oral Sildenafil Doses. Concentration-
time profiles represent a 50 mg [A] and 100 mg [B] doses of sildenafil. For all graphs, the 
solid black lines represent the simulated mean and the dashed lines represent the 95th and 
5th percentiles. Insets represent the concentration-profiles on a log scale.
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Figure 5. 13 Visual Predictive Checks for an Intravenous Infusion in Full Term 
Neonates. The simulated dose was based on an averaged administered dose from 
published reports [34]. The simulated concentration-time profiles were generated by varying 
the fu from the average adult value (fu = 0.036; black solid line) to the average neonatal 
value (fu = 0.061; blue solid line). The dashed lines represent the 95th and 5th percentiles. 
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Figure 5. 14 Predicted Sildenafil Clearance from Birth until Adulthood. Changes in total 
systemic clearance were predicted using intrinsic clearance values with population ontogeny 
and expression of CYP3A isoforms. The neonatal group was split into two groups to 
demonstrate the range in total systemic clearance attributable to differences in protein 
binding observed in full term neonates [34]. The boxes represent the median clearance and 
the bars show the minimum and maximum values for clearance.  
 
 
 
Figure 5. 15 Ontogeny of the Fraction of Sildenafil Metabolized by CYP3A Isoforms. Pie charts represent the predicted percent 
metabolized by each CYP3A isoform as well as the fraction excreted renally.  
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Figure 5. 16 Visual Predictive Checks for Oral Doses to Premature Newborns. Prospective PBPK models were created by 
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decreasing the fraction absorbed [A], increasing the unbound fraction of sildenafil [B], combining the increase in fraction unbound 
and the decrease in fraction absorbed [C]. The last iteration of the model included decreases in fraction unbound and fraction 
absorbed, but also incorporated higher intrinsic clearance for all three CYP3A isoforms [D] due to the administration of oral 
dexamethasone, indicated by the arrow. 
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Figure 5. 17 Sensitivity Analysis for Sildenafil Fraction Unbound. Sensitivity analyses were performed to assess the effect of 
increasing the fraction unbound for neonatal Vd and clearance [A], adult Vd and clearance [B], neonatal AUC and Cmax [C], and adult 
AUC and Cmax [D].  
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CHAPTER 6 
Conclusions and Future Directions 
 
An Introduction to the Historical Context of Pediatric Clinical Trials 
Approximately 26% of the worldwide population is under 15 years of age, and thus 
would be classified as pediatric population [1]. Even in the United States, a country in which 
most, if not all, pharmaceutical companies obtain regulatory approval for marketing new 
products, over a quarter of the population is under 18 years of age. Despite this sizable pediatric 
population in the United States and worldwide, drug development plans focus on adult patients 
over the age of 18 years. Traditionally, adult doses have been scaled down by normalizing to 
body weight to approximate the pediatric dose, assuming that distribution and clearance are the 
same between adults and children, and then adjusting that dose by trial and error until a clinical 
response is achieved. This watch-and-see method leaves children vulnerable to toxic doses or 
inadequate efficacy.  
Many obstacles have led to this reluctance by the pharmaceutical companies and clinical 
researchers in identifying safe and effective doses for various pediatric populations during drug 
development. Issues surrounding pediatric clinical trials arise include risk-to-benefit ratio 
associated with the clinical investigation, the blood volume available for multiple blood 
monitoring, the pain associated with blood collection, and the difficulty and ethical issues in 
obtaining consent. All of these factors increase the difficulty in recruiting pediatric patients into 
clinical trials. In spite of these significant impediments to pediatric research, safety and efficacy 
data are still needed for this population. As shown by Benjamin et al., pediatric patients can 
present significantly different adverse events and safety profiles than their adult counterparts, 
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and pediatric clinical trials are the only way to obtain these data [2]. Administering medications 
to children without a complete understanding of their efficacy and safety profile is unethical. 
Therefore, in 1997 the United States created a legal framework to incentivize pharmaceutical 
companies that developed clinical evidence for safety and efficacy in pediatric populations of 
new and marketed products by extending marketing exclusivity periods for approved drugs to 
these companies. However, it took another six years before the Pediatric Research Equity Act 
(PREA) was enacted in the United States, and pediatric studies became mandatory for 
medications that could be used in pediatric populations. These regulatory requirements 
compelled the research community to develop improved methods to optimize doses for the 
pediatric populations while minimizing the risk associated with clinical research involving these 
populations.  
Development of Methods to Improve Pediatric Dosing Selection 
Conventional methods to predict pediatric clearance and dose utilize allometric scaling. 
When scaling down adult doses based on body weight, allometry could not accurately predict 
pediatric clearance, and a few different equations (chapter 1) were formulated to address this 
failure in extrapolation [3, 4]. However, all these scaling variations exhibited high percent error 
rates, even as high as 800% in some instances. Furthermore, none of these variations 
consistently predicted clearance better than the others for compounds in different therapeutic 
areas. Overall, the best allometric equation to scale doses and clearance depended on the age 
group and compound. This limitation prevented allometric scaling to be used prospectively to 
predict clearance or doses.  
Due to these limitations for predicting pediatric clearance with any reliability, another 
approach was needed. In the 1930s, a technique incorporating physiological components as 
well as drug disposition was developed by Toesten Teorell [5], but this method was overly 
cumbersome and implausible to perform by hand. The availability of high powered computers 
allowed this physiologically based pharmacokinetic (PBPK) modeling method to be resurrected 
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and adapted to the healthy adult population as well as “special” populations. Significant 
progress has been made in PBPK modeling and in March 2012, a FDA Clinical Advisory 
Committee concluded that PBPK modeling should be incorporated into pediatric drug 
development programs. However, that vote was split 7 to 6, meaning that PBPK models were 
still a hotly debated approach and needed further validation in order to be recommended for use 
in drug development.  
In order to validate PBPK modeling, it is necessary to define how to use this type of 
modeling. Two distinct types of PBPK modeling exist, the top-down and bottom-up approaches. 
The top-down approach, as it is applied to pediatric populations, uses clearance values from 
pediatric clinical trials or observations that are combined with physicochemical properties of the 
compound of interest and age-appropriate physiologic parameters. The utility of the top-down 
method is limited and difficult to assess due to the limited pediatric clinical data collected. The 
validation necessitates a circular use of the same data used to create the model. The bottom-up 
approach utilizes physicochemical properties and physiologic parameters, but derives intrinsic 
clearance from in vitro experiments using human tissues and their subcellular components from 
target populations. The majority of the initial pediatric PBPK models to date have utilized a top-
down approach [6-9]. Gradually an increasing number of bottom-up approaches are being 
developed and implemented [10-13]. Most of these bottom-up approaches use intrinsic 
pharmacokinetic parameters derived from recombinant enzymes using allometrically scaled 
maturation functions to determine whole organ clearance.  
One major limitation in using recombinant enzymes is the assumption that an enzyme 
will function exactly the same in the healthy adults and special populations. These assumptions 
are not founded in robust experimental evidence. Thus, limitations exist with scaling intrinsic 
clearance values generated by recombinant enzymes that are similar to allometrically scaling 
clinical clearance values. For instance, the relative contribution of the three enzymes (CYP3A4, 
CYP2C19, and FMO3) in metabolic clearance of voriconazole was different when liver 
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microsomes from adults or children (ages 2 to 10) were used as the source of oxidative 
enzymes [14]. This study was the first to show comparative metabolism of a drug using pediatric 
and adult liver tissues reflecting clearance differences between children (2-10 year of age) and 
adults. Intrinsic clearance values derived with the use of these hepatic tissues from the 
populations of interest were predictive of hepatic clearance. Such studies demonstrated that 
cellular differences exist between adults and children, and require a more sophisticated 
approach than scaling recombinant enzymes can provide.  
Thus, it is reasonable to expect that integrating the metabolic data generated with the 
use of age-specific hepatic tissues into a bottom-up PBPK model, the whole-body voriconazole 
disposition could be predicted for target populations. However, evidence for success of a 
bottom-up modeling approach based on in vitro metabolism data generated from tissues is 
limited in adults, and untested in children. Therefore, the overarching goal of this dissertation 
was to first develop a bottom-up PBPK model from in vitro metabolism data generated with adult 
hepatic tissue, and refine/validate the model and its predictions by iteratively using readily 
available adult clinical data. Upon successful development of an adult PBPK model, a 
corresponding pediatric PBPK model could then be developed by incorporating the relevant 
pediatric physiologic parameters, including expression levels of the relevant metabolic enzymes.  
Rationale for Compound Selection 
In order to test that a bottom-up PBPK modeling approach can predict pediatric doses, 
two compounds were chosen. In the first part of the project, the goal was to test and validate 
this approach by choosing a drug for which the predictions of the pediatric PBPK model, 
developed using the above approach, can be substantiated with available pediatric clinical PK 
data. Voriconazole was selected for this retrospective proof-of-concept phase (Chapter 2). 
Voriconazole, a potent triazole antifungal used for life-threatening infections in 
immunocompromised patients, is predominantly cleared via oxidative metabolism by CYP3A4, 
CYP2C19, and FMO3 in the liver. It displays different PK parameters in adults and children 
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(ages 2 to 10) that have been conclusively established in the literature. These differences 
include nearly 3-fold higher clearance and nearly half the oral bioavailability in children 
compared to adults, requiring an adjustment to a higher weight-normalized dose in pediatric 
patients. It is important to note that metabolism of voriconazole by pediatric liver microsomes 
was approximately 3-fold faster compared to the rate of metabolism by liver microsomes from 
adult donors [14], indicating that the in vitro system reflected the higher in vivo hepatic 
clearance. Furthermore, these studies showed developmental changes in voriconazole drug 
metabolizing enzymes and revealed that two CYP450 enzymes, CYP3A4 and CYP2C19, and 
flavin-containing mono-oxygenase (FMO) 3 contribute to 50%, 35% and 15% of voriconazole 
metabolism in adults, respectively, versus 20%, 50% and 30% in children. Since intrinsic 
clearance between adults and children reflected the 3-fold increase in clearance in children 
compared to adults, there was now a clear rationale to use in vitro metabolism data to build a 
pediatric PBPK model. A PBPK model would not only enable prediction of doses in children but 
also provide the ability to predict changes in whole-body disposition of the drug in response to 
intrinsic (genetic) and extrinsic (interactions with food or co-administered drugs) factors. Finally, 
as was shown in Chapter 2, the model could raise important new questions about differences in 
disposition of the drug in children compared to adults – e.g. the model prediction that 
voriconazole is subject to intestinal first-pass metabolism in children but not in adults. 
After proving the utility of this approach, the second part of this project was to apply this 
model prospectively to another compound (for which robust clinical data in the target population 
are not yet available) that is also cleared predominantly by oxidative metabolism so as to extend 
the applicability of this method to younger children, i.e. premature neonates (Chapter 5). 
Sildenafil, a phosphodiesterase-5 inhibitor, is under evaluation as a treatment option for 
pulmonary arterial hypertension, a significant cause of mortality in premature neonates. Orally 
administered sildenafil is subject to extensive first-pass metabolism, and is cleared 
predominantly via hepatic metabolism with only 2% of the parent excreted unchanged [15]. 
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Evidence showed that sildenafil was metabolized by CYP3A4 and CYP2C9. Approximately 79% 
of the metabolism was due to the CYP3A family, 20% by CYP2C9, and CYP2D6 and CYP2C19 
together contributing to < 1% [16, 17]. Expression of metabolizing enzymes is often low or 
absent, or fetal forms (e.g. CYP3A7, FMO1) are expressed in this vulnerable population. 
Metabolic capacity of these fetal forms, including specificity towards sildenafil, has not been well 
established, demonstrating why allometric scaling of adult dosing is inappropriate for premature 
neonates whose enzymes have not fully matured. Furthermore, limited information exists on 
efficacy and safety of sildenafil at the doses used in the pediatric population. A bottom-up 
approach could better define the differences, if any, in the enzymes responsible for sildenafil 
metabolism in the adult and premature neonatal populations, and a pediatric PBPK model could 
then be adapted from a corresponding (validated) adult model to determine the exposure and 
clearance of sildenafil in premature neonates, and used to assess sildenafil safety and, 
eventually, its efficacy.  
Retrospective Pediatric PBPK Model Development for Voriconazole  
For the retrospective proof-of-concept PBPK model, voriconazole in vitro 
pharmacokinetic parameters, Vmax and Km, were generated using healthy adult and pediatric 
hepatic tissues in the Thakker laboratory [14]. The bottom-up PBPK model incorporated these 
intrinsic clearance values into a population-based PBPK model using Simcyp (version 12.1; 
Certara). The PBPK model predicted adult and pediatric voriconazole clearance of 2.4 and 5.0 
mL/min/kg, respectively, which was within 20 and 25% of observed values (2.0 and 6.7 
mL/min/kg) [14]. The good correspondence of the observed to the simulated clearance is 
important since in vitro clearance values were generated using hepatic tissue. These results 
confirm that bottom-up PBPK models created by considering metabolism by relevant tissues in 
target patient populations incorporate contribution and expression levels of key metabolizing 
enzymes and allow reliable prediction of clearance. The model also expanded previously 
published data on differences in voriconazole clearance between adults and children to describe 
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the whole-body disposition of voriconazole. The PBPK model predicted adult oral bioavailability 
to be 83% with a 90% confidence interval of 69-93%, which was consistent with the observed 
bioavailability of 87% (range of 75-96%). For the pediatric population, the simulated 
bioavailability was predicted to be nearly 2-fold higher than the observed bioavailability in this 
population. Despite accounting for the higher pediatric clearance of voriconazole by hepatic 
tissue, the pediatric model was unable to predict lower oral bioavailability of voriconazole 
compared to adults. This discrepancy pointed to factors affecting absorption and pre-hepatic 
(intestinal) clearance as likely causes for lower oral bioavailability in children compared to 
adults. The absorption rate constant was ruled out as a problem in the model since simulated 
Tmax values deviated from observed values by less than 20%. Therefore, intestinal first-pass 
metabolism was incorporated into the model. Interestingly, this refined model yielded an 
improved oral bioavailability prediction of 51% with a 90% confidence interval range of 27-76% 
that corresponds to the clinically observed range of 44-66%. The incorporation of intestinal first-
pass metabolism into the pediatric model also improved predictions of AUC and Cmax, lending 
further support that this could be the cause of lower bioavailability in children.  
The PBPK modeling process raised a very interesting possibility that the oxidative 
enzymes in the intestine of pediatric population are more effective than those in the intestine of 
adults in metabolizing compounds as they cross the intestinal epithelium. It was important to 
eliminate other factors that may influence oral bioavailability of voriconazole preferentially in 
children in order to subject the hypothesis put forward as a result of the modeling process to 
rigorous scrutiny. Two likely factors that could contribute to lower bioavailability, gastric 
emptying time and small intestinal transit time, were tested and rejected after performing a 
sensitivity analysis that varied these factors by ten-fold in each direction and established that 
these changes did not yield improvements or variations in relevant pharmacokinetic parameters. 
Secondly, voriconazole is a highly permeable compound with low solubility, and exhibits high 
oral bioavailability in adults, which preclude any likely dependence on transporters during 
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absorption. Additionally, unpublished data from the Thakker laboratory demonstrate that 
changes in bile salt concentration do not affect voriconazole permeability across human 
intestinal epithelium. Furthermore, these Ussing-chamber studies also showed that in adult 
intestinal tissue, voriconazole N-oxide formed during absorptive transport was quantifiable, thus 
confirming that intestinal oxidative enzymes can metabolize voriconazole. Combining this 
information with the intestinal enzyme gene expression results, which point to higher expression 
of CYP3A4 gene in the intestinal tissue from children than in the tissue from adults (Chapter 3) 
suggests that intestinal first-pass metabolism is the most likely cause of lower bioavailability in 
children. A population pharmacokinetic model of voriconazole in children suggested that greater 
hepatic blood flow in children may have contributed to lower oral bioavailability of voriconazole 
in the pediatric population.[18] However, without measuring blood flow or plasma concentrations 
in the hepatic vein or portal vein, this statement would be purely speculative. Furthermore, the 
idea that hepatic blood flow affects voriconazole bioavailability is without merit as voriconazole 
is a low extraction compound (0.09-0.39); thus hepatic blood flow should have little effect on 
hepatic clearance and is therefore not a concern for influencing bioavailability. This supposition 
is further refuted by the voriconazole PBPK model presented in this work since differences in 
hepatic blood flow between adults and children have already been incorporated in the model.  
The PBPK models for adult and pediatric IV infusions predicted voriconazole PK 
behavior within acceptable limits including 3-fold greater clearance in children compared to 
adults. This suggests that the model is able to adequately account for higher efficiency of 
voriconazole metabolism by hepatic enzymes in children. While the adult oral model 
successfully accounts for nearly 100% oral bioavailability, the pediatric oral model could not 
simulate voriconazole PK and over-predicted oral bioavailability. This model, taken in the 
context of the sensitivity analyses and physiological changes, clearly suggests that hepatic 
metabolism or intestinal absorption/permeability-related parameters do not contribute to poor 
prediction of oral bioavailability. With this preponderance of evidence, the novel hypothesis 
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suggesting higher first-pass intestinal metabolism in children, relative to adults, should inspire 
future studies that would examine intestinal oxidative enzyme composition and expression in 
pediatric and adult populations. In addition, future studies should examine if the kinetics of 
voriconazole intestinal metabolism in children is significantly different than in adults because of 
the possibility that voriconazole in the intestinal lumen of children may achieve significantly 
different concentrations than in the intestinal lumen of adults. The most obvious follow-up study 
would be to compare in vitro metabolism of voriconazole by microsomes prepared from pediatric 
and adult intestinal tissues, and determine if the microsomes from pediatric intestinal tissue 
metabolize the substrate faster than those from adult intestinal tissue. In fact, such a study was 
conceived and attempted (Chapter 3). However, as discussed in Chapter 3, fresh pediatric 
intestinal tissue is not available, and the enzymes in the intestinal tissue harvested post-mortem 
are degraded by proteolytic enzymes to the point that meaningful metabolism data cannot be 
obtained using the microsomes prepared form such tissue. The studies in Chapter 3 not only 
demonstrate this, but also provide an improved microsomal preparation method so that only 1-3 
in of pediatric intestinal tissue, procured during surgery, can yield sufficient catalytically active 
microsomal enzymes for future comparative intestinal metabolism studies. Surgical resection 
procedures in children involving intestinal diseases can yield 1-3 in of healthy intestinal tissue, 
and thus the methods developed in this work and reported in Chapter 3 open the door for future 
studies that can test the predictions of the voriconazole oral PBPK model developed for 
pediatric populations. 
Overall, this bottom-up PBPK approach facilitated the understanding of mechanistic 
reasons for lower bioavailability between adults and pediatric populations, which has not been 
previously demonstrated. Furthermore, it shows that bottom-up PBPK models are sophisticated 
enough to not only model age-related differences in metabolizing enzymes, but also provide 
insights into the mechanisms and sources of pharmacokinetic differences. However, the most 
important contribution of this retrospective model was to provide a proof-of-concept for the 
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proposed pediatric drug development paradigm for compounds predominantly cleared by 
oxidative metabolism. 
Defining Cellular Mechanisms of Pediatric Clearance 
Clear differences in CYP2C19 and FMO3 mediated voriconazole and probe substrate 
metabolism by liver microsomes from children and adults were shown in the preliminary in vitro 
work published by Yanni et al as well as the voriconazole PBPK model [13, 14]. In order to 
elucidate the differences in expression and function in enzymes, quantitative real-time 
polymerase chain reaction (qRT-PCR) and quantitative proteomic analysis by mass 
spectrometry were employed for accurate determination of expression of CYP enzymes in liver 
and intestinal tissues from children and adults. Expression data were also paired with functional 
data for a robust analysis of how changes in DMEs’ gene and protein expression affect 
functional activity of enzymes. It is interesting to note that CYP2C19 is expressed to a greater 
extent in pediatric samples that in adults. An even more interesting observation was the higher 
CYP2C19 catalytic activity of hepatic microsomes, normalized to CYP2C19 protein, prepared 
from pediatric tissues compared to adult tissues. This is a surprising result has not been 
previously reported, and it suggests that the environment (e.g. lipid membranes of the 
endoplasmic reticulum) of CYP2C19 protein or its coupling with NADPH cytochrome P450 
oxidoreductase is different in the pediatric tissue compared to adult tissue. Thus higher 
expression of CYP2C19, combined with its higher catalytic efficiency in pediatric tissue, may 
explain greater contribution of CYP2C19 toward metabolism of voriconazole in children 
compared to adults.  
Hepatic tissues were analyzed for gene and protein expression of the CYP3A isoforms 
in fetal, pediatric and adult tissues. In addition, gene and protein expression of CYP2C9 and 
FMO1/3 were also evaluated in these tissues. This is because the second drug examined in this 
dissertation research was sildenafil, which is known to be cleared by hepatic CYP3A4 and 
CYP2C9 [16, 17]. Since CYP3A7 is the fetal form of CYP3A and premature neonates are the 
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target population for studying disposition of sildenafil, information on this enzyme was deemed 
to be necessary. In addition, the tertiary nitrogens in sildenafil are likely targets for FMO-
mediated metabolism; and therefore FMO1 (fetal form) and FMO3 were also examined. The 
results showed that fetal samples expressed CYP3A7 and FMO1 at the highest levels with little 
to no expression of CYP3A4, CYP2C9, or CYP2C19. A maturational switch from 3A7 and 
FMO1 to 3A4 and FMO3, respectively, was evident from these fetal samples compared to 
pediatric and adult populations. Furthermore, CYP2C9 expression was similar, but CYP2C19 
expression was higher in children compared to adults. For the first time, quantitative expression 
levels of these enzymes in these two populations have been examined.  
A complete analysis of cellular activity requires the inclusion of functional activity. This 
research applied the quantitative protein expression to normalize respective probe substrate 
metabolism by each enzyme to the corresponding CYP or FMO protein. For measurement of 
the CYP3A activity, adult and pediatric microsomes, as well as recombinant CYP3A4 and 3A5 
were evaluated by analyzing the rate of formation of 6β-OH testosterone (peak at 2.51 min) 
from testosterone. In addition, a minor metabolite was formed with molecular weight of M+16 
(hydroxylated metabolite) that eulted at 2.61 min. Contrary to literature reports, analysis of the 
metabolites formed by fetal tissues and recombinant CYP3A7 revealed that the metabolite that 
eluted at 2.61 min was the major product, with 6β-OH testosterone (2.51 min) as a minor 
product. Since previous studies only considered formation of 6β-OH testosterone by CYP3A7, 
these studies had concluded that CYP3A7 metabolizes testosterone at rates that are only a 
small fraction of the rates of testosterone metabolism by CYP3A4. These results, for the first 
time, provide evidence that fetal tissue can metabolize testosterone at a higher rate than 
pediatric or adult liver tissue, and that expression of CYP3A7 in fetal tissue accounts for this 
high rate of testosterone metabolism. Furthermore, testosterone is differentially metabolized by 
the CYP3A7 isoform to a novel metabolite with a retention time distinct from that of 6β-OH 
testosterone, the major metabolite formed by CYP3A4 and CYP3A5. For the CYP2C family, 
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2C9 exhibited comparable activity observed in adult and pediatric populations with negligible 
activity in fetal tissues, corresponding well to the gene and protein expression.  
Prospectively Applying a Bottom-up PBPK Model to Predict Sildenafil Disposition in 
Premature Neonates 
Sildenafil, as mentioned previously, was chosen because it is predominantly cleared by 
oxidative metabolism and because of its proposed use in premature neonates. The two major 
isoforms that have been implicated in sildenafil metabolism are CYP3A4 and CYP2C9. 
Preliminary in vitro studies in this work indicated that significant discrepancies exist regarding 
the enzymes responsible for sildenafil metabolism. Contrary to published reports that the 
primary enzymes involved were CYP3A4 and CYP2C9, these studies showed that sildenafil is 
metabolized predominantly by CYP3A4 and CYP3A5 in the pediatric and adult tissues and by 
CYP3A5 and CYP3A7 in the fetal tissue. The switch from CYP3A7 to CYP3A4 within the first 
few months after birth adds an interesting and novel feature to the development of a PBPK 
model of sildenafil in premature newborns when compared to a pediatric or adult PBPK model 
for sildenafil.  
The same approach that was used to develop the PBPK model for disposition of 
voriconazole in children was adopted for designing the model to predict sildenafil disposition in 
premature neonates. The adult PBPK sildenafil models (IV and oral) validated the use of a 
bottom-up approach utilizing intrinsic clearance generated from hepatic tissues, with CYP3A4 
and CYP3A5 as major contributors to metabolism. Using this approach and the intrinsic 
clearance values, the full term neonatal models for sildenafil disposition after IV and oral 
administration were developed. Simulations were validated against the sparse clinical data 
available in the literature. Integration of the in vitro metabolism of sildenafil by liver tissues from 
neonates into the PBPK model yielded important new information on the fraction of sildenafil 
metabolized by CYP3A7. These predictions show that the high expression of the CYP3A7 
enzyme in neonates overcomes its lower intrinsic clearance compared to CYP3A4 and 
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CYP3A5. Modeling the expression and activity generated an ontogeny pattern for clearance and 
the fraction of sildenafil metabolized by each isoform. In future studies these predictions can be 
tested using testosterone as a probe since CYP3A7 and CYP3A4/5 form different metabolites. 
Finally, after determining the ontogeny of enzymes, the model was used prospectively to predict 
PK and the physiological factors most likely to influence this profile in premature neonates, 
which were confirmed by the visual predictive checks from patients enrolled in a phase I trial at 
UNC Hospitals.  
Most importantly, this section of the dissertation confirms that bottom-up PBPK 
modeling, using tissues from relevant populations, increases and refines the knowledge 
regarding the major metabolizing enzymes involved in metabolic clearance, and how they 
function in different populations. A wide array of medications administered to the premature 
neonatal population could potentially influence the expression and function of the CYP3A family. 
Therefore, understanding the impact of metabolic differences on the disposition of a drug, like 
sildenafil, caused by differential expression and/or catalytic function of major metabolizing 
enzymes (i.e. CYP3A7 versus CYP3A4) between adults and premature neonates can play a 
pivotal role in determining drug-drug interactions caused by inhibition or induction. 
Physiological Relevance of CYP3A7 – The Fetal Form of CYP3A Family 
In the process of developing an understanding of the impact of the expression of 
CYP3A7 instead of CYP3A4 in premature neonates on sildenafil disposition, the studies 
performed to elucidate the expression and catalytic activity of the CYP3A7 protein revealed a 
very interesting property of CYP3A7. These studies showed that CYP3A7 is a steroid-specific 
P450 that has much higher metabolic efficiency for testosterone than reported previously [19-
21]. Relating this information to the existing knowledge that there is a precipitous decline of 
CYP3A7 expression over the first month after birth with concomitant rise in the expression of 
CYP3A4, the results provide an interesting insight into an important question: why does an 
isoform of CYP3A, which has low catalytic activity for other CYP3A4 substrates but high 
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efficiency to metabolize a steroid, exhibit high expression in the fetus and then switch off at 
birth? It is hypothesized that CYP3A7 is expressed in the fetus predominantly to metabolize 
high concentrations of the steroidal hormones that the fetus is exposed to from mother’s blood. 
At birth, there is a sudden decline in the steroidal hormone in the baby’s blood, and thus 
CYP3A7 is switched off while CYP3A4, an enzyme with a broad substrate specificity, is 
switched on. 
Novelty of Approach and Future Directions 
The paradigm for predicting pediatric doses proposed and supported by this research 
provides a new approach to modeling pediatric drug disposition that may improve prediction of 
pharmacokinetic parameters in children and thus dosing, and reduce ineffective or unsafe 
therapy and the need for costly and uncomfortable therapeutic drug monitoring. While the 
concept of bottom-up PBPK modeling of pediatric drug disposition has been previously utilized, 
the true novelty and significance of the approach developed in this work lies in the fact that 
these models are built on in vitro data from pediatric tissues that inherently include expression 
and catalytic efficiency of the relevant enzymes involved in the metabolic clearance of the drug 
being considered. This information is further refined by understanding the relative contributions 
of these enzymes in the metabolic clearance of the drug. For each of the two drugs studied in 
this work, a role of a new enzyme, FMO3 for voriconazole and CYP3A5 instead of CYP2C9 for 
sildenafil, was uncovered that was not identified even after extensive metabolism work 
performed by the company to meet the regulatory requirement for a New Drug Application. This 
work highlights the importance of mechanistic cellular and molecular studies prior to building a 
bottom-up PBPK model. These results demonstrate that use of expressed enzymes to build the 
bottom-up model would miss important and relevant information about how these enzymes 
interact in the tissue to affect the overall metabolic clearance of drugs. Such an approach 
provides in vitro – in vivo correlation and avoids the creation of a model that succeeds as 
random chance. The true significance of this work lies in the fact that the modeling approach will 
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improve PK predictions before initiating a pediatric clinical trial since it can be used to 
understand the disposition of metabolically cleared drugs as well as improve the knowledge of 
age-related differences in cellular mechanisms of clearance. 
When considering the bottom-up PBPK modeling approach as an in vitro-in vivo 
extrapolation (IVIVE) technique, it is important to note that predicting PK behavior of a 
metabolically cleared drug from in vitro metabolism is not always successful, even in adults 
where we have substantial knowledge of physiology. While minimal IVIVE methods work 
sometimes, it has been shown time and again that this seemingly simple technique does not 
work at all times. For instance, using human liver microsomes to identify intrinsic 
pharmacokinetic parameters overestimated Km and Vmax of phenytoin due to the lack of 
consideration of the effect of albumin binding; predictions were improved with addition of bovine 
serum albumin and fatty acid-free human serum albumin to the incubations [22]. This type of 
limitation is overcome in PBPK models as albumin concentrations and fraction unbound can be 
incorporated into the model. If corrections for nonspecific binding in the assay are not taken into 
the account, as they are in PBPK models, then clearance values can be over-predicted [23]. 
Additionally, simple IVIVE methods fail to incorporate the variability in populations because they 
use the average results to predict population clearance [24]. Therefore, using a simple IVIVE 
approach to determine clearances in the pediatric population would be challenging and 
unreliable. Applying this proposed bottom-up PBPK model can improve pediatric predictions by 
combining physiological components with the understanding of the cellular and molecular basis 
for differences in in vitro metabolic behavior of pediatric and adult tissues.  
For the bottom-up model to be truly successful, the results in this dissertation show that 
a few key steps need to be taken (Figure 6.1). First and foremost, enzymes involved in major 
metabolic transformation must be identified. After identifying the predominant enzymes, the 
kinetic parameters for each enzyme and enzyme expression should be characterized in the 
adult population in order to create an adult in vitro-in vivo relationship. The next step is to 
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characterize the kinetic parameters and measure quantitative expression of these enzymes in 
the pediatric tissues to evaluate the contribution and efficiency of each enzyme to metabolism of 
the compound. Relating these results to the adult in vitro-in vivo relationship will help define the 
differences between the adult and pediatric populations. Finally, these cellular mechanisms, 
functional data, and expression can be incorporated into the bottom-up PBPK model to predict 
clinical pharmacokinetic parameters in each population.  
Applying these steps will allow this approach to be expanded to different areas of 
research. For instance, while the work shown in this dissertation focused solely on metabolically 
cleared compounds, it is a viable technique for compounds absorbed, distributed or cleared via 
transporters. Currently, the ontogeny of transporters is poorly defined. As with this work, there is 
a strong possibility that transporters can function differently in pediatric patients compared to 
adults. In order to apply this method, quantitative expression of the transporters and their 
functional activities across the age ranges of interest will be required. As mentioned previously, 
improvement in experimental techniques will be required in order to quantitate the expression 
and function of transporters that are localized on the cell membrane as these are the only 
pharmacokinetically- and pharmacodynamically-active transporters for trafficking drugs between 
cell and systemic circulation. After quantifying these data, this information can then be 
incorporated into a bottom-up PBPK model to assess the effects of the maturation of 
transporters on pharmacokinetics, and eventually, pharmacodynamics.  
However, this proposed bottom-up approach does not come without some limitations. 
Techniques to study hepatic metabolism and transport in children have evolved to allow 
rigorous metabolism studies as well as transport studies. Cryogenically preserved fetal 
hepatocytes are now available for purchase [25]. However, intestinal tissue samples of high 
quality for metabolic and/or transporter studies are difficult to obtain for children under the age 
of 12 years old. While sufficient amounts of healthy intestinal tissue could be procured during 
surgeries, particularly in light of the enhanced techniques developed in this work for isolation of 
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subcellular fractions, the number of children undergoing gastrointestinal surgery is limited. The 
problem associated with limited supply is further amplified due to the need to bin children into 
developmental age groups unlike with adults. Taken together, these factors contribute to poor 
outcomes in developing intrinsic clearance parameters. Yet, research on the differences in 
cellular systems is increasing due to the realization of the importance of basic biological input 
parameters for metabolism and transporters in the development of computational models. As 
was seen with hepatic tissue, intestinal tissue procurement is increasing as academia, the 
medical community, and the pharmaceutical industry respond to these scientific needs [26]. 
Furthermore, a large sample size is not always necessary. Population models add these 
specific input parameters into a larger system comprising physiological factors and simulate 
individuals with combinations and variability in these components, thereby decreasing the effect 
of the error of one component on all predictions. As science progresses and more samples 
become available, the predictions will continue to improve. Despite these limitations, this 
bottom-up method still represents the best technique for predicting pediatric PK.  
The aim of this research was to develop a modeling method to aid in predicting pediatric 
dosing and DDI. The research presented in this dissertation provides a reliable method to build 
a comprehensive PBPK model in order to understand the metabolic processes governing 
pediatric PK. However, this work highlights crucial gaps in our knowledge that need to be filled 
in order to improve current PBPK models. In order to improve the ability of the model to predict 
pediatric dosing and DDI, it is essential to understand the ontogeny of gastrointestinal enzymes 
and how this affects their activity and expression during development. In addition, more 
information is required in premature neonates to define the differences in binding proteins as 
well as how prematurity affects the development of organs and drug distribution. By adding 
these important physiological ontogeny data, the bottom-up PBPK model will be able to 
accurately predict dosing and DDI driven by PK differences between adults and children.  
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The potential of these models is not limited solely to understanding age-dependent PK 
differences in the general pediatric population. With the addition of data describing the 
relationship between genetic polymorphisms and ontogeny, the physiological changes 
associated with specific pediatric disease states, and the differences in distribution and 
ontogeny of pharmacodynamic targets between adult and pediatric patients, these models can 
evolve to become a tool used by clinicians. Ultimately, this line of investigation will expand the 
models to improve individual pediatric therapy at the bedside.   
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Figure 6. 1 Proposed Paradigm in Prediction of Pediatric Drug Disposition and its Use in 
Pediatric Drug Development. 
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